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ABSTRACT
Essential thrombocythaemia (ET) is a chronic myeloproliferative disorder of unknown 
aetiology, characterized by sustained thrombocytosis and megakaryocyte hyperplasia. 
Three strategies were used to investigate disease pathology. Firstly, PCR-based assays 
using fluorescently labelled primers to measure X-chromosome inactivation patterns were 
evaluated and clonality status shown to be stable in 14 patients with polyclonal and 8 
patients with clonal myelopoiesis studied over a median of 54 months (range 10-102) and 
52 months (range 5-97) respectively. Secondly, mutations and polymorphisms in cytokines 
implicated in thrombopoiesis were investigated in ET patients. No mutations in the 5’ 
untranslated region of the thrombopoietin gene, previously described in hereditary 
thrombocythaemia, were found. Genotypes and gene frequencies for polymorphisms 
previously shown to affect circulating cytokine levels in the transforming growth factor pi 
and interleukin-6 genes did not differ between patients and controls. Thirdly, 
representational difference analysis was used to compare global gene expression in platelet 
mRNA from an ET patient with monoclonal myelopoiesis with that from a normal control. 
Three genes were identified as differentially expressed: RANTES, CD32 (FcylIRA), and 
FLP. CD32 expression was further investigated using a multiplex semi-quantitative RT- 
PCR assay. Platelet CD32 expression was increased in 52 ET patients compared to normal 
controls (median CD32:GAPDH ratio 21, range 2-73 and 1, range <1-3 respectively, 
p=0.005). However, expression levels were not significantly different between 15 
polyclonal and 18 clonal patients (median ratios 23, range 2-73, and 25, range 8-60, 
respectively, p=0.281), nor between 11 polycythaemia vera patients and eight patients with 
reactive thrombocytosis (median ratios 30, range 7-63, and 10, range 2-25, respectively). 
Therefore, whilst this cohort of ET patients has raised levels of CD32 mRNA, this cannot 
currently be used as a diagnostic marker, or to identify patients at higher risk of thrombotic 
complications.
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Chapter 1
Introduction
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1.1 Haemopoiesis
All blood cells in the circulation are produced by the proliferation and 
differentiation of a small pool of multipotent haemopoietic stem cells (HSC) primarily 
located in the bone marrow (BM). This process is termed haemopoiesis and is vital to the 
effective functioning of the circulatory system as it allows the many different types of 
specialist blood cells, each with a differing and finite life span, to be continuously 
replenished. The requirement for production of particular types of blood cell can vary 
dramatically, for example an acute bacterial infection requires a dramatic increase in 
neutrophil numbers, or red cell production needs to be increased in the event of blood loss, 
and the HSC/BM system is able to react to these stimuli in order to alter the rate of 
production of a specific haemopoietic cell when required. This balance occurs via 
regulation of cell proliferation, commitment, maturation, survival and removal. Mature 
haemopoietic cells are produced by proliferation of HSCs, whose progeny become 
progressively more committed to specific cell lineages. One of the first events appears to 
be commitment to either the myeloid or lymphoid cell lineages. Granulocytes, erythrocytes, 
monocytes/macrophages and megakaryocytes (MKs) form the myeloid lineage and so 
progenitor cells committed to the myeloid lineage are termed colony forming unit GEMM 
(CFU-GEMM). Early lymphoid committed progenitors are called CFU-L (Figure 1.1). 
These committed progenitor cells are limited in the number of cell types that they can 
produce, and as they proceed further along the differentiation pathway they mature until 
they become morphologically, immunologically and functionally distinct haemopoietic 
cells. Cell division also occurs during the maturation process which enables haemopoiesis 
to produce the large numbers of functionally distinct granulocytes (neutrophils, eosinophils, 
basophils), monocytes/macrophages, erythrocytes, platelets, T and B lymphocytes seen in 
the circulation.
Haemopoiesis is kept under tight control by a number of regulatory molecules that 
stimulate and coordinate proliferation of HSCs and their progeny, and which initiate 
progress along specific maturation pathways (Metcalf, 1998). These haemopoietic growth 
factors and cytokines are able to act on one or more lineages and often exhibit synergistic 
actions. Stem cell factor (SCF) and fms-like tyrosine kinase-3 (FLT-3) are key regulators of 
the initial generation of progenitor cells from HSCs. Simultaneous stimulation from several
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Figure 1.1
M odel o f  haem opoiesis Haemopoietic stem cells (HSC) in the bone 
marrow differentiate into the various lineages under the control o f  cytokines 
and growth factors. The important cytokines and growth factors are shown in 
bold type. Adapted from Hara and Miyajima (1999)*CFU -  colony forming 
unit, BFU -  burst forming unit, Eo -  eosinophil, GM -  granulocyte 
macrophage, MK -  megakaryocyte, E -  erythroid, NK -  natural killer, SCF -  
stem cell factor, FLT3-L -  fims like tyrosine kinase-3 ligand, IL- - interleukin, 
CSF -  colony stimulating factor, TPO -  thrombopoietin, EPO- erythropoietin, 
t  See additional references p255 20
regulators is required for the differentiation of stem cells, and it has been shown that the 
interleukins -3, -6, -7, -11 (IL-3. IL-6. IL-7. IL-11) and granulocyte and granulocyte- 
macrophage colony stimulating factors (G-CSF. GM-CSF) are important in SCF mediated 
stimulation. IL-3, G-CSF and thrombopoietin (TPO) are cytokines which are active in both 
the early and late stages of haemopoiesis. Factors such as G-CSF. GM-CSF. macrophage- 
colony stimulating factor (M-CSF) and IL-3 are important in the development of mature 
granulocytes and monocytes, and other regulators such as erythropoietin (LPO), G-CSF, 
M-CSF, and TPO have important actions in terms of commitment to a specitlc lineage. 
LPO is key for promoting the production of erythrocytes, G-CSF for neutrophils, M-CSF is 
specific for promoting monocyte and macrophage production and TPO is the prime 
regulator for platelet production (Fraser et al. 1996). A suitable microenvironment for the 
regulation of haemopoiesis is provided by BM stromal cells, which secrete regulatory 
growth factors and cytokines and allow cell-to-cell interactions to take place (Torok-Storb 
etal. 1999).
1.2 T hrom b op oiesis
Thrombopoiesis is the process of proliferation and maturation of HSCs along the 
MK lineage to form mature platelet shedding MKs. The process can be artificially divided 
into 3 stages: a highly proliferative progenitor stage, an intermediate immature MK stage 
and a terminally differentiated mature MK stage (Long, 1998).
The earliest MK lineage restricted progenitor cell identified to date is the high 
proliferative potential cell MK (HPPC-MK) (Bruno et al, 1996). Isolated from foetal BM, 
the HPPC-MK has yet to be identified in adults, but shares the characteristics of the murine 
high proliferative potential colony forming unit MK (HPP-CFU-MK) isolated from both 
foetal and adult mice (Jackson et al. 1994a). Each HPPC-MK can generate a colony of 300- 
1000 MKs in semi solid culture medium after 21 days incubation in a serum-depleted fibrin 
clot assay system (Bruno et al, 1996). HPPC-MK express CD34 and CDwl09 on their 
surface and mature into burst forming unit MKs (BFU-MK). BFU-MK are the earliest MK 
progenitor isolated from adult human BM and are able to produce colonies of 100-500 
cells. While BFU-MK still express CD34, they have a more mature immunophenotype than 
HPPC-MK as they also express c-kit, the SCF receptor, at their cell surface. The most
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mature cell in the progenitor stage of thrombopoiesis is the colony forming unit MK (CFU- 
MK), which gives rise to colonies containing 4-36 cells. CFU-MK are still CD34+ and c- 
kit+, but also express HLA-DR (Figure 1.2).
During the immature MK stage of thrombopoiesis progenitor cells mature 
morphologically and immunophenotypically and cease to proliferate. Two cell types make 
up the immature MK stage: the promegakaryoblast (pMKb) and the more mature 
megakaryoblast (MKb). pMKbs have restricted proliferative potential, but display mature 
MK markers at the cell surface such as the platelet glycoprotein GPlIb/IIIa (CD41) and von 
Willebrand factor (vWF), although they still express the immature marker CD34 (Rabellino 
et al, 1981). The endomitotic increase in DNA content characteristic of MKs mainly occurs 
in pMKbs (Ebbe & Stohlman, Jr., 1965), and they are the first cell in the MK lineage to 
increase in number during thrombocytosis (Jackson, 1973). MKbs are more mature than 
pMKbs, and it is during this stage of development that CD34 expression is lost. 
Morphologically, MKbs have a high nucleus to cytoplasm ratio and basophilic cytoplasm 
indicative of a high level of protein synthesis. MKbs have a very low proliferative potential 
even when positive for CD34 expression (Debili et al, 1992).
The mature MK stage of differentiation consists of promegakaryocytes (proMK) 
and fully mature, platelet shedding MKs. ProMK are CD34-, HLA-DR+ and CD41+. 
During this stage of maturation the nucleus to cytoplasm ratio increases further, and platelet 
specific granules start to appear. Mature platelet shedding MKs have an abundant mature 
cytoplasm and large lobulated nucleus. DNA content has increased by doublings to a model 
ploidy of 16N, although MKs with ploidy levels of 8-128N are normal. An increase in 
membrane synthesis occurs in mature MKs, which invaginates to form a tubular system at 
the cell margin termed the demarcation membrane system (DMS). The DMS is thought to 
divide the cytoplasm into platelet fields, although its exact role remains obscure. The final 
stage of thrombopoiesis occurs when long cytoplasmic projections extend from the MK 
periphery. Platelets detach from the tip of these projections and are released into the 
circulation (Cramer et al, 1997).
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1.3 Regulation of Thrombopoiesis
1.3.1 Thrombopoietin and c-mpl
Thrombopoietin (TPO), also known as megakaryocyte growth and development 
factor (MGDF), is the prime regulator of thrombopoiesis and interacts specifically with its 
receptor Mpl on the surface of all cells of the MK lineage to promote proliferation, 
differentiation and ultimately platelet production. TPO was discovered in 1994 
independently by four groups as the ligand to the then orphan receptor Mpl. It has since 
been shown to stimulate the proliferation and maturation of cells of the MK lineage at all 
stages of development and to be responsible for the increase in ploidy seen in MKs by 
stimulating endomitosis. However, TPO may have an inhibitory effect on the terminal 
phase of platelet formation, proplatelet budding, as it was shown that when MKs were 
plated in the presence of a number of cytokines, TPO specifically reduced platelet 
formation (Ito el al, 1996).
1.3.2 Stem Cell Factor
SCF on its own has little effect on thrombopoiesis. However, it acts synergistically 
with TPO, 1L-6, IL-3 and GM-CSF to stimulate thrombopoiesis. This was demonstrated 
with IL-3 and GM-CSF by an increase in cloning efficiency and size of MK colonies in 
clonogenic assays with the addition of SCF (Briddell et al, 1991). Also, TPO activation of 
STAT5 was enhanced 1.6 fold in Mo7e cells by costimulation with SCF (Drayer et al, 
2005). Platelet counts in mice treated with SCF have been shown to increase by 30% 
(Chow et al, 1993). However, this was not reproducible in primate models where BM MK 
levels increased but not platelet counts in the peripheral blood (Andrews et al, 1994). SCF 
may also have an effect on mature MKs, inducing polyploidisation and enhancing the 
terminal stages of maturation (Avraham, 1993; Debili et al. 1993). SCF-deficient mice have 
abnormal thrombocytosis, with a reduction in the number of MKs and an increase in MK 
size (Hunt et al. 1992).
1.3.2 IL-3 /GM -CSF
GM-CSF and IL-3 are functionally related glycoproteins which both stimulate MK 
colony growth, although IL-3 is more potent and can act directly, whereas GM-CSF
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appears to act in synergy with IL-3 to promote thrombopoiesis. In serum-free cultures IL-3 
seems to act on the late stages of MK differentiation (Suda et al, 1986). Administration to 
mice augments platelet production (Carrington et al, 1991) and clinical trials have shown 
that this is also the case in humans. A hybrid IL-3/GM-CSF molecule PIXY321 was shown 
to support various stages of thrombopoiesis in vitro and in a phase I study was found to be 
effective at increasing both neutrophil and platelet counts in patients with sarcoma 
(Vadhan-Raj et al, 1994). However, phase III trials have shown that PIXY321 is no better 
than GM-CSF alone in supporting thrombopoiesis (O'Shaughnessy et al, 1996) and a 
further study showed no effect on thrombopoiesis but systemic toxicity, so the clinical 
impact of PIXY321 has been small (Jones et al, 1999).
1.3.3 IL-6, IL -ll and Leukaemia inhibitory factor
IL-6, IL -ll and leukaemia inhibitory factor (LIF) are members of a family of 
cytokines which have similar, but not identical, modes of action on thrombopoiesis. IL-6 
supports MK maturation in the absence of other growth factors and can augment platelet 
production in addition and synergy with other growth factors. However, IL-6 knock-out 
mice have normal platelet counts so it is unlikely IL-6 is crucial for MK development (IL-6 
is discussed in more detail in Chapter 6 -  6.1.5). IL-ll is similar in its actions to LIF, 
inducing MK progenitor maturation and proliferation. However, IL-11 can also act alone to 
promote MK maturation (Bruno et al, 1991a). When administered to mice, IL-11 increases 
the number of MK progenitors, stimulates polyploidisation of BM MK and increases 
platelet count (Neben et al, 1993). However, mice deficient for IL-11 have normal levels of 
circulating platelets (Gainsford et al, 2000). Mice deficient for LIF do not develop 
thrombocytopenia but they do have dramatically reduced numbers of progenitor cells in 
their BM and spleen (Escary et al, 1993).
1.3.4 Erythropoietin and other cytokines
Erythropoietin (EPO)-enriched preparations were a requirement in early MK culture 
systems (Vainchenker et al, 1979), and it has been suggested that EPO exerts its action 
mainly in the maturation stages of MK development. The EPO receptor is found on MKs, 
and clinical administration of EPO can lead to an increase in platelet count (Stone et al, 
1988). However, EPO is unlikely to play a significant role in thrombopoiesis as patients 
with chronic renal failure who are treated with EPO show no increase in platelet counts,
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and anephric animals and patients, made anaemic by reduced EPO expression, do not 
display thrombocytopenia. IL-1 has no direct effect on thrombopoiesis, but it does induce 
the synthesis of factors that do, such as SCF, IL-6 and GM-CSF. IL-1 can also act in 
synergy with TPO and IL-6 to promote MK proliferation. IL-10 has been shown to 
stimulate the proliferation of CFU-MK, but only in combination with EPO, IL-3, or IL-11. 
IL-13 continuously administered to mice can increase the numbers of immature MKs in the 
spleen but this does not lead to significant changes in platelet numbers. The major 
cytokines involved in thrombopoiesis and the stage of the lineage at which they influence 
development is outlined in Figure 1.3.
1.4 Chronic Myeloproliferative disorders
Essential thrombocythaemia (ET) is one of a group of disorders termed chronic 
myeloproliferative disorders (cMPD) which are characterised by dysregulation of myeloid 
elements. The term cMPD was first used by Damashek in 1951 who suggested that these 
interrelated disorders arose from a defect in the BM causing hyperproliferation of cells of 
the myeloid lineage. The cMPDs consist of four major disorders, chronic myeloid 
leukaemia (CML), chronic idiopathic myelofibrosis (cIMF), polycythaemia vera (PV) and 
ET, although CML is often considered separately from the others as its clinical course is 
more aggressive and its aetiology is better understood. CML patients are characterised by a 
t(9;22) translocation which produces the fusion protein BCR-ABL. The chromosome 
produced by the translocation is called the Philadelphia chromosome (Ph1). Non-CML 
cMPDs are often referred to as the Ph1 negative cMPDs. The Ph1 negative cMPDs are 
classified according to predominant phenotype. As the underlying defect involves a 
common haemopoietic progenitor, categorisation can be difficult, for example all cMPDs 
may have an associated thrombocytosis, but in each disorder the proliferation of one cell 
type predominates, platelets in ET, red cells in PV and fibroblasts in cIMF. A cMPD can 
acquire features of another cMPD and therefore patients may switch to another cMPD 
during the course of the disease. However, the clinical course and management differs 
between each syndrome so a correct diagnosis is essential.
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1.5 Essential Thrombocythaemia
1.5.1 Overview
ET is characterised by a sustained thrombocytosis of the blood and 
megakaryocytosis of the BM. A blood smear may display abnormal platelets, giant 
platelets are often present, and abnormally shaped platelets are sometimes, but not always, 
observed. In the BM a marked proliferation of large, mature MKs with multi-lobed nuclei is 
characteristic. Although the clinical course of ET is often benign, the main complications 
for patients are life threatening thrombotic and/or haemorrhagic events. The aetiology of 
ET is unknown and no disease-specific markers have been identified to date. Therefore, 
diagnosis of ET is currently one of exclusion of other causes of thrombocytosis which 
include inflammation and infection, solid tumours and other cMPDs. ET is estimated to 
occur in 1-2.5/100.000 of the population, although the true incidence is unknown (Mesa et 
al. 1999). The modal age at diagnosis is 50-60 years, and there is no predilection for either 
sex. However, a second diagnostic peak is seen at 30 years where women are more 
frequently affected (Mesa et al, 1999; Murphy et al, 1986).
1.5.2 Diagnosis
The diagnostic criteria for ET was first established by the polycythemia vera study 
group (PVSG) in 1976. The criteria contained guidelines for the exclusion of other cMPDs 
and a diagnostic platelet threshold of 1000 x 106/ml. This criteria was subsequently updated 
in 1986 to reduce the diagnostic platelet threshold to 600 x 106/ml (Murphy et al, 1986). 
The criteria was again modified in the final report of the PVSG in 1997 to include a clause 
to exclude myelodysplasia (Murphy et al. 1997). Thus a diagnosis of ET by the PVSG 
criteria requires a platelet count >600 x 106/ml, PV exclusion by either haematocrit of 
less than 40 or a normal red cell mass in the presence of normal iron stores, exclusion 
of myelofibrosis by the absence of collagen fibrosis (less than 33% fibrosis of trephine 
biopsy) with a lack of leucoerythroblastic features on a blood film and exclusion of CML 
by lack of Ph1. More recently these criteria have been updated by the World Health 
Organisation (WHO) to including BM morphology in the diagnostic criteria, and its 
description of ET is outlined below (Pierre et al, 2001). The PSVG and WHO diagnostic
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criteria are given in Table 1.1 and Table 1.2 respectively. Most studies into the biological 
and/or molecular pathogenesis of ET have used the PVSG criteria to diagnose patients.
1.5.3 Clinical Features
More than 50% of all ET patients are asymptomatic at diagnosis, and are often
identified from a routine blood count showing an increase in platelet numbers. However,
(Pierre et al, 2001)
20-50% of patients present with a vascular occlusion or haemorrnage.^ivucro vascular
occlusion can occur, often leading to cerebral or digital ischaemia, as well as thrombosis of
the major arteries and veins. Haemorrhage, commonly from the mucosal surfaces of the
upper airway passages and gastrointestinal tract has also been documented. Approximately
50% of ET patients display modest splenomegaly and 15-20% hepatomegaly. (Pierre et al, 2001)
(Murphy e ta l , 1997)
1.5.4 Cell morphology
A marked thrombocytosis is the most striking feature of a blood smear obtained 
from an ET patient. The platelets are often unequal in size, ranging from tiny forms to giant 
platelets, and while unusually shaped platelets can occur, they are uncommon. The numbers 
of white blood cells (WBCs) in the peripheral blood (PB) are often mildly elevated. Red 
blood cells (RBCs) are normal except where haemorrhage has occurred, when the RBCs 
often show signs of iron deficiency. (Pierre et ah 2001)
BM aspirate smears show a large increase in MK numbers compared to normal with 
large sheets of platelets also evident. Stainable iron is present in 40-70% of patients at 
diagnosis. (Pierre et al, 2001)
BM trephines are often normal in appearance but for a marked megakaryocytosis, 
with large to giant MKs. The MKs are usually found to be in loose clusters, but can be 
regularly dispersed throughout the BM, and have deeply lobulated and hyperlobulated 
nuclei. The presence of a normal or minimally increased reticulin fibre network is 
characteristic of ET, a large increase in the amount of reticulin fibres in the BM biopsy is 
indicative of the early stages of cIMF. (Pierre et al, 2001)
Extramedullary tissues are rarely involved in the MK proliferation, and where 
extramedullary haemopoiesis is seen in the liver or spleen, it is usually scant. The spleen 
may become enlarged due to high levels of platelets and platelet aggregates filling the 
splenic sinuses and cords. However, this often does not occur because of splenic atrophy 
due to platelet ‘clogs’. (Pierre et ah 2001)
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1 Platelet count >600x106/ml
2 Haematocrit <40 or normal red cell mass( males <36ml/kg, females 
<32ml/kg)
3 Stainable iron in the marrow or normal RBC mean corpuscular volume*
4 No Philadelphia chromosome or bcr/abl gene rearrangement
5 Collagen fibrosis of the bone marrow
A: Absent or
B: Less than one third of the biopsy area without both marked 
splenomegaly and a leucoerythroblastic blood film
6 No cytogenetic or morphological evidence for myelodysplastic syndrome
7 No cause for reactive thrombocytosis.
Table 1.1 
Polycythaemia vera study group criteria for the diagnosis of ET.
* If these measurements suggest iron deficiency, PV cannot be excluded 
unless a trial of iron therapy fails to increase the red cell mass into the 
polycythaemic range.
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Positive Criteria
1 Sustained platelet count >600 x 106/ml
2 Bone marrow biopsy specimen showing proliferation mainly of the MK lineage 
with increased numbers of enlarged, mature megakaryocytes
Criteria of exclusion
1 No evidence of polycythaemia vera (PV):
Normal red cell mass Hb <18.5g/dl in men, 16.5g/dl in woman 
Stainable iron in marrow, normal serum ferritin or normal MCV 
If the former condition is met, failure of iron trial to increase red cell mass or 
Hb levels in the PV range
2 No evidence of CML:
- No Philadelphia chromosome and no BCR/ABL fusion gene
3 No evidence of chronic idiopathic myelofibrosis:
- Collagen fibrosis absent 
Reticulin fibrosis minimal or absent
4 No evidence of myelodysplastic syndrome:
- No del(5q), t(3;3)(q21 ;q26), inv(3)(q21 ;q26)
No significant granulocytic dysplasia, few if any micromegakaryocytes
5 No evidence that thrombocytosis is reactive due to:
Underlying inflammation or infection
- Underlying neoplasm 
Prior splenectomy
Table 1.2 
World health organisation diagnostic criteria for essential 
th rom bocy thaemia
31
7.5.5 Cytogenetics
To date, no specific cytogenetic marker has been identified for ET, although a small 
number of patients do have cytogenetic abnormalities. Cytogenetic studies need to be 
carried out routinely in ET patients though, as exclusion of the Ph1 chromosome is essential 
for exclusion of CML at diagnosis, therefore it is unlikely that a common gross 
chromosomal abnormality would have been overlooked. Approximately 5-10% of ET 
patients do have chromosomal abnormalities, the most commonly occurring are del( 13q22),
+8 and +9. (pierre et al, 2001) (Barbui et al, 1999)
Many distinctive abnormalities are associated with rearrangements of chromosome 
17, particularly in patients that have progressed to myelodysplasia (MDS) or acute myeloid 
leukaemia (AML). However, the possibility that these alterations are therapy-related is high
as most of these patients were treated with hydroxyurea (HU) prior to transformation.
(Finnazi et al, 1999) (Murphy et al, 1997)
1.5.6 Prognosis
ET is an indolent disorder, with long periods of symptom-free intervals, punctuated
with life-threatening thromboembolic or haemorrhagic events. Median survival times of 10-
15 years are common, and because modal diagnosis r»f ET is at 50-60 years of age, many
(Tefferi, 2001) t
patients have a near normal life expectancy^,splenectomy can result in an increase in 
platelet count and increased mortality as the spleen is a major sequestration site for 
platelets. ET can transform into other less benign cMPDs such as PV or cIMF but this is 
only an occasional occurrence. Fewer than 5% of patients transform to AML or a 
myelodysplastic syndrome, although it is difficult to determine whether this is due to 
genuine disease progression or is related to cytoreductive therapy. (Tefferi et al, 2000) t
The major complication in ET is thrombosis, in one study of 100 patients 
haemorrhagic events occurred at the rate of 0.33%/patient-year (pt-yr), but thrombotic 
events were noted in 6.6%/pt-yr (Cortelazzo et al, 1990). The rate of thrombosis could be 
matched to patient age and previous history of thrombosis. Patients less than 40 years of 
age had a thrombotic rate of 1.7%/pt-yr, 40-60 years of age 6.3%/pt-yr and patients aged 
over 60 years 15.1%/pt-yr. In patients with a previous history of thrombosis the thrombotic 
rate increased from 3.4-31.4/pt-yr, even though all these patients were receiving treatment 
with cytoreductive therapy. In the light of these figures, ET patients can be classed as low 
risk if they are asymptomatic and less than 60 years of age, or high risk if they have a 
history of thrombosis or are aged over 60 years. A platelet count in excess of 1500 x 106/ml 
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would also signify high risk as an increase in the risk of haemorrhage has been noted in 
these patients (van Gameren et al, 1994). However, increasing platelet count does not 
correlate with an increase in thrombotic events.
1.5.7 Therapy
A number of therapeutic strategies are available to control thrombocytosis in ET. In 
low risk patients, withholding chemotherapy is thought to be the best therapy, although 
anti-aggregation therapy such as aspirin is often still used. In a study of 65 ET patients 
under 60 years of age with no history of thrombosis or major bleeding and a platelet count 
of less than 1500 x 106/ml, cytoreductive therapy was withheld until occurrence of a major 
clinical event (Cortelazzo et al, 1990). After a median 4.1 year follow-up, the incidence of 
thrombosis was 1.91%/pt-yr for ET patients and 1.43%/pt-yr for sex matched normal 
controls. No major bleeding was observed. This study indicated that low risk ET patients 
are not at higher risk of thrombotic events than the normal population. These findings were 
supported by another study which followed 28 low risk ET patients for a median of 4.6 
years and found that only 1 thrombotic event occurred during the time of the study (Randi 
e ta l, 1999).
In high risk patients, cytoreductive therapy is recommended. However, there are a 
number of different agents that can be administered, and each has its own drawbacks.
Hydroxyurea
HU is non-alkylating antimetabolite which inhibits the enzyme ribonucleoside
reductase, preventing DNA synthesis. The convenience of use, efficacy and low acute
toxicity of HU has made it a common treatment choice in ET. The dose administered can
be adjusted to maintain maximal platelet reduction without excessive lowering of WBC
count, and continuous treatment reduces platelet counts to below 500 x 106/ml in 80% of
(Barbui e ta l , 1999)
patients within 8 weeks of the initial aose^.Tne major short term toxic effect is leukopenia 
caused by haemopoietic damage, but this is reversed upon withdrawal of HU. 
Discontinuation of HU is accompanied by a rebound of platelet count, so continuous 
administration is necessary. Patients can become resistant to the effects of HU and may also 
develop serious side effects which limits its usefulness in some individuals. (Barbui et al, 1996)
Significant improvements in reducing the occurrence of thrombotic events can be 
achieved with the use of HU. A trial involving 114 ET patients with median age 68 years
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(range 40-85), and median platelet count at entry to trial 780 x 106/ml (range 533-1240) 
was carried out over 27 months (Cortelazzo et al, 1995). HU was administered to 56 
patients, the other 58 patients received no cytoreductive therapy. In the group receiving 
HU, only 2 thrombotic events were recorded (1.6%/pt-yr), but in the group receiving no 
cytoreductive therapy there were 14 thrombotic events (10.7%/pt-yr) (p=0.003). After 78 
months follow-up, 5 patients from the HU group had a thrombotic event compared to 26 
from the non-HU treated group (Finazzi et al, 2000).
As a non-alkylating agent, HU was originally thought to be non mutagenic. 
However, long term studies of patients treated with HU have shown 5-10% develop acute 
leukemia (Sterkers et al, 1998). More recently, trial data has shown that while none of the 
20 ET patients receiving no cytoreductive therapy developed secondary malignancies, only 
3 out of 77 patients receiving HU alone did, but 5/15 patients who received HU after 
previously receiving busulphan developed malignancies (Finazzi et al, 2000). This suggests 
that the rate of transformation to AML or a myelodysplastic syndrome with HU alone is 
minor, but that the combination of HU and other chemotherapeutic agents may significantly 
increase the risk of secondary malignancies.
Interferon-a (IFN-a)
IFN-a is a naturally occurring agent with antiproliferative actions in haemopoiesis 
and is a myelosuppressive. The response rate for platelet reduction with the administration 
of IFN-a is high at approximately 90% (Barbui et al, 2005). During maintenance the dose 
can be altered to tightly regulate platelet counts, but if treatment is suspended platelet 
counts rebound. Long term use of IFN-a is severely limited by side effects; in a review of 
273 patients published in the literature, 206 cases (75%) were either withdrawn from 
studies due to side effects (55%) or patients refused to comply with treatment regimens or 
were lost to follow-up (20%) (Lengfelder et al, 1996).
Anagrelide
Anagrelide is an oral imidazo-quinazoline derivative which specifically suppresses 
platelet production. Although its mode of action is poorly understood, it is thought to 
interfere with MK maturation. The efficacy of anagrelide as a treatment for ET has been 
assessed in non-comparative clinical studies. A response was defined as a reduction in 
platelet count to less than 500 or 600 x 106/ml, or a 50% drop in platelet count, and a
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response rate of 60-93% has been described in a total of 577 patients (Anagrelide Study 
Group, 1992). However, neurological and gastrointestinal complications have been 
reported, as well as two sudden deaths related to heart disease. More recently a study of 37 
young ET patients (median age 40 years, range 18-49) with a median follow-up of 10.7 
years (range 5.2-13.7 years) showed that while the response rate was 90%, and the 
reduction in platelet count was sustained in over 80% of patients, 4 patients (11%) 
discontinued treatment due to toxicity, thromboembolic complications occurred in 7 
patients (19%) and haemorrhagic complications in 6 patients (16%). None of these patients 
developed a secondary malignancy (Storen & Tefferi, 2001). Also, the PT-1 trial 
investigating 809 ET patients randomized to receive either HU and aspirin or anagrelide 
and aspirin has shown that anagrelide and aspirin use was associated with an increase risk 
o f arterial thrombosis, haemorrhage and transformation to cIMF compared to HU and 
aspirin therapy (Green et al, 2004). Therefore, while anagrelide is well tolerated in most 
patients and efficient at lowering platelet counts, it may not prevent thrombotic or 
haemorrhagic events with long term use.
1.6 Potential Molecular Markers of ET
1.6.1 Clonality
Chromosomal alterations are rare in ET and therefore studies to determine clonality 
status in patients have predominantly relied on an indirect technique which analyses the 
relative expression of X-linked alleles in females -  i.e. the X-chromosome inactivation 
pattern (XCIP). Initial studies using XCIPs suggested that ET was a clonal disorder (Anger 
et al, 1990; Fialkow et al, 1981; Raskind et al, 1985), but advances in the biologic and 
technical understanding of this technique have indicated a need for these results to be 
reappraised. This subject is discussed further in chapters 3 and 4, but an overview is given 
below.
A clonal XCIP pattern has been arbitrarily defined as 75% expression of one allele, 
but approximately 25% of normal females have a constitutively imbalanced pattern 
probably due to the small number of HSCs present at the time of X-inactivation. Therefore 
T-cells are analyzed to control for this (Gale et al, 1991). Also, the myeloid lineage is more
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susceptible to acquired age-related skewing of XCIPs than the T-cell lineage and therefore 
only patients less than 65 years of age are defined as clonal by XCIP (Gale et al, 1997). 
Using these caveats, and larger numbers of patients, it has been shown that a large 
proportion of ET patients have polyclonal myelopoiesis, ranging from 31% (Shih et al, 
2002) to 57% (Harrison et al, 1999a) with a mean of 40% from all studies (Chiusolo et ah 
2001; el Kassar et al, 1997; Ferraris et al, 1999; Liu et al, 2003; Shih et al, 2002; Teofili et 
al, 2002a; Vannucchi et al, 2004). Four groups have independently demonstrated an 
association between the presence of clonal myelopoiesis and increased risk of thrombosis, 
suggesting that ET patients could be divided into two groups, one having polyclonal 
myelopoiesis and a second with clonal myelopoiesis and an increased risk of thrombotic 
events (Chiusolo et al, 2001; Harrison et al, 1999a; Shih et al, 2002; Vannucchi et al, 
2004).
1.6.2 Thrombopoietin and Mpl
TPO is the primary physiological regulator of thrombopoiesis, and as such much 
research has been carried out to identify abnormalities in this cytokine in ET patients. This 
subject is discussed in more detail in chapter 5, but an overview is given below.
Studies on the inherited form of ET, hereditary thrombocythaemia (HT), have 
shown that mutations in the 5’ untranslated region (UTR) of the TPO gene can lead to an 
increase in TPO expression (Ghilardi et al, 1999; Jorgensen et al, 1998; Kondo et al, 1998; 
Wiestner et al, 1998). However, these mutations have not yet been shown to be present in 
ET patients (Harrison et al, 1998b).
Normal or elevated serum or plasma TPO concentrations have been widely reported 
in ET patients (el Kassar et al, 1998; Griesshammer et al, 1998; Harrison et al, 1999c). 
This finding is counter-intuitive as TPO is thought to be constitutively produced and 
circulating levels are mainly regulated by, and inversely proportional to, platelet and MK 
mass (Kuter & Rosenberg, 1995). The evidence seems to suggest that this may be due to 
reduced clearance rather than a defect in TPO expression. TPO is removed from the 
circulation by binding its specific receptor Mpl on the surface of MKs and platelets. A 
number of studies have demonstrated that mRNA expression of the Mpl gene, c-mpl, is 
reduced in ET and that the surface expression of Mpl protein is also reduced (Harrison et 
al, 1999c; Horikawa et al, 1997; Li et al, 2000). This would prevent the removal of TPO 
from the circulation, leading to the normal or elevated levels of circulating TPO seen in
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patients. However, elevated TPO levels are also seen in other cMPDs and in patients with 
reactive thrombocytosis (Harrison et al, 1999c), and platelet Mpl levels do not correlate 
with thrombosis (Vannucchi et al, 2004).
Normal BM cells stained for Mpl have a strong uniform staining pattern, but ET 
patients have a characteristically heterogeneous pattern of staining, with variation of both 
the site (membranous or cytoplasmic) and intensity (some strong, but predominantly 
moderate or weak) of staining. Also, not all cells are Mpl positive (Harrison et al, 1999c; 
Mesa et al, 2002).
The expression of TPO may not be entirely constitutive, IL-6 has been shown to 
augment TPO production in mice in a dose-dependent manner, which led to a 2.5 fold 
increase in platelet count (Kaser et al, 2001). Also, addition of the platelet a-granule 
proteins, platelet derived growth factor (PDGF) and fibroblast growth factor-2 (FGF-2), led 
to increased TPO mRNA expression in cultures of normal BM stromal cells by 2 and 1.5 
fold respectively (Sungaran et al, 2000). Transforming growth factor (3 1 (TGFpi) added to 
cultured BM stromal cells from normal individuals also led to elevated TPO mRNA 
expression, up to 7 times normal levels (Sakamaki et al, 1999). This effect could be 
blocked by addition of a TGFp blocking antibody prior to treatment, showing that the effect 
was due to TGFpi alone. Thus the normal or raised expression of TPO could be due to a 
combination of both decreased clearance and increased expression due to stimulation by 
other cytokines.
1.6.3 PRV-1 expression
A novel cell surface receptor, termed PRV-1, has recently been cloned using 
subtractive hybridisation techniques (Temerinac et al, 2000). It is most closely related to 
the uPAR/Ly6/CD59 receptor and its expression appears to be restricted to haemopoietic 
cells. Initial studies found PRV-1 to be overexpressed in granulocytes obtained from PV 
patients at the mRNA level. The initial study used Northern blot analysis to demonstrate 
PRV-1 mRNA expression in all of 19 PV patients studied and 4 out of 6 ET patients, but 
not in the 21 normal controls or the 4 patients with secondary erythrocytoses (Temerinac et 
al, 2000). Further studies by this group using a more sensitive quantitative RT-PCR method 
found that 18 out of 29 ET patients studied had a raised level of PRV-1 mRNA compared 
to normal controls, as did all the 48 PV patients, and that those ET patients with raised
37
PRV-1 were also positive for endogenous erythroid colony (EEC) growth, suggesting 
masked PV (Klippel et al, 2001). One study, using a non-quantitative method, has shown 
that all of 37 ET patients had raised PRV-1 levels compared to 20 normal control samples, 
but 25 patients with reactive thrombocytosis did not (Teofili et al, 2002a). However, others 
have not reproduced these resuits and most studies show a proportion of the ET patients 
with high levels of PRV-1 expression, but with the rest having normal levels. The 
proportion of ET patients with high PRV-1 mRNA expression ranges from 16% of 12 
patients studied to 100% (Liu et al, 2003; Florensa et al, 2004; Tefferi et al, 2004; Teofili 
et al, 2002a). One group has been able to show an association between PRV-1 positivity, 
EEC growth and the risk of thrombotic events. In a cohort of 30 ET patients 15 (50%) had 
increased expression of PRV-1 and EEC growth and 12 of those 15 (80%) patients had a 
thromboembolic or microcirculatory complication, compared to 4/15 (26%) PRV-1 
negative patients (Griesshammer et al, 2004). However, a second group could not 
demonstrate a correlation between PRV-1 expression and either thrombosis or clonality in 
88 ET patients, suggesting that while PRV-1 may be useful as a marker for diagnosis of 
cMPDs, it may not have clinical relevance (Vannucchi et al, 2004). High PRV-1 levels may 
just reflect hyper-activation present in these disorders. Granulocytes from normal 
individuals treated with G-CSF to stimulate proliferation of the myeloid lineage also have 
high levels of PRV-1 mRNA expression, as do mature granulocytes stimulated with either 
G-CSF or GM-CSF in vitro (Temerinac et al, 2000), suggesting that highly proliferating 
myeloid cells may increase PRV-1 expression.
1.6.4 Endogenous Erythroid and MK Colony formation
Erythroid progenitor cells isolated from peripheral blood or BM of PV patients have 
the ability to proliferate and differentiate in the absence of the major cytokine of the 
erythroid lineage, EPO (Correa et al, 1994; Prchal & Axelrad, 1974). This process is 
termed endogenous erythroid colony (EEC) formation and is considered diagnostic in PV. 
However, approximately 50% of ET patients also form EECs. It has been suggested that 
these patients have a masked PV, but whether this is the case is unclear as the number of 
ET patients who transform to PV is low (Shih & Lee, 1994). In a recent study of 88 ET 
patients, 39.4% were positive for EECs, but no association could be shown between rates of 
thrombosis and EEC positivity (Vannucchi et al, 2004). This suggests that while EEC 
positivity may be a useful marker to aid identification of cMPD from reactive disorders, it
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does not contribute to thrombotic risk. Assays for EECs are notoriously difficult to 
standardise due to technical variations in the procedure and the inherent variation between 
different batches of foetal calf serum and media. They are also time consuming to conduct 
and deciding if an assay is positive is highly subjective, therefore assays for EEC are not 
currently used widely for cMPD diagnosis.
MK progenitor cells isolated from the BM or peripheral blood of ET patients may 
also have the ability for spontaneous colony formation in the absence of the main regulator 
of the MK lineage TPO. Some studies have found that endogenous MK colonies are 
detectable and can be used to discriminate ET from a reactive disorder. In a culture system 
using 30% plasma from haemochromatosis patients, BM samples from all 24 patients with 
ET and 18/36 patients with other cMPDs grew spontaneous MK colonies, but such colonies 
were absent in cultures from reactive patients or normal control samples (Rolovic et al, 
1995). However, other groups have not been able to reproduce these data and have found 
that not all ET patients grow spontaneous MK colonies (Abgrall et al, 1992; Juvonen et al, 
1993), and some even describe colonies in cultures from patients with reactive 
thrombocytosis (Hamaguchi et al, 1988). More recently a report described the in vitro 
hypersensitivity of peripheral blood mononuclear cells from ET patients to TPO (Axelrad et 
al, 2000). However, as only 18/26 ET patients displayed hypersensitivity, and this was also 
observed in 1/8 patients with a reactive thrombocytosis, it would not be possible to use this 
test to confirm a diagnosis of ET.
1.6.5 Other markers
EPO A significant proportion of ET patients have reduced levels of circulating 
EPO measured from both serum and plasma samples. A study of serum samples from 49 
ET patients showed that 16 (33%) had subnormal EPO levels by ELISA, and there was an 
association between these patients and an increased risk of thrombosis (Messinezy et al,
2002). A similar study of plasma samples obtained from 65 ET patients demonstrated that 
approximately 50% of the patients had low EPO using an immunoradiometric method 
(Andreasson et al, 2000). However, patients treated with cytoreductive therapy do not have 
subnormal EPO, one study reported that 12 out of 24 plasma samples from untreated ET 
patients obtained at diagnosis had subnormal EPO, but none of the 28 samples from 
patients that had received cytoreductive treatment were outside of the normal range 
(Cameskog et al, 1998). This effect is also seen in serum; in samples obtained from
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untreated ET patients a mean EPO concentration of 6.6 mU/ml ± 8.0 (range 4.5-26.1) was 
recorded, compared to mean levels of 9.4 mU/ml ± 3.7 (range 2 -  17.9) for normal control 
samples and 14.1 ± 8.0 (range 4.5 -  26.1) for patients receiving cytoreductive therapy 
(Griesshammer et al, 2000). Also, EPO levels in plasma samples from all 20 ET patients 
analysed before and after treatment in one study rose to normal levels after treatment 
(Andreasson et al, 2000). However, the significance of this is still unclear as subnormal 
EPO levels do not correlate with clonality status (Andreasson et al, 2003) and have not yet 
been definitively shown to differentiate patients with higher risk of thrombosis.
NF-E2 and Antiphospholipid antibodies The transcription factor NF-E2 is involved in
MK maturation and platelet production, independent of the actions of TPO (Shivdasani et
al, 1995). In CD34+-derived MKs obtained from 5 normal controls and 8 ET patients, the
level of NF-E2 in ET patients was decreased at the mRNA level. The levels of 2 isoforms
were measured, the a and f  isoforms. Both isoforms were significantly reduced when
compared to expression levels of GAPDH control gene by quantitative-RT-PCR, the ratio
of NF-E2/GAPDH for the a isoform was 0.32 (range 0.24-0.4) in controls and 0.085 (range
0.026-0.16) in ET samples, and the ratio for the f  isoform was 0.03 (range 0.025-0.042) in
controls and 0.01 (range 0.006-0.027) in ET samples. This was shown to lead to a reduction
in expression of the thromboxane synthase gene, a gene which is directly regulated by NF-
E2. However, no decrease in protein expression could be demonstrated in the a isoform, but
(Catani et al, 2002) t
it could be demonstrated in the f  isororm^it was suggested that this dysregulation of NF-E2 
production may alter activity rather than absolute levels of NF-E2 in some ET patients.
Antiphospholipid antibodies (APA) have been shown to be risk factors for 
thrombosis in primary antiphospholipid syndrome and systemic lupus erythematosis 
(Donohoe et al, 2001; Horbach et al, 1996). Serum samples obtained from 20 out of 68 ET 
patients (29%) were shown to contain APAs, and of those, 10 (50%) had had a thrombotic 
event. Of the 48 patients without detectable APAs only 12 (6%) had had a thrombotic event 
(p=0.04) (Harrison et al, 2002). APAs may cause persistent activation of the coagulation 
cascade, inhibit the anticoagulant actions of protein C activation or have a direct effect on 
platelet activation (Greaves et al, 2000). The presence of APAs is unlikely to mark a 
primary event in the pathogenesis of ET, but may be useful to identify patients at higher 
risk of thrombosis, 
f  See additional references p255
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Markers o f  platelet activation A number of groups have investigated markers of
platelet activation in an attempt to identify patients at a higher risk of thrombotic events. 
CD36 (glycoprotein IV) is a platelet receptor that binds collagen and thrombospondin, and 
as such may be involved in haemostasis and thrombosis. Using a radio-immunoassay a 2-3 
fold increase in the number of CD36 molecules at the platelet surface was demonstrated in 
ET patients compared to normal controls (Thibert et al, 1995). Normal controls had a mean 
27,500 ±6160 molecules of CD36/platelet compared to 65,820 ± 29,500 molecules/platelet 
in 13 ET patients. Patients with a reactive thrombocytosis had similar CD36 levels to 
control of 26,800 ± 4,500 molecules/platelet, but levels were raised in 10 PV patients 
(44,960 ± 12,200 molecules/platelet) suggesting that this may be a general marker of cMPD 
rather than specific for ET.
Vascular endothelial growth factor (VEGF) may be involved in thrombosis 
formation, and levels of VEGF protein have been shown to be elevated in platelets from ET 
patients compared to normal controls (Cacciola et al, 2003). This elevation was shown to 
be more severe in patients that had had a thrombotic event than those which had not. Mean 
VEGF levels were 2.4 ±1.5 pg/106platelets for patients with thrombotic events, compared 
to 1.2 ± 0.8 pg/106platelets for patients without thrombotic events.
CD40 ligand is expressed on the surface of activated platelets, and a soluble form of 
CD40 ligand (sCD40L) can be produced via proteolytic cleavage. An increase in sCD40L 
levels has been described in plasma from ET patients, but not from normal controls or 
patients with a reactive thrombocytosis (Viallard et al, 2002). There was also a direct 
correlation between platelet count and sCD40L levels. As platelets shed sCD40L 
throughout their lifetime, it is possible that this is a reflection of long-lived platelets in 
patients with ET.
The platelet activation markers P-selectin (CD62p) and thrombospondin (TSP) were 
elevated in a cohort of 34 ET patients compared to 25 normal controls (Griesshammer et al, 
1999). The mean percentage of CD62p and TSP positive platelets was 14.7 ± 15.0% and 
12.4 ± 9.9% respectively, compared to 3.0 ± 4% and 3.2 ± 3.2% for normal controls. This 
suggests that increased platelet activation may be a feature of ET. However, in this study no 
comparison of either CD62p or TSP levels was made between patients who had had a 
thrombotic event and those which had not had a thrombotic event.
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Cytokines The megakaryocytic-derived cytokines platelet derived growth factor 
(PDGF) -A, -B, and basic fibroblast growth factor (bFGF) have been investigated in a 
cohort of nine ET patients treated with anagrelide both before and after treatment. All these 
cytokines are synthesised in the a-granules of platelets and released upon platelet 
activation. A semi-quantitative RT-PCR method was used to measure levels of mRNA 
compared to a control gene (Lev et al, 2005). The study was able to show that mRNA 
levels of PDGF A and PDGF B were reduced compared to normal controls prior to 
treatment, but that levels normalised following treatment, bFGF levels were normal prior to 
treatment, but also increased after treatment. This group had previously shown a decrease 
in the levels of PDGF A and PDGF B protein which normalised during treatment, but they 
also showed an increase in the protein levels of bFGF (Lev et al, 2002). These data suggest 
that the expression of platelet cytokines in these 9 ET patients is aberrant and that this can 
be partly corrected by treatment.
1.6.6 Correlation o f markers
Although a large number of markers for ET, and thrombotic risk in ET, have been 
described, only a few reports have investigated a number of markers using a single sample 
cohort. Vannucchi et al (2004) investigated PRV-1 over expression, EEC positivity, 
platelet c-mpl levels and clonality status in a single cohort of 88 ET patients, and correlated 
the results to the incidence of thrombotic events. They found that while patients with clonal 
myelopoiesis were at higher risk of thrombotic events, none of the other markers studied 
showed a significant association with the incidence of thrombosis in the cohort. They were 
also unable to show a significant clustering of markers in specific patients. A second group 
has investigated Mpl levels, PRV-1 positivity, EEC formation and the loss of 
heterozygosity on the short arm of chromosome 9 (9pLOH), the most common 
chromosomal abnormality described with PV, in a cohort of 15 ET patients (Kralovics et al,
2003). Again, they were unable to demonstrate any significant grouping of these potential 
molecular markers, only one patient was positive for all markers, 3/15 were positive for 
decreased platelet Mpl levels, PRV-1 over expression and EEC formation, but 2 were 
negative for all markers studied. These data suggest that ET is a very complex and 
heterogeneous disorder and that more work is needed to positively identify significant 
molecular markers which can be used for diagnosis and/or for identifying patients at greater 
risk of thrombotic events.
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1.7 Aims
The aim of the work presented in this thesis was to investigate the pathogenesis of 
ET in an attempt to further characterise existing molecular markers and identify novel 
molecular markers which may be of use in the diagnosis of ET or in identifying those 
patients at higher risk of thrombotic events. Firstly, the existing radiolabelled clonality 
assay previously used in the laboratory was converted to an assay which used a 
fluorescently labelled primer. This assay was then used to asses the long-term clonality 
status of ET patients. Secondly, the 5’ UTR of the TPO gene was investigated for the 
presence of mutations which may effect TPO expression levels, and polymorphisms which 
may influence the rate of thrombopoiesis were investigated in the TGF(31 and IL-6 genes. 
Finally, representational difference analysis (RDA) was used in an attempt to identify novel 
molecular markers in ET by comparison of the global gene expression levels of a clonal ET 
patient compared with a normal control at the mRNA level.
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Chapter 2
Materials and Methods
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2.1 General materials and reagents
Phosphate Buffered Saline (PBS) 
Ficoll-paque™
RPM1 1640 medium with L-glutamine 
Foetal Calf Serum (FCS)
Anti CD3 magnetic beads 
Dextran T500 
Penicillin and streptomycin 
NaCl
Tris (Hydroxymethyl) methylamine 
Orthoboric acid
EDTA (ethylenediaminetetra acetic acid 
disodium salt)
DTAB (dodecyl-trimethyl ammonium 
bromide)
TRlzol reagent
2-ME (p-mercaptoethanol)
Ethanol (AnalaR)
Isopropanol (AnalaR)
Chloroform (AnalaR)
Sodium acetate
SDS (sodium dodecyl sulphate)
Agarose
Low melting point agarose 
Ethidium Bromide 
Polyacrylamide
TEMED (tetramethylethylenediamine) 
APS (ammonium persulphate)
PCR primers
Restriction enzymes / buffers 
3MM Chr chromatography paper
Invitrogen
Amersham Pharmacia
Invitrogen
Invitrogen
Dynal
Amersham Pharmacia
Invitrogen
VWR International
VWR International
VWR International
Sigma
Sigma
Invitrogen 
VWR International 
VWR International 
VWR International 
VWR International 
VWR International 
Sigma
Sigma/Bioline
Invitrogen
Invitrogen
National Diagnostics
Sigma
Sigma
Invitrogen/Oswel
New England Biolabs / Roche
Whatman
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Hyperfilm 
TA cloning kit 
Taq polymerase 
Taq buffer 
dNTPs
Magnesium Chloride 
T4 Polynucleotide kinase 
Reverse Transcriptase 
RNase inhibitor 
DNace quick clean 
L-Broth 
Agar
Ampicillin
X-gal
IPTG
Amersham Pharmacia
Invitrogen
Promega/Bioline
Promega/Bioline
Promega/Bioline
Promega
Promega
Promega
Promega
Bioline
Bio 101 Inc
Calbiochem
Invitrogen
Sigma
Sigma
1 Ox TBE Buffer (pH 8.3). For 1L -Tris 108.9g
-Orthoboric acid 55.7g
-EDTA 7.4g
DTAB (8%). For 250ml - DTAB 20.0g
- NaCl 22g
- EDTA 4.65g
-Tris 3.05g
10% Dextran. For 250ml - Dextran 500 25g
-NaCl 2.25g
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2.2 Methods
2.2.1 Isolation o f blood cell types
General Method Approximately 32ml of peripheral blood, collected using EDTA as 
an anticoagulant, was obtained with informed consent and centrifuged at 200g for 15 
minutes. The upper layer of platelet rich plasma was removed for isolation of platelets. PBS 
was added to the remaining blood until the original volume was reached and dextran (10%) 
added to a final concentration of 1%. Sedimentation of the RBCs occurred after 
approximately 15 minutes and the top layer, containing the white blood cells, was removed 
and layered onto Ficoll-paque™ plus. To maximise mononuclear cell (MNC) recovery, the 
remaining blood was centrifuged at 3,000rpm for 5 minutes and buffy coats collected. 
These were diluted with PBS to 14ml, and layered onto Ficoll-paque™. Because of the 
high red cell content of the buffy coat preparations, no neutrophils were prepared from 
them. The Ficoll-paque™ preparations were centrifuged at 800g for 20 minutes. The 
remainder of the method is outlined below in Platelets, CD3+ cells, or Neutrophils.
Platelets The platelet rich plasma was centrifuged at 2,000g for 15 minutes. The 
supernatant was discarded and the platelet pellet carefully resuspended in PBS containing 
lOmM EDTA. RBC contamination of the platelets could be seen at the base of each pellet. 
Resuspending only the upper portion of each pellet reduced contamination of the platelet 
sample by RBC. The resuspended pellet was transferred to a new 15ml tube and spun at 
2,000g for 15 minutes. This wash procedure was repeated twice. After washing, the 
platelets were counted, centrifuged at 2,000g for 15 minutes and resuspended in TRIzol at 
2xl09platelets/ml for RNA extraction. TRIzol preparations were stored at -20°C.
CD3+ cells After centrifugation of the Ficoll-paque™ preparations, the MNC layer at 
the interface between the upper aqueous layer and the lower Ficoll-paque™ layer was 
harvested. To remove the Ficoll paque™, the MNCs were diluted in at least 2 volumes of 
RPM1 1640 medium with L-Glutamine, supplemented with 2% FCS (RF2%), and 
centrifuged for 6 minutes at l,800rpm to remove the Ficoll-paque™. The pellets were 
resuspended in RF2»/o and pooled, to a final volume of 10ml. Anti-CD3 beads were added to
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the MNCs (at a ratio of 1 bead to 1 MNC) followed by incubation for 1 hour at 4°C with 
end over-end-rotation. After incubation, CD3+ cells were isolated using a magnet and 
washed 3 times in RF2%. For DNA, 10-50xl06 cells were re-suspended in 2.4ml RF2o/o. For 
RNA, cells were resuspended in TRIzol at 5xl06/ml. To enable the purity of the sample to 
be measured, 5x 104 cells were added to 300pl RF2»/o and 2 cytospins prepared.
Neutrophils After centrifugation o f the Ficoll-paquerM preparations and removal of the 
MNC layer, all remaining Ficoll-paque™ was discarded. The resultant pellet was 
resuspended to a volume o f 2.5ml in PBS and 8ml ice-cold water added to lyse the red 
cells. After 60 seconds, 4ml 3.5% NaCl was added to prevent lysis of the neutrophils. The 
cells were then spun at 800g for 5 minutes and pellets resuspend in PBS. For DNA 10- 
50x106 cells were re-suspended in 2.4ml PBS. For RNA, cells were resuspended in TRIzol 
at 5xl06/ml. To enable the purity of the sample to be measured, 5xl04 cells were added to 
300pl of RF2o/o and 2 cytospins prepared.
2.2.2 DNA Extraction
(Adapted from(Gustincich et al, 1991). Neutrophils or T-cells (10-50xl06) were 
suspended in 2.4ml PBS or RF2o/o respectively. DTAB reagent (4.8ml) was added, mixed 
thoroughly and incubated at 68°C for 5 minutes. After cooling, samples were stored at 
-20°C for >17 hours. Once thawed, an equal volume of chloroform (7.2ml) was then added 
to the cells, mixed thoroughly and centrifuged at 2,000g for 20 minutes. The upper aqueous 
layer was decanted into a new 15ml centrifuge tube and the DNA precipitated with an equal 
volume of ethanol (100%). The DNA precipitate was then transferred to a 1.5ml tube and 
washed in 0.5ml 75% ethanol. The DNA was allowed to air dry for approximately 5 
minutes before being resuspended in an appropriate volume of water and dissolved 
thoroughly, by end-over-end rotation, overnight at 4°C. DNA samples were stored at 4°C.
2.2.3 RNA Extraction
Neutrophils or T-cells (5xl06) were suspended in 1ml of Trizol reagent and stored 
at -20°C for >17 hours. Once thawed, 200pl chloroform was added and mixed well by 
shaking for 15 seconds. Samples were incubated at room temperature for 2-3 minutes, and 
then centrifuged at 15,000g for 15 minutes at 4°C. The upper aqueous phase was
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transferred to a clean 1.5ml tube and the RNA precipitated with 0.5ml isopropanol. The 
samples were then centrifuged at 15,000g for 10 minutes at 4°C, the supernatant discarded 
and the pellet washed in 300pl 70% ethanol. The samples were centrifuged at 15,000g for 5 
minutes at 4°C and the supernatant removed by aspiration. Pellets were allowed to air dry 
for 5 minutes before being resuspended in an appropriate volume of water. Once dissolved, 
RNA samples were stored at -70°C.
2.2.4 Agarose gel electrophoresis
Agarose gels (1.0 - 3.5%) were used to check PCR products for size and purity prior 
to sequencing and to identify size differences after restriction enzyme digestion. The 
appropriate amount of agarose was added to 35ml of lx TBE, heated in a microwave oven 
until dissolved and allowed to cool before the addition of 5pl ethidium bromide (1 mg/ml). 
The gel was poured into a mould and allowed to set. Appropriate volumes of PCR products 
or restriction enzyme digestions were mixed with loading buffer (30% glycerol, 0.025% 
Bromophenol blue), loaded into the wells and electrophoresed in lx TBE (containing 
200ng/ml ethidium bromide) under appropriate current and voltage conditions. PCR 
products were visualised on a UV transilluminator. Polaroid photographic equipment was 
used to make a permanent record.
2.2.5 Polyacrylamide gel electrophoresis
Denaturing polyacrylamide gels were used for quantitative RT-PCR analysis and 
non-denaturing gels for RT-PCR-SSCP analysis. Denaturing gels consisted of 6% 
polyacrylamide (37.5:1 acrylamide to bis acrylamide) in 0.5xTBE containing 8M urea. 
Non-denaturing gels were prepared in the same way but without urea. To catalyse the 
acrylamide polymerisation 50pl TEMED and 250pl 10% APS were added to 50ml of gel 
immediately prior to pouring. Before loading, PCR products were mixed with loading 
solution (95% formamide, 20mM EDTA, 0.05% Bromophenol blue, 0.05% xylene cyanol), 
incubated for 5 minutes at 95°C to denature and quenched on ice. The samples were 
electrophoresed in 0.5xTBE under appropriate current and voltage conditions. After 
electrophoresis, gels were transferred to 3MM Chr chromatography paper, dried and 
exposed to autoradiography film for visualisation.
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2.2.6 Reverse transcription (RT)
Reverse transcription reactions convert RNA into complementary DNA (cDNA) to 
enable its use as template in polymerase chain reactions (PCR). RTs were carried out in a 
20pl reaction volume, and the final concentrations of each reagent were lx Bioline reaction 
buffer (160mM (NH4)2S0 4 , 67mM Tris-HCl, 0.1% Tween-20), 5.25mM MgCI2, ImM each 
dNTP, 20 units RNase inhibitor (Promega), 3.75 units reverse transcriptase (Promega), 
250ng oligo dT and Ipg RNA. Template RNA and oligo dT in a volume of 12.9pl were 
incubated for 5 minutes at 65°C followed by 10 minutes at room temperature. This allowed 
denaturation of RNA secondary structure and binding of the oligo dT primer. The 
remaining reaction components were then added and the reaction mixture incubated at 42°C 
for 1 hour followed by 95°C for 5 minutes to denature the enzyme. The cDNA was stable 
for several weeks when stored at 4°C.
2.2.7 Polymerase chain reaction (PCR)
The PCR allows the amplification of sequence-specific portions of DNA by 
successive cycles of denaturation, sequence specific primer annealing and DNA 
polymerisation (primer extension). Two different Taq polymerase enzymes were used 
during this work, Taq DNA polymerase (Promega) and Biotaq™ DNA polymerase 
(Bioline). To ensure identical concentrations of each reagent in each reaction tube, a master 
mix of the reagents was made (minus the template and Taq polymerase) with final 
concentrations of lx reaction buffer (Bioline: 160mM (NH4)2S04, 67mM Tris-HCl, 0.1% 
Tween-20, or Promega: 50mM KC1, lOmM Tris-HCl, 1% Triton X-100) 1.0-2.5 mM 
MgCl2 optimised for maximal amplification, 200pM each dNTP, 32pmol each of forward 
(5’) and reverse (3') oligonucleotide primer and water to a final volume of 17pl or 18.5pl, 
and either cDNA (2pl) or DNA (0.5pl) added. A drop of mineral oil was added to each tube 
as an evaporation barrier. Where a hot-start method was employed, the tubes were placed in 
the thermocycler block and heated to 95°C for 5 minutes. The temperature was then 
lowered to 85°C and Ipl of hot start mix, containing 0.5U of Taq DNA polymerase, was 
added to each tube prior to thermal cycling. Thermal cycling consisted of a denaturation 
step at 95°C for 30 seconds, a primer-annealing step where temperature was dependent on 
the composition of the primers for 30 seconds, and a primer extension step at 72°C for 30 
seconds. The number of amplification cycles used varied between 22 and 35. A final
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extension was carried out at 72°C for 5-15 minutes to ensure complete extension of all PCR 
fragments.
2.2.8 End-labelling o f primers
One primer from a given primer pair for SSCP and semi-quantitative RT-PCR were 
labelled with a radioactive isotope to allow visualisation on autoradiography film. Ten 
pmol of primer was incubated with 10 units of T4 polynucleotide kinase in lx reaction 
buffer (70mM Tris-HCl, lOmM MgCl2, 50mM DDT) and 3pl y-[32P]-ATP (0.37 
MBq/|il)(Amersham Pharmacia) for 30 minutes at 37°C. This reaction transfers the y- 
phosphate from the y-[32P]-ATP to the polynucleotide primer. After the transfer reaction 
was complete, samples were incubated at 95°C for 5 minutes to inactivate the enzyme. The 
labelled primer was then added to the hot start mix for addition to PCRs.
2.2.9 Sequencing o f  PCR products
PCR products were purified using Wizard Plus PCR™ columns (Promega) or 
Qiaquick PCR purification kit (Qiagen). Cycle sequencing was performed by addition of 
10-100ng purified PCR product and 3.2pmol of an oligonucleotide primer to BigDye™ 
Terminator Cycle Sequencing Ready Reaction, 310 Genetic Analyser Kit (Applied 
Biosystems), a single reaction mix that contained the dye terminators, DNA polymerase, 
MgCh and reaction buffer. Twenty five amplification cycles of 96°C for 10 seconds, 50°C 
for 5 seconds and 60°C for 4 minutes each were carried out on a Perkin Elmer GeneAmp 
PCR system 9600 thermocycler (Applied Biosystems). The cycle sequencing products were 
precipitated using 2.0p.l Na acetate (3M, pH 4.6) and 50pl ethanol (95%) and incubated at 
room temperature for 10 minutes. The DNA precipitate was pelleted by centrifugation at 
15,000g for 20 minutes. The supernatant was removed and the pellet washed in 75% 
ethanol. After further centrifugation for 5 minutes at 15,000g, the ethanol was discarded 
and samples allowed to air dry for 15 minutes prior to resuspention in 15pl Template 
Suppression Reagent™ (Applied Biosystems). Sequencing results were visualised using 
the ABI Prism™ 310 Genetic Analyser (Applied Biosystems), a single capillary, 
fluorescence based, automated genetic analyser. Samples were denatured at 95°C for 5 
minutes and quenched on ice prior to electrophoresis on the 310 genetic analyser using 
performance optimised polymer 6.
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2.2.10 Cloning o f PCR products
PCR products were cloned using the TA cloning system that utilises the single 
deoxyadenosine overhang at the 3' end of PCR products. Fresh PCR products were ligated 
into pCR®2.1-TOPO vector with deoxythymidine overhangs at the insertion site. This was 
performed by incubating 0.5 - 4pl PCR product with Ipl vector and lpl salt solution 
(200mM NaCl; lOmM MgCh) in a final volume of 6pl at room temperature for 5 minutes. 
The vector was transformed into TOPI OF’ competent bacteria by heatshock at 42°C for 30 
seconds. LB agar plates (lx  LB medium, 15% agar, lOOpg/ml ampicillin) were pre-coated 
with 40pl IPTG (lOOmM) and 20pl X-Gal (50mg/ml) which was allowed to absorb for 30 
minutes at 37°C. Transformed bacteria were selected by resistance to ampicillin and the 
presence of an inserted PCR sequence was selected by p-galactosidase activity after plating 
and incubation at 37°C overnight. Transformed clones with inserted sequence (white 
colonies) were picked and expanded in LB medium containing lOOpg/ml ampicillin. PCR 
was performed directly on the bacteria to select clones for sequencing.
2.2.11 Mutation specific enzyme digests
An appropriate volume of PCR product was digested overnight at the manufacturers 
specified temperature with 1 U/pl of restriction enzyme in the appropriate buffer. Samples 
were then electrophoresed in 1.5 to 3.5% agarose gels and bands visualised by ethidium 
bromide staining of the gels.
Where a direct digest was not available to identify sequence changes, a mismatch 
primer could often be designed to introduce base changes into PCR products and enable 
restriction enzyme analysis. A mismatch primer is so called because one or more of the 
nucleotides in the primer sequence are altered from the published sequence. The 
mismatched bases must not reduce the ability of the primer to anneal to its specific location 
in the genome or prevent the Taq polymerase from recognising a double stranded primer 
site, therefore the extreme 3’ base pair cannot be changed and a longer primer than is usual 
is often designed. As the alteration is in the primer sequence, all subsequently produced 
PCR products will faithfully copy the mismatch leading to the introduction of the alteration 
into all exponentially amplified products. Enzyme digestions are then carried out as 
described above. As the enzyme cutting site is partially within the primer sequence, the use
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of a long primer (>30bp) also facilitates separation of the bands representing cut and uncut 
PCR products when visualised using agarose gels.
53
C h ap ter  3
Optimization of PCR based clonality assays using a 
fluorescently labelled primer
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3.1 Introduction
3.1.1 Clonality in cell lineages
Expansion of a specific cell lineage can arise in either a clonal or polyclonal 
fashion. Alterations acquired in the DNA of a single cell may lead to a growth and/or 
survival advantage for that cell and its progeny, giving rise to a clonal expansion of the cell 
lineage. However, expansion may also occur by over-stimulation of cell proliferation by 
exogenous factors, such as cytokines or growth hormones, leading to a non-clonal, or 
polyclonal, expansion of the cell lineage. Understanding the clonal basis of the expansion is 
fundamental to its study.
A number of strategies are available to study clonality. If a chromosomal 
abnormality is associated with a disease, karyotype analysis can be used. Nearly all 
classical CML patients have a t(9;22) translocation, termed the Philadelphia chromosome 
(Ph1), in 90-100% of their BM cells (Guilhot, 1999). As haematologically normal controls 
display no Ph1 it can be used as a marker for the clonal expansion of the myeloid lineage in 
CML. The study of oncogenic mutations can also be used to determine the clonality of 
neoplasia. Mutations of the RAS superfamily of GDP/GTP-binding proteins have been 
identified in 15-25% of AML cases where they can be used as a marker for diagnosis and 
clonality in those patients (Farr et al, 1988; Stirewalt et al, 2003). Immunoglobulin gene 
rearrangements can be used to identify clonality in some diseases, particularly in lymphoid 
malignancies. A normal population of B or T-cells will contain a large number of gene 
rearrangements giving a diversity of immunoglobulins or T-cell receptors. In lymphoid 
neoplasia this diversity is often reduced to a single or predominant immunoglobulin or T- 
cell receptor (TCR) indicating a clonal expansion (Gilliland et al, 1991a). However, 
infection can also lead to a clonal expansion of a single or predominant TCR or 
immunoglobulin, so results must be interpreted with care.
In diseases where a direct marker of clonality is not known, clonality can be 
measured in female patients by indirect means using X-chromosome inactivation patterns.
3.1.2 Lyonization and XCIPs
All mammalian female somatic cells have one active and one inactive X- 
chromosome which prevents a lethal double dose of genes from the X-chromosome.
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Inactivation occurs during embryogenesis where either the maternal or paternal X- 
chromosome is inactivated at random. This process is known as Lyonization (Lyon, 1961). 
Once inactivation has occurred it is fixed and the same inactive X-chromosome is inherited 
in all progeny cells even if the cell becomes neoplastic (Gartler & Riggs, 1983) (Figure 
3.1). Therefore, if the expansion of a cell lineage is derived from increased 
proliferation/survival of a single cell, all cells of that lineage would have the same active X- 
chromosome leading to an imbalanced XCIP. To use Lyonization as a marker for clonality 
the active and inactive X-chromosome must be able to be identified, as well as the maternal 
and paternal X-chromosomes. Protein variants and polymorphisms of genes located on the 
X-chromosome enable this distinction to be made. The following assays have proved to be 
useful tools for investigating the clonal derivation of a cell population.
3.1.3 Studying clonality with protein isozymes
The earliest use of XCIPs to determine clonality used the housekeeping gene 
glucose-6-phosphate dehydrogenase (G6PD) which has been used to study the cellular 
origin and development of a number of different tumours (Beutler et al, 1962; Fialkow, 
1976; Raskind & Fialkow, 1987). A number of G6PD protein variants occur in different 
ethnic populations, the most common of which is type B G6PD. Most females are 
homozygous for type B, and this lack of heterogeneity limits the usefulness of the 
technology. However, 30-40% of males of African origin have a variant enzyme, type A 
(Fialkow, 1972). The A and B forms differ by one amino acid substitution and are readily 
distinguishable using electrophoresis (Boyer et al, 1962). Thus heterozygous females can 
be studied, a clonal population being indicated by a single band in the neoplastic cell 
lineage, and a polyclonal population indicated by two bands (Beutler et al, 1962). As the 
technique used protein as the test material, the clonality of non-nucleated cells, for example 
RBCs or platelets, could be deduced.
3.1.4 Studying clonality with DNA assays
3.1.4.1 Southern blot techniques
The use of G6PD isozymes to measure XCIPs is restricted as few patients are 
heterozygous. Therefore other assays were developed to allow study of a larger number of 
individuals. No other protein isozymes have been identified to date that can be used for 
clonality assays. However, the discovery that inactivation of the X-chromosome is
56
Sperm Egg
xax,xax,xax xax,
X
Gametes
Zygote
Embryo
Random
Inactivation
Progeny
Figure 3.1
Schem atic o f  X -chrom osom e inactivation
Active X-chromosomes shown in large, bold, black type, inactivated chromosomes in small grey type. 
Xa represents paternal chromosome, Xb represents maternal chromosome.
accompanied by DNA methylation o f specific cytosine residues within certain genes 
enabled DNA techniques to be developed (Razin & Riggs, 1980). By using DNA 
polymorphisms, to distinguish between the two X-chromosomes, and differential 
methylation, investigators were able to examine clonality in a much larger number of 
individuals. Two general techniques have been established for Southern blot based clonality 
assays: (1) -  restriction enzyme digestion and (2) - short tandem repeat (STR) based assays.
The first DNA clonality assay used a polymorphic restriction enzyme cutting site in 
the hypoxanthine phosphoribosyl transferase (HPRT) gene to distinguish between maternal 
and paternal alleles (Vogelstein et al, 1985). Females polymorphic at the HPRT locus 
produce DNA fragments of 18kb and 12kb by Southern blot after BamHl digestion of 
genomic DNA. These bands contain six methylation-sensitive Hha\ sites which allow the 
active and inactive X-chromosomes to be distinguished. Methylation-sensitive restriction 
enzymes only cut non-methylated DNA so only active alleles are digested. Between 12 and 
27% of females are polymorphic at the HPRT locus (Anger et al, 1990; Browett et al, 
1988; Gale et al, 1991; Vogelstein et al, 1985). At the phosphoglycerate kinase (PGK) gene 
locus two polymorphisms in the CpG rich 5’ region are close to sites that show differential 
methylation and thus allow its use for clonality studies (Vogelstein et al, 1987). Restriction 
enzyme digestion with BstXI and PstI is used to distinguish between the two polymorphic 
alleles, in combination with HpaW to distinguish active and inactive X-chromosomes. 
Between 30 and 40% of females are heterozygous for the PGK polymorphism (Anger et al, 
1990; Gale et al, 1991).
The second type of Southern blot based DNA clonality assay uses variable number 
tandem repeat sequences (VNTRs) close to sites of differential methylation to distinguish 
between polymorphic alleles. The gene locus DXS255, identified by the probe M27(3, has 
also been widely used to determine clonality (Abrahamson et al, 1990; Boyd & Fraser, 
1990; Fey et al, 1992). The heterozygosity rate for M27p can be as high as 93%, much 
higher than for HPRT, and has been used successfully by a number of groups (Fey et al, 
1994; Gale et al, 1992). However, use of M27p has been hampered because the extent of 
methylation of inactive alleles is variable at this locus, leading to XCIPs that can be very 
difficult to interpret with the methylation-sensitive restriction enzyme HpaW (Hodges et al, 
1991). This problem can be reduced by using Hha\ for digestions (Gale & Linch, 1994b).
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3.1.4.2 PCR Techniques
Southern blot analysis is time consuming and labour intensive and typically 5-20pg 
of DNA is required to generate the high levels of signal required. To allow clonality to be 
studied more easily, and in individual haematological cell lineages where the quantity of 
DNA available is often small, PCR technology has been used to amplify the DNA. Most 
studies to date have used polymorphic loci in either the human androgen receptor (Allen et 
al, 1992; Gale et al, 1996) or PGK gene (Gilliland et al, 1991b; van Kamp et al, 1991). 
PCR based assays rely on the proximity of the methylation-sensitive restriction sites to 
polymorphisms, allowing relatively short PCR products to be used.
The human androgen receptor assay (HUMARA) utilizes an STR in the coding 
region of the human androgen receptor gene which is close to a differentially methylated 
HpaW restriction site. The STR is 3bp in length and is highly polymorphic, with one study 
describing 20 different alleles corresponding to 11-31 CAG repeat units, and a 
heterozygosity level of 90% (Allen et al, 1992). The STR generates a size difference 
enabling identification of the polymorphic alleles. Samples are digested with HpaW prior to 
amplification as PCR does not preserve methylation. Unmethylated DNA is cut between 
the two primer annealing sites, preventing PCR amplification (Figure 3.2). However, 
methylated DNA remains uncut and the inactive X-chromosome is amplified. As the 
difference between alleles can be as little as three base pairs, and the results obtained 
require quantification, either isotope labelled PCR amplification and electrophoresis 
through acrylamide gels, or fluorescent labelled PCR amplification and the use of a genetic 
analyser, is required.
The PGK assay is similar to the HUMARA but identification of the polymorphic 
alleles occurs via the use of a single nucleotide polymorphism (SNP). Samples are digested 
with HpaW prior to PCR amplification to cut the DNA between the two primer sites thus 
preventing amplification of active alleles. After amplification, PCR products are digested 
with BstXI to distinguish between the polymorphic alleles. Isotope-labelling and 
densitometry, or fluorescently labelled PCR and the use of a genetic analyser, allow 
quantification (Gilliland et al, 1991b).
3.1.5 Studying clonality with RNA assays
DNA methods, especially the HUMARA, have been widely used to measure XCIPs 
because of high heterozygosity rates in the population. However, only nucleated cells can
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be studied with DNA techniques and the polymorphism at a DNA locus must be near to a 
differentially methylated site which can be recognized by a methylation-sensitive restriction 
enzyme. Also methylation patterns at some loci are complex due to sites with variable 
methylation (Gale & Linch, 1994b) and both hyper- and hypomethylation have been 
documented in tumour samples and cMPDs (Herman & Baylin, 2003; Ihalainen et ah 1994; 
Jones et al, 2004).
To avoid these problems RNA based clonality assays have been developed that 
directly measure transcript levels of polymorphic genes located on the active X- 
chromosome. They circumvent the problems associated with techniques using methylation 
and allow measurement of clonality in non-nucleated cells such as reticulocytes and 
platelets. Any SNP present in mRNA derived from the X-chromosome can be used for the 
RNA assays so long as it is expressed in the cells being investigated. As with DNA, RNA 
can be extracted from small numbers of cells, which allows measurement of clonality from 
specific cell lineages where few cells may be available. To prevent contaminating DNA in 
the RNA preparations interfering with quantification, PCR primers are designed which 
cover exon/intron boundaries. This ensures that contaminating DNA either does not 
amplify, or produces a PCR product larger than that from RNA.
A number of polymorphic genes on the X-chromosome can be used to study 
clonality at the RNA level. The first of these uses the polymorphic G6PD housekeeping 
gene. A ligase detection reaction was originally used to study the G6PD polymorphism (a C 
to T substitution at nucleotide 438) (Prchal & Guan, 1993). However, a simpler mismatch 
primer (Chapter 2 section 2.2.8) and labelled PCR, followed by Mlu\ restriction enzyme 
digestion can also be used (Harrison et al, 1999a).
Two other polymorphic loci are commonly used; iduronate-2-sulphatase (IDS) 
(Hopwood et al, 1993; Harrison et al, 1998a), and the palmitoylated membrane protein p55 
(Luhovy et al, 1995). The IDS assay exploits a C to T substitution in codon 146 of the IDS 
gene that, by introducing a mismatch with the 3’ primer (Figure 3.3), can be cut using Bel I 
(Harrison et al, 1998a). The p55 polymorphism is used in a similar way, by the introduction 
of a RFLP by the use of a mismatch primer allowing digestion by Bstli 1 to identify the two 
alleles.
Two further polymorphic loci in the Bruton tyrosine kinase (BTK) and four and a 
half LIM domain 1 (FHL-1) genes have recently been described (Liu et aL 2003). Up to
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95% of females are informative for at least one of these five loci, enabling clonality at the 
expression level to be studied in most female patients (Liu et al, 2003).
RNA clonality assays are useful tools, but they do have their own specific problems. 
DNA heteroduplexes can form during the last cycle of PCR amplification as the primers are 
incorporated into the PCR products and the amount of product increases. This heteroduplex 
DNA will not have the recognition sequence required for restriction enzyme binding and 
digestion and so will not be cut by restriction enzymes. This leads to the artificial altering 
of clonality results towards a balanced XCIP. DNA assays control for this by comparison of 
two aliquots from each sample, one with and one without HpaW digestion. However, this is 
not possible for RNA assays as there is only one aliquot per sample. A further concern is 
the effect of contamination with cells from a different lineage as transcript levels in T-cells, 
neutrophils and platelets can differ for any given gene. At the IDS loci, transcript levels 
from one T-cell were equivalent to those from six neutrophils or 800 platelets (Harrison et 
ah 1998a). As clonality may differ between lineages, contaminating cells can affect 
clonality results.
3.1.6 Measuring clonality
Interpretation of clonality results is required before a sample can be classified as 
clonal or polyclonal. Cells may be present in a sample which are not derived from the 
expanding clonal population. This may be because the clone does not have sufficient 
growth advantage to overwhelm the entire lineage. Therefore, while the tumour may derive 
from a clonal expansion of a progenitor cell, the clonality assay may still show the presence 
of both alleles. Both polymorphic alleles were present in tumour samples from 41 patients, 
but their relative expression had become imbalanced therefore an arbitrary definition of a 
clonal pattern was defined (Vogelstein et al, 1987). An 80% or greater decrease in the 
intensity of one allele with a decrease in intensity of less than 40% in the other allele 
following digestion with methylation-sensitive restriction enzymes was suggested as the 
definition of a clonal XCIP (Vogelstein et ah 1987). This equates to less than 20% 
expression of one allele compared to more than 60% of the other allele or a 1:3 expression 
ratio. Using this definition, 36 of 41 patients with a neoplastic disorder had a clonal pattern, 
with the other 5 being uninterpretable by the HPRT assay used in these studies. Normal 
tissue from 40/41 of the patients had a polyclonal pattern of XCIP using this criteria, the 
other patient was constitutively skewed (discussed below) (Vogelstein et ah 1987). Many
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early studies using XCIPs gave results as a ratio of one allele to the other as described 
above. However, it is now more common to express the ratio as a percentage, with <25% 
expression of one allele indicating an imbalanced XCIP.
A second consideration is constitutive skewing which is thought to occur because 
the stem cell pool is small at the time of X-chromosome inactivation. Estimates of the 
progenitor cell pool size for human haemopoietic cells have ranged from 7 to 16 (Fialkow, 
1973; Gale et al, 1991; Puck et al, 1992; Gale & Linch, 1994a). Therefore, due to the 
random nature of Lyonization, 20-40% of haematologically normal samples would be 
expected to have an imbalanced XCIP. To control for constitutive skewing of myeloid 
lineage cells the XCIP of T-cells is also measured. T-cells are derived from the same 
embryonic stem cell as myeloid cells and are more appropriate than other tissues such as 
skin or cultured fibroblasts as a number of studies have indicated that XCIPs are tissue 
specific (Brown et al, 1990; Fey et al, 1992; Gale et al, 1994).
With the use of T-cell control tissue it has become clear that a caveat must be placed 
upon the classification of clonal samples. In one study of 24 haematologically normal 
controls, the results for T-cells and neutrophils differed by 0-13% and 10 out of the 24 
samples showed an imbalanced XCIP in neutrophils (Gale et al, 1994). Therefore a 
difference of 20% between T-cell and neutrophil results was arbitrarily chosen as a further 
requirement for a sample to be classified as clonal.
Several studies have suggested that XCIPs can change with age. In a study of 105 
healthy females, significantly more individuals had an imbalanced XCIP in the elderly 
group (75-96 years) compared to the young group (20-58 years) (Fey et al, 1994). Another 
study showed imbalanced XCIPs in haematologically normal samples in 14/162 (8.6%) 
neonates, 11/67 (16.4%) subject aged 28-32 years and 22/66 (37.9%) females aged 60 years 
or over (Busque et al, 1996). However, these studies are difficult to interpret as they used 
DNA from whole blood for the assays. In a cohort of 80 normal individuals aged 75 years 
and over, 56% had an imbalanced XCIP in the myeloid compartment compared to only 
22% of 94 subjects aged 17-50 years (Gale et al, 1997). The difference between neutrophil 
and T-cell results in the elderly group was greater than the 20% variability previously 
outlined. It was also demonstrated that the imbalanced XCIP associated with age was more 
pronounced in the myeloid lineage than the lymphoid lineage. Therefore, an upper age limit 
for a clonal result from clonality assays of sixty five years of age was arbitrarily chosen to 
exclude patients with age related skewing of the myeloid lineage.
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The XCIP based clonality assays are therefore limited in their use. For patients to be 
entered into a clonality study they must be young females (<65 years), polymorphic for one 
or more assay, and without a constitutively imbalanced XCIP. Individuals who meet this 
criteria are defined as clonal when expression of one allele in the myeloid lineage is less 
than 25% and the difference between T-cell and neutrophil results is greater than 20%.
A technical consideration is also required. To control for incomplete digestion of 
restriction enzymes in the DNA assays two aliquots are prepared for each sample, one with 
and one without the methylation-sensitive restriction enzyme. Comparison of the two 
aliquots allows correction for incomplete digestion.
3.1.7 Drawbacks o f a radio labelled assay
Many of the studies described above used a radioactive isotope to enable 
quantification of clonality results. However, radioactivity is a mutagen, and is therefore 
highly toxic. It is invisible and requires the use of a Geiger counter for detection. Its use 
and disposal are highly regulated due to the hazard it poses to the user and the environment, 
and it is expensive to manufacture. The 32P used in these assays has a short shelf life due to 
the 14.5 day half life of the isotope and is a high energy p-particle emitter. All handling 
must therefore be carried out behind 1cm or more of Perspex shielding to protect the user. 
Visualization may require a number of exposures to autoradiography film to enable reliable 
densitometry, extending the time taken from sample acquisition to accurate result.
The PCR based assays enable the use of fluorescent labels for quantification rather 
than radioisotopes. Fluorescent dyes are less hazardous to the user and the environment, 
and because a shield is not required, their use is less laborious than radioactive isotopes. 
They are less expensive to purchase, store and dispose of than radioisotopes, and the 
electrophoresis step can be automated by the use of an automated genetic analyzer 
eliminating the need for multiple exposures of autoradiography film and densitometry.
3.1.8 Aim
The aim of the work detailed in this chapter was to develop a quantitative, 
fluorescently labelled clonality assay for DNA and RNA samples, and to ensure results 
were reliable and reproducible.
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3.2 Methods and Results
3.2.1 Calculating clonality
All clonality results obtained during this work are expressed as the percentage 
expression of the smaller allele. The first stutter peak was included in calculations for 
HUMARA when there was more than one repeat difference between alleles (see section 
3.22.3). Results used for comparison with radioactive results were obtained in duplicate 
and the results expressed as the mean of the two values.
3.2.2 HUMARA
3.2.2.1 Screen
Patients were screened to determine whether they were informative for HUMARA. 
Previously, this had been achieved by radiolabelled PCR and electrophoresis through 
acrylamide gels. However, after the initial work detailed in this chapter had been carried 
out, the fluorescent system was used. Approximately 200ng of DNA was digested with 5U 
Rsa\ (Roche) and lx buffer L in a final volume of 5pl and incubated for 17 hours at 37°C. 
PCR was then carried out as described in chapter 2 (2.2.7), using the fluorescently labelled 
primer HUM/F (5’FAM) and the unlabelled primer HUM/R (Table 3.1), at an annealing 
temperature of 68°C with Promega reagents, and 2pl PCR product was loaded onto the 
ABB 10 with an injection time of 10 seconds. Informative patients have two peaks on 
electrophoretograms.
3.2.2.2 Radioactive Assay
All radioactive clonality data presented had been previously obtained in the 
laboratory (Gale et al, 1996).
66
Assay Forward primer (5'—>3') Reverse primer (5'—*3')
Fragment Annealing 
Size (bp) Temp (°C)
HUMARA TCCAGAATCTGTTCCAGAGCGTGC GCTGTGAAGGTTGCTGTTCCTCAT Variable 68
IDS (D) GCCCCAAAGAAGGGAGGGTCC TGGAAAAGACCAGCTATACGGAGAATGATC* 160 64
IDS (R) TTTGCGCAGCAAGCAGTGTGCG TGGAAAAGACCAGCTATACGGAGAATGATC* 236 64
Table 3.1
PCR primers and fragment sizes for HUMARA and IDS clonality assays and IDS heterozygosity 
screen.
Both DNA (D = heterozygosity screen) and RNA (R = clonality assay) sizes are shown for the IDS assays as well as 
the appropriate annealing temperature for each PCR reaction. 
f Mismatch primers with mismatched bases underlined
3.2.2.3 Fluorescent assay Optimization
Basic Conditions
To ensure that the fluorescent technique was accurate and reproducible, it was 
important to establish the basic conditions required for the new technology. The assay was 
set up with the same initial parameters as the radioactive assay. For each sample two 
aliquots were prepared for enzyme digestion; one aliquot contained approximately 200ng of 
DNA with 5U Rsa\ (Roche) and lx buffer L, the other aliquot contained approximately 
400ng of DNA and 5U of the methylation sensitive restriction enzyme HpaW (Roche) in 
addition to 5U /foal and lx buffer L. Both aliquots were in a final volume of 5pl and were 
incubated at 37°C for 17h. Rsa\ was used in both aliquots to fragment the DNA and thus 
increase the efficiency of the PCR. Twice the amount of DNA was used in the HpaW 
containing aliquot because HpaW digests non-methylated DNA between the primer 
annealing sites, and thus no PCR product is produced from the active X-chromosome (50% 
of the sample). PCR was then carried out as described in chapter 2 using the fluorescently 
labelled primer HUM/F (5’FAM) and the unlabelled primer HUM/R at an annealing 
temperature of 68°C with Promega reagents (Table 3.1). The first variable condition 
investigated was the number of PCR cycles.
Number o f amplification cycles required
PCR cycles should be kept as low as possible for the HUMARA. Smaller fragments 
are preferentially amplified in a PCR reaction, which could skew clonality results in favour 
of the smaller allele, giving false results; this is of particular importance when the size 
difference between alleles is large (Gale et al, 1996). Also, higher cycle numbers increase 
the intensity of stutter peaks (Kunkel & Bebenek, 2000). Stutter peaks are caused when the 
Taq DNA polymerase makes copying errors as it scans the STR and single units of the 
repeat are lost. This is a rare event, and at low cycle numbers only a small number of extra 
bands can be seen, 3bp smaller than the main band (Figure 3.4). However, stutter can still 
cause problems when the two different alleles are only one repeat unit different in size, 
because in this situation the major stutter peak migrates at the same speed as the smaller 
allele and interferes with the measurement of the allelic ratio.
To test how many PCR cycles were necessary to give peaks within the limits of 
detection of the instrument, 3 DNA samples with differing numbers of repeat units between
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alleles (2, 3 and 5) were digested with Rsa\ only and three separate PCR reactions were 
carried out using the fluorescently labelled forward primer HUM/F (5’FAM) and HUM/R 
for 20, 25 or 30 PCR cycles. Samples were loaded onto the instrument in a mix containing 
1 2jli1 de-ionized formamide, 0.5p.l GS500 TAMRA size standard and ljil of PCR product. 
Samples were then incubated at 95°C for 5 minutes to denature and quenched on ice. An 
injection time of 5 seconds was used and a run time of 22 minutes. The results for each 
sample were similar and displayed the same trend of increasing peak height with increasing 
cycle number. A representative sample (shown in Figure 3.4) had two repeat units between 
alleles and both alleles gave approximately equal peak heights. At 20 cycles the highest 
peak measured approximately 240 fluorescent units (FU), at 25 cycles over 2000FU and at 
30 cycles over 6000FU. The instrument’s detectors become saturated at 7000FU, so 30 
amplification cycles was thought to be too close to the detection limit of the instrument for 
good reliability. The peak height of approximately 240FU seen with 20 cycles is towards 
the lower limit of detection and the base line was not flat. The preferred option was 25 
amplification cycles as this gave a peak height of 2000FU, with is towards the middle of 
the detection range of the instrument and gave a flat base line. However, to minimize the 
number of cycles, and as the previously used radioactive methodology used 20 PCR cycles, 
other conditions were investigated to try to increase peak height without increasing the 
number of amplification cycles beyond 20.
Sample volume and injection time required
The volume of PCR product used and the length of time the DNA is 
electrophoresed onto the capillary (injection time) were investigated for their effect on peak 
height. One DNA sample was used to test the effect on peak height of loading different 
volumes of PCR product onto the instrument. Aliquots of 1, 2 or 5fJ were taken from a 
PCR amplified for 20 cycles. Each aliquot was added to 12jnl de-ionized formamide and 
0.5pl GS500 TAMRA size standard and run on the ABB 10 using an injection time of 5 
seconds. While a small increase in peak height was seen from lpl (approximately 250FU) 
to 2jn! (approximately 300FU), this difference was minor and still gave peak heights close 
to the instrument’s detection limit (Figure 3.5). A DNA volume of 5jnl gave similar results 
to 2pl.
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More significant changes in peak height were obtained by altering the injection 
time. Each DNA sample is loaded onto the polymer by electrophoresis with the capillary 
end in the sample tube. The capillary end is then transferred to a tube containing TBE 
buffer for sample separation. The time allowed for this electrophoresis is termed the 
injection time, and can be altered. Four aliquots containing lpl PCR product from one 
DNA sample were injected for 5, 10, 15 or 20 seconds. A 2-fold increase in peak height 
was seen by increasing the injection time from 5 to 10 seconds (Figure 3.6A) and a smaller, 
but still significant, increase from 10 to 15 seconds. However, no significant difference in 
peak height could be seen between 15 and 20 seconds injection times. A graph of peak 
heights (Figure 3.6B) indicated a plateau effect occurring at an injection time of greater 
than 15 seconds, suggesting a factor had become rate limiting. This may be because most of 
the DNA sample had been electrophoresed out of the loading solution, so increasing the 
injection time further would not increase the amount of DNA loaded onto the capillary.
Increasing both the DNA amount and the injection time may overcome this 
problem. Three aliquots containing lpl PCR product from one DNA sample were injected 
for 5, 10 or 15 seconds and a fourth aliquot, containing 2pl PCR product was injected for 
15 seconds. With a 15 second injection time an increase in peak height was seen with 2pl 
PCR product compared to lpl, suggesting that the entire sample had indeed been 
electrophoresed onto the capillary using only 1 jul of PCR product and a high injection time 
(Figure 3.7). However, the height of the peaks was still too near the lower limit of detection 
to ensure results would be accurate and reproducible. To ensure sufficient PCR product was 
obtained, PCR amplification were increased from 20 to 22 cycles, and 2pl of PCR product 
was used with an injection time of 10 seconds.
3.2.2.4 Test Samples
After establishing initial running conditions for the HUMARA it was important to 
ensure that, not only did these conditions give reproducible results, but also that they were 
comparable with previously obtained radioactive results. The HUMARA was carried out on 
a set of 25 samples which included 7 neutrophil samples from AML patients and 18 DNA 
samples from normal controls. All 25 samples had previously been assayed by radioactive 
HUMARA and were chosen because their clonality results covered the entire range of 
results possible, from 0% to 100% lower allele. Two aliquots of each DNA sample were 
digested with either Rsa\ alone or both Rsa\ and HpaW in buffer L (Roche) in a final
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volume of 5fxl for 17 hours at 37°C. PCRs were then set up as outlined in chapter 2 (2.2.7) 
using primers HUM/F and HUM/R and the 5pi digest reaction as DNA template. Reactions 
were incubated without Taq 95°C for 5 minutes, followed by addition of 5U Taq (Promega) 
and 22 amplification cycles at an annealing temperature of 68°C. After amplification a 2pl 
aliquot of PCR product was added to 12pl de-ionised formamide containing 0.5pl GS500 
TAMRA size standard and loaded onto the ABB 10 genetic analyser with an injection time 
of lOsec. Duplicate results were obtained for each sample and compared for reproducibility. 
The mean of the two duplicates was calculated and compared with previously obtained 
radioactive data for each sample.
The mode difference between duplicate results of the 25 samples was 0%, the mean 
difference 1.3%, and the median difference was 1%. The difference between duplicate 
results ranged from 0% to 4% (Figure 3.8A, Table 3.2). Correlation coefficients were high 
at r=0.998 and 1^=0.996. The mean of the duplicate results obtained using the fluorescent 
HUMARA were compared to results obtained on the same set of samples using radioactive 
HUMARA. The mode difference between results from each HUMARA methodology was 
0%, the mean difference was 3.5%, and the median difference was 3%. Differences 
between each result ranged from 0% to 10% (Figure 3.8B, Table 3.2). Values for r and r2 
were 0.992 and 0.983 respectively. These data showed that the fluorescent HUMARA is 
highly reproducible between multiple assays of the same sample and also that the results 
obtained by fluorescent HUMARA were equivalent to those obtained by radioactive 
HUMARA.
3.2.2.5 ET Clonality Comparisons
As the results from the test samples compared accurately with previous radioactive 
results, the HUMARA was tested for reproducibility and comparison to radioactive data in 
18 ET patients. The HUMARA was carried out as described above using DNA obtained 
from the neutrophils (test tissue) and T-cells (control tissue) of the 18 ET patients. As for 
the test samples, duplicate results were obtained and the mean of the 2 results compared to 
radioactive data.
The mode difference between duplicates was 1%, the mean difference was 3.1% 
and the median difference was 2%. The percentage difference between duplicate results 
ranged from 0% to 22%, and the correlation coefficients were r=0.980 and r2=0.960 (Figure 
3.9A, Table 3.3). The result which had a difference of 22% between duplicates in the
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Figure 3.8  
H U M A R A  : G raphic com parison o f test sam ple results
(A) - comparison o f the lower allele percentage for duplicate runs o f each sample
(B) - comparison o f fluorescent data to previously obtained radioactive data
Sample First run 
% lower 
allele
Second run 
% lower 
allele
Fluorescent 
average % 
lower allele
Radioactive 
average % 
lower allele
Percentage difference between 
average fluorescent and 
radioactive results
1 69 68 69 75 6
2 29 31 30 30 0
3 73 73 73 80 7
4 72 73 73 81 8
5 40 43 42 44 2
6 49 47 48 46 2
7 29 29 29 23 6
8 44 42 43 33 10
9 53 50 52 55 3
10 46 46 46 47 1
11 36 34 35 32 3
12 56 58 57 60 3
13 45 44 45 42 3
14 62 60 61 67 6
15 59 61 60 65 5
16 25 22 24 21 3
17 72 70 71 76 5
18 64 65 65 68 3
19 86 86 86 91 5
20 100 100 100 100 0
21 0 0 0 0 0
22 0 0 0 0 0
23 76 80 78 85 7
24 0 0 0 0 0
25 100 100 100 100 0
Table 3.2 
HUMARA assay test data
Table showing the two HUMARA results for each sample, 
their averages and comparitive radioactive data
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Figure 3.9  
H U M A R A  : G raphic com parison o f  ET sam ple results
A - comparison o f the lower allele percentage for duplicate results o f each sample 
B - comparison o f fluorescent data to previously obtained radioactive data
oo
Fluorescent assay Radioactive assay
Sample Cell First Second Mean Mean Difference Difference
Number type run % run % % lower T-N % lower T-N between between
lower lower allele allele means T-Ns
allele allele
1 T 54 52 53 55 2
N 63 64 64 11 66 11 2 0
2 T 64 66 65 65 0
N 73 73 73 8 73 8 0 0
3 T 48 51 50 52 2
N 41 42 42 8 36 16 6 8
4 T 64 67 66 73 7
N 18 23 21 45 15 58 6 13
5 T 40 40 40 40 0
N 36 37 37 3 35 5 2 2
6 T 69 70 70 72 2
N 75 77 76 6 79 7 3 1
7 T 35 35 35 33 3
N 80 80 80 46 81 45 1 1
8 T 62 61 62 64 2
N 100 100 100 38 100 36 0 2
9 T 59 57 58 55 3
N 39 35 37 21 41 14 4 7
10 T 37 38 38 39 1
N 29 30 30 8 31 8 1 0
11 T 37 34 36 35 1
N 42 41 42 6 41 6 1 0
12 T 16 18 17 21 4
N 36 35 36 19 36 15 0 4
13 T 100 100 100 100 0
N 100 100 100 0 100 0 0 0
14 T 24 29 27 30 3
N 19 10 15 12 15 15 0 3
15 T 50 53 52 50 1
N 79 77 78 26 74 24 5 2
16 T 59 48 54 60 6
N 37 15 26 28 26 34 0 6
17 T 56 56 56 41 15
N 11 0 6 50 0 41 6 9
18 T 17 10 14 19 5
N 51 45 48 34 47 28 1 6
Table 3.3
HUMARA: Clonality test data for the ET samples
Table showing the two results for each sample and the equivalent 
radioactive results. T=T-cells, N=Neutrophils 
T-N=Difference between T-cells and neutrophils
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neutrophil fraction gave a mean neutrophil value that exactly matched the radioactive data 
(Table 3.3 number 16). Therefore, this sample was not investigated further. These data 
show that the fluorescent HUMARA is highly reproducible in ET patients. The results 
obtained by the fluorescent HUMARA compared well to results obtained by radioactive 
HUMARA. The mode difference between the fluorescent and radioactive data sets was 0%, 
the mean difference was 2.6%, and the median difference was 2%, range 0-15% (Figure 
3.9A, Table 3.3). Values for r and r2 were 0.987 and 0.974 respectively. Using the criteria 
of greater than 75% expression of one allele and more than 20% difference between T-cell 
and neutrophil results, twelve of the 18 ET patients tested were polyclonal by radioactive 
assay, 5 were clonal and 1 was uninterpretable due to an imbalanced XCIP in the T-cell 
fraction. All 18 ET patients tested by fluorescent HUMARA had the same clonality 
outcome as that obtained by the radioactive method. These data show that the mean of the 
duplicate results obtained by fluorescent HUMARA are equivalent to results obtained by 
radioactive HUMARA in ET patients.
3.2.3 IDS assay
Clonality assays which use RNA as the sample material can often be used when 
individuals are not informative for the DNA assays. They can also be used to confirm 
results obtained by DNA methods. Therefore, development of fluorescent RNA clonality 
assays was desirable. RNA based clonality assays use direct measurement of gene 
expression to establish a clonality result, and of the five RNA assays available (IDS, p55, 
G6PD, FHL and BTK), the IDS assay was studied because the polymorphism has a 
widespread distribution in the general population and the assay gave reliable, reproducible 
results as a radioactive assay. As all the RNA based clonality assays use the same 
methodology, i.e. a PCR reaction followed by a restriction enzyme digestion of the PCR 
product, the optimized conditions required for the IDS assay should apply to all the other 
RNA assays.
3.2.3.1 Screen
DNA was used to screen samples for the IDS polymorphism. Patients polymorphic 
at the IDS locus were identified by RFLP analysis. Thirty five cycles of PCR were carried
80
out with 0.5pl of DNA using primers IDS/FD and IDS/RB (Table 3.1) at an annealing 
temperature of 64°C with Bioline reagents. A digestion reaction containing lOpl of PCR 
product, 5U Bell and lx  buffer 3 (NEB) was incubated at 50°C for 4 hours prior to 
electrophoresis on 3% agarose gel to identify heterozygotes for the C to T polymorphism in 
codon 146 o f the IDS gene. T containing alleles were digested tol30bp and 30bp products. 
C containing alleles remained undigested at 160bp.
3.2.3.2 Radioactive assay
All radioactive clonality data presented had been previously obtained in the 
laboratory (Harrison et al, 1998a).
3.2.3.3 Fluorescent assay Optimization
Basic Conditions
As with the HUMARA assay, the initial emphasis was directed at obtaining a peak 
height within the limits of detection o f the instrument. Only PCR cycle number was studied 
as appropriate injection times and loading volumes had been previously established during 
the optimization of the HUMARA. Neutrophil RNA from three haematologically normal 
control subjects was used to generate RT-PCR products. An RT reaction was set up as 
described in chapter 2 (2.2.6). PCR was carried out as described in chapter 2 (2.2.7) using 
2pl RT reaction, at an annealing temperature o f 64°C with primers IDS/FR (5’ FAM 
fluorescent label) and IDS/RB (Table 3.1) to produce a product of 232bp. Primers were 
designed to so that RT-PCR product spanned an intron/exon boundary. This would enabled 
contaminating DNA to be detected due to its increased size compared to the RNA product. 
Separate PCR reactions were carried out for each sample at 20, 25 and 30 cycles. Two pi 
PCR product was added to 12(4.1 de-ionized formamide and 0.5pl GS500 TAMRA size 
standard and loaded onto the ABB 10 with an injection time of 10 seconds and a run time of 
19 minutes.
The initial objective was simply to obtain a clean PCR product with a peak height 
within the detection limits of the instrument, so initially samples were not digested. If any 
problems were experienced this would help to identify the cause, i.e. whether they were 
related to the PCR reaction or to the digest conditions.
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The results for each sample were similar and displayed the same trend of increasing 
peak height with increasing cycle number. A representative sample is shown in Figure 3.10. 
Twenty cycles produced a very small peak of approximately 200bp and nearly 200FU in 
height. Results were further complicated by high background and the presence of a spurious 
peak which was more rounded than the IDS peak, but of similar height and size, and would 
therefore interfere with quantification. Thirty cycles saturated the detector, the IDS peak 
had a flat top (indicative o f saturation) and a number of smaller, less intense, spurious 
peaks were evident. However, 25 cycles gave a large peak of approximately 7000FU, 
unsaturated, but very close to saturation point. While even here there were a number of 
spurious peaks, they were tiny in relation the IDS peak and should not interfere with 
quantification. Because the effects o f the restriction enzyme digestion on peak height were 
unknown at this point, 25 cycles were chosen as an appropriate starting point.
3.2.3.4 The effect of enzyme digestion on peak height
The effect of enzyme digestion on peak height was investigated. PCR products were 
generated from each of 3 neutrophil samples, as described above, using 25 amplification 
cycles. To an enzyme digestion reaction containing 5U Bell and lx buffer 3 (NEB), 15pl of 
PCR product was used in a total volume of 18pl. The reaction was incubated at 50°C for 4 
hours. T containing alleles were digested to 206bp and 30bp products. C containing alleles 
remained undigested at 236bp. Two pi each of the digestion reaction and the undigested 
PCR product were added to separate aliquots of 12pl de-ionized formamide and 0.5pl 
GS500 TAMRA size standard. Samples were then loaded onto the ABB 10 with 10 seconds 
injection time and 19 minutes run time.
Digestion of the PCR product had a profound effect on the peak height (Figure 3.11 
- the blue peaks are from the PCR product while the red peaks are from the GS500 
TAMRA size standard used to accurately size the PCR product peaks). In spite of peak 
heights in excess of 3000FU for undigested PCR product, the peak height after digestion 
was reduced to only 600FU. There was concern that the DNA may be degrading during the 
enzyme reaction because the optimal temperature for Bell digestion is 50°C. Also the 
digestion is carried out under higher salt conditions than the PCR and this may affect the 
efficiency with which DNA is electrophoresed onto the capillary. The final salt
82
Number of 
amplification cycles 20 25 30
600 “ 6 0 0 0 -
400 - 4000 -
200 -
. .  . h
2 0 0 0 “
o - o -
Sample peaks 
Spurious peaks
TT
I
6000 -
4000 -
2000 -
0 - |
t t t t Tr
Figure 3.10  
ID S : The effect o f  increasing PC R  cycles on peak height
Black arrows indicate spurious peaks which affect quantification when peak height is low, but 
are negligible with higher peaks. Correct IDS peak at 236bp is indicated by a red arrow.
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IDS : Effect o f  Bell d igestion on the peak height o f fluorescently labelled IDS PC R  product
GS500 size standard peaks are shown in red, sample peaks are blue. A spurious peak is visible in the untreated 
PCR product at around 200bp.
concentrations for the enzyme digestion are lOOmM NaCi and lOmM MgC^ compared to
the salt in the PCR reaction of 16mM (N H ^SC^ and ImM MgC^.
To test the effect of the high incubation temperature and salt concentration on peak 
height, one neutrophil sample was treated in six different ways prior to loading onto the 
instrument: (a) PCR product digested for 1 hour, (b) PCR product digested for 2 hours, (c) 
PCR product digested for 4 hours, (d) PCR product, (e) PCR product incubated at 50°C for 
4 hours and (f) PCR product incubated under digestion reaction conditions for 4 hours, but 
in the absence of enzyme (Figure 3.12). The PCR product (d) had a peak height of over 
3000FU. Incubation of the PCR product at 50°C for 4 hours (e) had no effect on peak 
height. All 4 samples (a-c, f) that were incubated at the high salt conditions of the digestion 
reaction showed a reduction in peak height to less than 1000FU, irrespective of incubation 
time or presence of enzyme. This suggested that the reduction in peak height following 
digestion was due to the high salt content of the digest reaction conditions rather than the 
high incubation temperature.
The QIAquick PCR purification kit (Qiagen) was used to remove the excess salt 
from the restriction enzyme reaction. This kit uses silica-membrane spin columns that bind 
DNA under high salt and low pH conditions. Five volumes of the binding buffer PB were 
mixed with the restriction enzyme digest prior to loading onto a spin column. The column 
was centrifuged at 18,000g for 30 seconds. The columns were then washed by addition of 
0.75ml of wash buffer PE to the column and centrifuged at 18,000g for 30 seconds. The 
wash buffer flow through was discarded and the column centrifuged for a further minute at 
18,000g. The DNA was eluted from the column by addition of 30pl of water to the centre 
of the membrane. The column was incubated at room temperature for 1 minute, and 
centrifuged for 1 minute at 18,000g to elute the DNA.
One neutrophil sample and one T-cell sample were used to evaluate the clean-up
system. PCR products were generated using 25 cycles of amplification and digested as as 
previously described. A 2pl aliquot of the digestion product was loaded onto the instrument 
without any further treatment. The remaining digest reaction was cleaned using the 
QIAquick PCR purification kit prior to loading. The product peaks from un-cleaned 
aliquots were approximately 200FU and 700FU for T-cells and neutrophils respectively 
(Figure 3.13). A number of spurious peaks were also evident, some of which may interfere 
with quantification. However, use o f the clean-up prevented the reduction in peak height
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IDS : Effect o f Bell d igestion  conditions on peak height.
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IDS : E ffect on peak height o f  rem oving salt from  digested  sam ples.
Large spurious bands are indicated by black arrows, IDS peaks are indicated by red arrows
seen after digestion. The 2 samples that had been cleaned both had highest peak heights in 
excess of 4000FU, and while spurious peaks were still present, they were small and 
unlikely to interfere with quantification.
3.2.3.5 Reproducibility o f the IDS assay
After establishing the basic criteria for the IDS clonality assay, it was important to 
determine that it was reliable and reproducible. The IDS assay was carried out on a set of 
10 patients with a thrombocytosis. The 10 patients had previously been studied by 
radioactive IDS assay or HUMARA, and were chosen because their previous clonality 
results represented a range of results from 0% lower allele to 100% lower allele. PCR 
products were generated from neutrophil, T-cell and platelet RNA for each of the 10 
patients giving a total of 30 samples. PCR was followed by digestion with Bell as 
previously described. After 4 hours incubation at 50°C, excess salt was removed from the 
digest reaction using the QIAquick PCR purification kit as described above. A 2pl aliquot 
of PCR product was added to 12pl de-ionized formamide and 0.5pl GS500 TAMRA size 
standard and loaded onto the ABI310 genetic analyser with an injection time of 10 seconds. 
Duplicate results were obtained from each sample and the two results were compared to 
establish reproducibility. The mean difference between duplicate results was 2.4%, with 
mode difference 2% and median difference 2%, range 0-10% (Figure 3.14 A, Table 3.4). 
The correlation coefficients between the 2 duplicate results were r=0.994 and r2=0.989. 
These data demonstrate the high level of reliability of the fluorescent IDS for these test 
samples.
Data obtained from neutrophils and platelets were also compared. As the MK 
lineage is expanded in ET, measurement of XCIPs in platelets provides a direct measure of 
the XCIP of the affected cell lineage. As platelets are anucleate, only RNA assays can 
directly measure their XCIP. DNA assays use neutrophils to measure clonality of the 
myeloid cell lineage as neutrophils and MKs are derived from a common myeloid 
progenitor. RNA assays can be used to establish whether neutrophils are a valid tissue to 
use to measure clonality in ET, as a comparison between XCIP results for neutrophils and 
platelets can be made. The mean difference between neutrophil and platelet XCIP results 
for the 10 patients was 3.7%, with mode difference 4% and median difference 3.5%, range 
0-10% (Figure 3.14 B, Table 3.4). Values for r and r2 were 0.991 and 0.983 respectively. 
This data suggests that the XCIP of the neutrophil sample is representative of the XCIP in
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IDS C om parison G raphs
(A) - comparison o f the lower allele percentage for duplicates o f each sample
(B) - comparison o f results obtained for neutrophils and platelets
(C) - comparison o f results obtained by DNA HUMARA and RNA IDS for each sample
oo'O
Sample Cell
Type
First run 
% lower 
allele
Second run 
% lower 
allele
Mean 
% lower 
allele
Difference
between
means
T-N T-P
Difference 
between 
T-N and T-P
1 T 38 38 38 0
N 34 30 32 4 6 2
P 41 42 42 1 4
2 T 45 47 46 2
N 63 65 64 2 18
P 59 61 60 2 14 4
3 T 9 19 14 10
N 0 0 0 0 14
P 0 0 0 0 14 0
4 T 77 71 74 6
N 100 100 100 0 26
P 100 100 100 0 26 0
5 T 2 2 2 0
N 3 2 3 1 1
P 8 3 6 5 4 3
6 T 43 41 42 2
N 40 45 43 5 1
P 36 41 39 5 3 2
7 T 24 23 24 1
N 27 25 26 2 2
P 26 21 24 5 0 2
8 T 39 34 37 5
N 6 4 5 2 32
P 0 0 0 0 37 5
9 T 80 79 80 1
N 100 97 99 3 19
P 92 90 91 2 11 8
10 T 53 51 52 2 1
N 55 57 56 2 4
P 56 54 55 2 3 1
Table 3.4
IDS clonality test data
Table showing the two IDS results for each sample, the average result 
and the difference between the two results 
T=T-cells N=neutrophils P=platelets 
T-N=Difference between T-cell and neutrophil results 
T-P=Difference between T-cell and platelet results
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platelets for patients with a thrombocytosis, giving validity to the assumption that 
neutrophils can be used as a measure of XCIP in the megakaryocytic compartment in ET 
patients.
3.2.4 Comparison o f DNA and RNA clonality results
DNA and RNA clonality assays should give equivalent results. The average of 
duplicate HUMARA and IDS assay results were examined to ensure this was the case. The 
results from a total o f 18 individuals were used. Of the 18 individuals 9 were ET patients, 6 
were normal controls and 3 were patients with a reactive thrombocytosis.
HUMARA and IDS assay results from 9 ET patients were obtained, generating 17 
comparisons from 8 T-cell results and 9 neutrophil results. The mean difference between 
HUMARA and IDS assay results for ET patients was 7.2%, and the median difference was 
6%, range 0-22% (Figure 3.14 C, Table 3.4). Values for r and r2 were 0.95 and 0.90 
respectively. O f the 9 patients studied 2 were clonal, 4 were polyclonal and 2 were 
uninterpretable by both HUMARA and IDS assay. The remaining patient could only be 
analysed by neutrophils at both RNA and DNA levels and thus clonality could not be 
established by either HUMARA or IDS assay due to the lack of control tissue results. 
However, this patient had only a 1% difference between HUMARA and IDS assay results. 
In this cohort of nine patients, DNA results by HUMARA are equivalent to RNA results by 
IDS assay.
HUMARA and IDS assay results from 6 haematologically normal control subjects 
were obtained, generating 12 results for comparison, 6 from T-cells and 6 from neutrophils. 
The mean difference between DNA and RNA results was 3.5% and the median difference 
was 4.8%, range 1-11%. Correlation coefficients were r=0.96 and r2=0.91. All normal 
controls were either polyclonal or uninterpretable due to an imbalance XCIP in both T-cells 
and neutrophils, by both HUMARA and IDS assay.
Overall 16 T-cell results and 18 neutrophil results were obtained from both 
HUMARA and IDS assay for the 18 individuals studied. The mean difference between 
DNA and RNA results was 6.3% and the median difference was 5.5%, range 0-22%. 
Correlation coefficients were r=0.95 and ^=0.90.
These data confirm the accuracy of results obtained by both the HUMARA and IDS 
assays as differences between XCIP results obtained from them are low, the two sets of
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results have correlation coefficients greater than 0.9, and both assays give the same 
clonality outcome for both patients and normal controls.
3.3 Discussion
The use of fluorescently labelled PCR primers has become feasible in the research 
laboratory due to their wide availability and falling costs. They have begun to replace 
radioactive isotopes as they have a number of advantages over them. However, to replace 
radioactive isotopes in established clonality assays it was important to ensure that reliable, 
reproducible results could be achieved using fluorescent primers and an automated genetic 
analyser. By establishing appropriate conditions for fluorescent clonality assays, and by 
comparison of clonality data obtained by fluorescent technology with previously obtained 
data using radioactive technology, this could be determined.
HUMARA assay
The basic conditions for the use of HUMARA were established as 22 PCR cycles 
with a 15 second injection time and a PCR product volume of 2pl. These conditions gave a 
peak height within the detection limits of the ABI310 genetic analyser, and results that 
were reliable and reproducible
IDS assay
The basic conditions of the IDS assay were established as 25 PCR cycles with 15 
seconds injection time and a sample volume of 2pl. While restriction enzyme digestion 
reduced the peak height to very low levels, this was shown to be due to the high 
concentration of salt in the digest reaction. Peak height equivalent to the original PCR 
products was restored after removal of the excess ions with a PCR clean-up kit. The 
negatively charged ions in the digest reaction are a problem because they carry the same 
charge as DNA, but as they are much smaller molecules than the DNA of the digest 
product, they are more readily electrophoresed onto the capillary. Thus, although the 
amount of digest product in the loading solution may be high, it is mainly the cationic salts 
that are loaded onto the capillary during the injection of the sample. As the salt 
concentration of a PCR reaction is lower than in an enzyme digest, this problem was not so
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evident with the HUMARA. Once a clean up protocol was used, results became reliable 
and reproducible.
A good correlation could also be demonstrated between RNA and DNA results 
obtained by fluorescent and radioactive techniques. Results obtained from 36 samples, 
assayed by both HUMARA and IDS, showed a good correlation with r=0.950 and r^O.903. 
The clonality results were the same using either RNA or DNA based assays, and whether 
using neutrophils or platelets as the test tissue.
As the peak height between different samples is variable depending on the starting 
amount of DNA or RNA, it was important to define a set of criteria that needed to be met 
before a clonality result could be accepted. After gaining some experience with the 
technique it was decided that the following criteria must be met in order for the clonality 
result to be accepted.
1: The height o f the highest peak must be greater than 1,000FU
2: The overall clonality result should be based on the average of two results, and as 
result variability can be as high as 20%, the duplicate results should be within 10% of one 
another.
3: If the first criteria is not met, then the result can be accepted if one result has a 
highest peak height of over 1,000FU, and the second result is within 10% of the first, 
without the presence of spurious peaks which may interfere with quantification.
Accurate, reproducible quantitative fluorescently labelled HUMARA and IDS 
assays can be carried out by following the above criteria. Results which are equivalent to 
the previously used radioactive technique can be obtained, but without the problems 
associated with the handling of radioactive isotopes. All the other PCR based clonality 
assays in common usage can also be carried out using the techniques described above, but 
with the PCR primers and restriction enzymes appropriate to that assay.
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Chapter 4
Clonality in Essential Thrombocythaemia
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4.1 Introduction
4.1.1 Clonality in E T
The World Health Organization describes ET as a clonal disorder, caused by one or 
more unknown, acquired alterations in a haemopoietic stem cell leading to an expansion of 
the MK compartment (Pierre et al, 2001). This view stems from the first clonality study of 
ET patients using the G6PD isozyme assay (Fialkow et al, 1981). As no molecular markers 
have yet been identified for ET and the proportion of patients with cytogenetic 
abnormalities is small, clonality in ET patients cannot be evaluated directly. However, 
clonality can be assessed in female ET patients using XCIPs. In the Fialkow study, both the 
A and B form of G6PD were present in non-haemopoietic tissue obtained from two patients 
with a diagnosis of ET, and one patient with a probable diagnosis of ET. However, only 
one isoform could be found in the MK, red cell and granulocytic cell lineages, indicating 
that ET was clonal and arose from a multipotent haemopoietic stem cell. Another study 
used Epstein-Barr Virus-transformed lymphoblastoid cell lines derived from one ET patient 
to show a clonal pattern of cell growth (Raskind et al, 1985); 104 of 109 EBV cell lines 
monotypic for G6PD isozyme carried the enzyme type of the abnormal stem cell clone, 
indicating a largely clonal cell population. A third study used PGK and HPRT Southern 
blot assays to study clonality in ET (Anger et al, 1990). Three out of four patients displayed 
a predominantly clonal pattern in peripheral blood samples. One of the three was further 
investigated and demonstrated a clonal granulocyte fraction and a non-clonal T-lymphocyte 
fraction.
The studies described above are limited in their usefulness. They used small 
numbers of patients (just 8 patients in total from the three studies), did not exclude patients 
due to age, and either used none or inappropriate control and/or test material. As described 
in chapter 3 (3.1.6) a number of exclusion criteria must be applied to XCIP assays. T-cell 
control tissue must be used as a reference to control for a constitutively imbalanced XCIP, 
and the difference between T-cell and neutrophil results should be greater than 20%. Also, 
samples should be from individuals less than 65 years of age to eliminate age related 
skewing. As more groups investigated clonality in larger ET cohorts and used appropriate 
exclusion criteria, it became obvious that a proportion of ET patients do not have a clonal
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disorder. The results of these studies are summarized in Table 4.1. The earliest of these 
studies showed that a proportion of female ET patients interpretable by XCIP analysis 
(10/29, 34%) appeared not to have clonal myelopoiesis (el Kassar et al, 1997). Another 
study showed that in 46 patients only 23 were interpretable by XCIP, and of those 10 (43%) 
were clonal and 13 (57%) were polyclonal by DNA and RNA XCIP analysis (Harrison et 
al, 1999a). This data was confirmed by other groups with the percentage of clonal patients 
within the ET cohorts varying from 43% to 67% (Liu et al, 2003; Teofili et al, 2002a). The 
largest study investigated clonality in 88 interpretable ET patients, 53 (60%) patients had 
clonal myelopoiesis and 35 (40%) had polyclonal myelopoiesis (Vannucchi et al, 2004). 
When taken together, these studies clearly demonstrate that ET patients can be divided into 
two groups based on clonality status, those with a clonal disorder and those with a 
polyclonal disorder. Of the 245 ET patients studied in total, 146 (60%) had clonal 
myelopoiesis and 99 (40%) had polyclonal myelopoiesis.
4.1.2 Significance o f Clonality Status in ET
To further characterize the 2 groups of ET patients, a number of studies have 
compared clonality with the clinical features associated with ET. In a study of 46 ET 
patients, 23 were un-interpretable due to a constitutively imbalanced XCIP in T-cell control 
tissue or because they had a clonal XCIP but were greater than 65 years of age. Of the 
remaining 23, 10 were clonal and 13 were polyclonal by DNA and RNA XCIP analysis 
(Harrison et al, 1999a). No difference between the clonal or polyclonal groups could be 
found in age, platelet count at diagnosis, incidence of hepatomegaly or splenomegaly, or 
haemorrhagic complications. However, there was a significant association between clonal 
myelopoiesis and the incidence of thrombosis. Six of the 10 clonal patients (60%) had had 
thrombotic events compared to 2/13 (15%) polyclonal patients (p<0.039).
Three other groups have reproduced this data. The first of these described a cohort 
of 40 ET patients in which 32 were informative and interpretable for DNA-based 
HUMARA XCIP analysis or RNA-based IDS or p55 analysis (Chiusolo et al, 2001). A 
significant correlation was found between clonal myelopoiesis and an increase in 
thrombotic risk, 7 (41%) out of 17 clonal patients had had a thrombotic event, compared to
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Study *n Clonal
Patients
Polyclonal
Patients
(el Kassar et al, 1997)# 29 19(66%) 10(34%)
(Harrison et al, 1999a) 23 10 (43%) 13 (57%)
(Ferraris et al, 1999)+ 13 6 (46%) 7 (54%)
(Chiusolo et al, 2001) 32 17(53%) 15 (47%)
(Shih et al, 2002) 48 33 (69%) 15(31%)
(Teofili et al, 2002a) 12 8 (67%) 4 (33%)
(Liu et al, 2003)^ 12 8 (67%) 4 (33%)
(Vannucchi et al, 2004) 88 53 (60%) 35 (40%)
Total 245 146 (60%) 99 (40%)
Table 4.1 
Clonality studies in ET patients.
* Number of patients interpretable by XCIP analysis
# No exclusion due to age
+ No exclusion due to age or a constitutively imbalanced XCIP 
^SSCP transcriptional clonality assay
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1 (6.7%) of the 15 polyclonal patients (p=0.04). No correlation was found between 
clonality results and age, platelet count at diagnosis, or EEC positivity. In the large cohort 
of a second group, 17/53 (31%) clonal patients had had a thrombotic complication 
compared to 2/35 (6%) polyclonal patients (p<0.009) (Vannucchi et al, 2004). In this 
cohort EEC positivity, increased PRV-1 expression and c-mpl mRNA expression levels 
were also investigated with respect to incidence of thrombosis, but no correlation between 
thrombotic events and any of these markers could be found. Results from a third group did 
not reach statistical significance, with 11/33 (33%) clonal ET patients and 2/15 (13%) 
polyclonal patients having had a thrombotic event (p=0.073), but the results did support the 
trend towards clonal patients being at higher risk of thrombotic events (Shih et al, 2002).
4.1.3 Clonality status and disease progression
Why ET patients can have either a clonal or polyclonal disorder, but still present 
with similar symptoms is unclear. Clonality may define two distinct ET subgroups which 
present with similar symptoms, but have different underlying defects and are 
phenotypically distinct, at least in relation to thrombotic risk. Clonal ET may represent a 
low grade malignant disorder and polyclonal ET a dysregulation of platelet production due 
to either extracellular stimulatory facts such as raised levels of cytokines, or an intrinsic 
hyper-responsiveness to such stimuli. However, it is unknown whether a polyclonal 
disorder can progress to a clonal disorder.
Polyclonal ET may represent an initial phase of ET during which there is excessive 
external drive to megakaryocytopoiesis. Stem cell mutations may then arise which impart a 
growth or survival advantage leading to a clonal proliferation. Secondly, polyclonal ET 
could represent a situation where a hyperproliferating clone is contributory to the platelet 
and myeloid production but is not yet sufficient for the whole population to be deemed 
clonal by XCIP analysis, for this to be true the normal platelet production would not have 
to be subject to end cell negative feedback control. Thirdly, it is possible that a stem cell 
defect could give rise to variable numbers of mature end cells in the different lineages. 
Thus it is conceivable that a mutated stem cell could contribute to nearly all the platelet 
pool without contributing greatly to the neutrophil pool, these being largely derived from 
residual normal stem cells
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4.1.4 Technical considerations
In spite of the large number of studies describing polyclonal ET there is still 
controversy concerning the high proportion of polyclonal patients, and some questions 
remain over technical aspects of the assays. Hypermethylation is a common feature of 
neoplasia, and has often been reported in gene promoter regions, where it can suppress gene 
transcription (Herman & Baylin, 2003). It has also been shown to occur in some genes from 
patients with each of the cMPDs. The promoter region of the calcitonin gene has been 
shown to be highly hypermethylated in cIMF, and to a lesser degree in PV and ET 
(Ihalainen et al, 1994). In CML the promoter region of JunB was hypermethylated in all 32 
patients studied, with no hypermethylation evident in 17 controls (Yang et al, 2003). More 
recently, the RARp2 gene promoter was shown to be hypermethylated in CD34+ cells from 
89% (16/18) of cIMF patients compared to methylation levels observed in any of the 9 
control CD34+ samples (Jones et al, 2004). These studies suggest that hypermethylation 
could occur in ET and therefore may affect results of clonality studies which exclusively 
use DNA based assays.
The majority of ET clonality publications have made use of the DNA-based 
HUMARA which relies on digestion of unmethylated DNA to distinguish between the 
active and inactive X-chromosomes. Technical problems may arise if hypermethylation 
occurs at the CpG island in the HpaW recognition sequence of the HUMARA PCR product. 
Methylation patterns can be heterogeneous and it has been shown that one of the HpaW 
sites at the DXS255 locus, identified by the M27p probe, can be variably methylated. In 37 
haematologically normal females there was a mean of only 67% digestion at the DXS255 
locus using HpaW, but digestion with a second methylation-sensitive restriction enzyme, 
Hhal, with different cutting sites at the same locus, had a mean 95% digestion (Gale & 
Linch, 1994b). However, in this case the variable methylation did not affect the clonality 
results as the correlation coefficient between XCIP results using HpaW and Hhal digestion 
was 0.97, suggesting that methylation occurred at the same rate on each allele. In an 
extreme situation of hypermethylation, some of the active alleles from patients with a 
completely monoclonal XCIP would become methylated, and would not be digested by 
methylation-sensitive enzymes. This could lead to the XCIP from a patient with clonal 
myelopoiesis having a balanced XCIP, as PCR product would be generated from alleles 
methylated due to hypermethylation as well as from alleles methylated due to X- 
chromosome inactivation (Figure 4.1). This would only affect results obtained using DNA
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Figure 4.1 
The effect o f  hyperm ethylation on clonality results using DNA and RNA based assays
(A) -  The results obtained from patients with normal methylation by DNA and RNA clonality assays
(B) -  The results obtained from patients with extreme hypermethylation by DNA and RNA clonality assays 
Percentages in blue represent the percentage o f methylated X-chromosomes. Xa and Xb represent 
maternal and paternally inherited X-chromosomes.
assays, where the amount of inactive (methylated) gene is measured. RNA assays that 
measure active (expressed) genes may see a decrease in expression levels, but the relative 
expression of each allele should remain the same assuming that hypermethylation occurs at 
the same rate on each allele.
4.1.5 Aim
The aim of the work presented in this chapter was to investigate whether clonality 
status changes during the clinical course of ET and whether hypermethylation of the human 
androgen receptor locus is a feature of ET.
4.2 Materials and Methods
4.2.1 Patients and Samples
Peripheral blood samples were obtained from 111 individuals, 100 from females 
and 11 from males. Of the 100 female samples, 92 had a persistent thrombocytosis and 8 
were haematologically normal controls. The 11 male samples had a diagnosis of ET. DNA 
and RNA were prepared from purified CD3+cells and neutrophils, as outlined in Chapter 2 
(2.2.1/2/3).
4.2.2 Heterozygosity at clonality assay loci
Neutrophil DNA from 100 females was screened for heterozygosity of the 
following genes; PGK, IDS, p55, G6PD, BTK and FHL using PCR as outlined in Chapter 2 
(2.2.7). Bioline reagents were used with 35 amplification cycles and the appropriate 
primers and annealing temperatures for each assay as detailed in Table 4.2. Ten pi PCR 
product was digested with appropriate enzyme and buffer, as shown in Table 4.3, in a total 
volume of 12pl. Digestion reactions were incubated for at least 4 hours at the 
manufacturer’s recommended temperature. Samples were then electrophoresed through 3% 
agarose gels except for samples prepared for the PGK screen, where 1.5% agarose gels 
were used. The expected product sizes after digestion are shown in Figure 4.2. As 
heterozygosity at the human androgen receptor locus is over 90% (Edwards et al, 1992),
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Assay Forward primer (5'—>3') Reverse primer (5'—>3')
Fragment Annealing 
Size (bp) Temp (°C)
HUMARA TCCAGAATCTGTTCCAGAGCGTGC GCTGTGAAGGTTGCTGTTCCTCAT Variable 68
PGK AGCTGGACGTTAAAGGGAAG TGTGAGATGTGGGCCGTTTC 474 60
p55 (D) CTCCTCAAAGCAGGCTTCATGCCTG CGTACAGGACTGTTTTTCATTCAGCTTCCG+ 191 64
p55 (R) CACAGAAGAGCCCATGGGAATCGCf CGCCTTCTGCAGCTGATCCAC 178 64
IDS (D) GCCCCAAAGAAGGGAGGGTCC TGGAAAAGACCAGCTATACGGAGAATGATC* 160 64
IDS (R) TTTGCGCAGCAAGCAGTGTGCG TGGAAAAGACCAGCTATACGGAGAATGATC+ 236 64
G6PD (D) ATACAAGAACGTGAAGCTCCCTGACGCGTA* GTGGGTGCCCAGGGCTCAGAG 480 66
G6PD (R) ATACAAGAACGTGAAGCTCCCTGACGCGTA+ GTGGGTGCCCAGGGCTCAGAG 281 66
FHL-1 ATGTTCCTGCAGTGCTGAAATTCATCCTCCf CAGAAGGGACTTTGCAGTCCTC 189 62
BTK (D) TAGGAAGACTAGGACCCCTGC AGATCCTAATAAAGCACTTACCTCATGCIA+ 247 62
BTK (R) GCTCAGTAGGCTCCAAATTTG AGTGGGACGCTCATCTGCTTTCTCATGCIA+ 271 62
Table 4.2 
PCR primers for each of the heterozygosity screens and clonality assays
Expected fragment sizes and appropriate annealing temperatures are shown for each primer pair 
D = Primers for heterozygosity screen R = Primers for RNA clonality assays 
FHL-1 and PGK primer pairs were used for both the heterozygosity screen and clonality assay. HUMARA primers were only 
used for HUMARA clonality assay. 
f Mismatch primers with mismatched bases underlined
oto
Assay Primers
Annealing
temperature
(°C)
Number of 
amplification Cycles
Restriction Buffer used for restriction Incubation
enzyme enzyme digestion temperature
(NEB)_____________ (NEB)_______________ (°C)
p55 p55 (R) forward and reverse 64 28 BstUl 60
G6PD G6PD (R) forward and reverse 66 28 Rsa\ 37
BTK BTK (R) forward and reverse 62 29 Nhel 2 + BSA 37
FHL FHL (R) forward and reverse 62 32 Mspl 37
IDS IDS (R) forward and reverse 64 26 Bell 50
Table 4.3 
Conditions used for the RNA clonality assays
Table showing the basic conditions for the PCR reactions and restriction enzyme digests used in each o f the five 
RNA based clonality assays. Primer sequences are detailed in Table 4.2. R = Primers for RNA clonality assay 
NEB -  New England Biolabs.
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Figure 4.2
The restriction enzym e digestions used to screen for 
heterozygosity at 6 o f  the clonality  assay loci
Diagram showing the enzymes required and digestion product sizes (bp) 
for each RNA clonality assay screen from DNA template. PCR product 
shown in red, products o f  enzyme digestion shown in black.
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samples were not separately screened for this polymorphism. However, heterozygous 
patients could be identified during the HUMARA from the aliquot containing Rsa\ only.
4.2.3 HUMARA assay
DNA clonality results were compared using 3 technologies, radio-labelling of 
primers and acrylamide gel electrophoresis, fluorescent labelling with visualization using 
an ABI Prism™ 310 genetic analyser (ABB 10), or fluorescent labelling with visualization 
using a CEQ™ 8000 genetic analysis system (CEQ8000) (Beckman Coulter). All radio­
labelled HUMARA data had been previously obtained in the laboratory.
HUMARA clonality data was obtained on 4 aliquots from each patient. Neutrophil 
and T-cell DNA were digested as outlined in chapter 3 (3.2.2.3) with either Rsa\ alone or 
both Rsa\ and HpaW. Twenty two cycles of PCR were then carried out on each aliquot, 
using either a 5’ FAM labelled HUM/F primer for the ABB 10 or a DP4 labelled HUM/F 
primer for the CEQ8000, and the unlabelled HUM/R primer (Table 4.2) at an annealing 
temperature of 68°C.
Samples to be analysed on the ABB 10 were prepared by adding 2pl PCR product to 
12pl of de-ionized formamide and 0.5pl GS500 size standard. Samples were incubated at 
95°C for 5 minutes and quenched on ice. The denatured product was then loaded onto the 
ABB 10 genetic analyzer with an injection time of 10 seconds, and electrophoresed at 15 
kV for 24 minutes. These conditions were determined by the optimization carried out in 
chapter 3. Samples to be analysed on the CEQ8000 were prepared by adding 2pl of PCR 
product to 40pl of sample loading solution (SLS) containing 0.5pl of 400PA size standard. 
Samples were run using fragment analysis program Frag 3. Results were analyzed as 
outlined in chapter 3 (3.2.1) and reported as the percentage expression of each allele, with 
the smaller allele quoted first. Each sample was analyzed in duplicate and the results 
expressed as the mean of the two duplicates.
4.2.4 RNA assays
A reverse transcription reaction was carried out as described in chapter 2 (2.2.6) 
using approximately lpg of RNA from T-cells, neutrophils or platelets from each 
informative ET patient. PCR was then carried out as described in chapter 2 (2.2.7), with 
Bioline reagents. The primers used for each assay are given in Tables 4.2 and 4.3. The non
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mis-match primer was labelled with either 5’FAM fluorescent label for use with the 
AB1310 or DP4 label for use with the CEQ8000, and PCR carried out using the appropriate 
number of cycles and annealing temperature detailed in Table 4.3. Samples were incubated 
at 95°C for 5 minutes prior to adding the Taq polymerase to ensure template cDNA was 
completely denatured before carrying out amplification. Ten pi PCR product was added to 
a reaction mixture containing 5U of restriction enzyme and lpl of appropriate buffer (with 
O.lpg/pl BSA if required) (Table 4.3). Each reaction was incubated for at least 4 hours at 
manufacturer's recommended temperature (Table 4.3). The results were visualized using 
either the ABI310 or CEQ8000 genetic analyser.
Samples prepared for analysis on the ABB 10 required the removal of excess salt 
from the restriction enzyme reaction using the QIAquick PCR purification kit (Qiagen) as 
described in chapter 3 (3.2.3.4). After clean up, 2 pi sample was mixed with 12pl de­
ionized formamide and 0.5pl GS500 size standard, incubated at 95°C for 5 minutes and 
quenched on ice. The denatured product was loaded onto the ABB 10 with an injection time 
of 10 seconds, and electrophoresed at 15kV for 20 minutes. When using the CEQ8000, 
digestion products were diluted 1 part PCR product to 2 parts SLS to reduce the salt 
concentration, and 2pl diluted product added to 40pl SLS containing 0.5pl 400PA size 
standard. The mix was then run on the CEQ8000 using fragment analysis program Frag 3 
and results reported as the percentage expression of the lower allele. Each sample was 
analyzed in duplicate and the results expressed as the mean of the two duplicates.
4.3 Results
4.3.1 Incidence o f  heterozygosity at the loci used fo r  clonality assays
Heterozygosity was determined using neutrophil DNA from 100 females at each of 
the polymorphic loci used to study clonality by XCIP analysis, 90% were heterozygous for 
the HUMARA, 37% for PGK, 36% for IDS, 34% for G6PD, 44% for FHL-1, 38% for p55 
and 28% for the BTK assay. Overall, 90% were informative for at least one of the RNA 
assays (Figure 4.3), and of these 60% (54 out of 90) were heterozygous at more than one 
locus. Ninety seven percent were heterozygous for at least one DNA locus, with 30 out of 
97 (31%) heterozygous for both PGK and HUMARA.
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4.3.2 HUMARA results
Of the 92 female patients with persistent thrombocytosis, 80 had a diagnosis of ET 
according to the PVSG criteria. Of these patients 20 were shown to have clonal 
myelopoiesis by XCIP assay, 28 had polyclonal myelopoiesis and 29 were uninterpretable 
due to a constitutively imbalanced XCIP or because they had a clonal pattern and were 
more than 65 years of age. The remaining 3 patients were not informative for XCIP 
analysis. Therefore, 42% of interpretable patients had clonal myelopoiesis and 58% had 
polyclonal myelopoiesis. A representative HUMARA of one clonal and one polyclonal 
patient is shown in Figure 4.4.
Follow-up samples were obtained from 8 patients with clonal myelopoiesis at first 
test and 14 patients with polyclonal myelopoiesis at first test. Median age at first test for the 
clonal cohort was 55 years (range 10 -  61). Between one and 4 additional samples were 
obtained for each patient, median time since first test was 52 months (range 5-97) and mean 
time since first test 44 months. Diagnosis dates were available from 6 out of the 8 patients 
clonal at first test. Both median and mean time since diagnosis was 102 months (range 23- 
252). The polyclonal cohort had a median age at first test of 49 years (range 25 -  84). 
Between one and 5 additional samples were obtained for each patient, median time since 
first test was 54 months (range 10-102), mean time since first test 56 months. Diagnosis 
dates were available from 11 of the 14 polyclonal patients. Mean time since diagnosis was 
99 months and median time since diagnosis was 78 months (range 45-188).
Clonality status did not change during follow up in any of the patients studied 
(Tables 4.4 and 4.5). The XCIPs obtained from neutrophils from all 8 patients clonal at first 
test remained imbalanced at >75% expression of one allele, T-cell results were balanced at 
<75% expression of one allele and the difference between T-cell and neutrophil results 
remained >20%. Median change in neutrophil result was 1.5% (range 0 -1 6 )  (Figure 4.5).
Clonality status remained constant throughout the course of follow up for patients 
polyclonal at first test, and the median change of neutrophil XCIPs was 6% (range 0 -  25) 
for the polyclonal patient cohort (Figure 4.6). However, XCIPs from 4 patients did become 
imbalanced in neutrophil samples during the course of follow up. Patient 9 had a neutrophil 
XCIP result of 74%:26% expression of each allele at first test which changed by 6% to 
80%:20% 48 months later and remained at 80%:20% after 87 months. At the time of first 
test patient 9 was 66 years of age and at last test was 73 years of age, therefore the change 
in neutrophil result could be due to age-related skewing (Gale et al, 1997). However, it is
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Figure 4.4 
R epresentative X C IP from  one clonal and one polyclonal ET patient using the 
H U M A R A  clonality assay
The blue trace represents PCR products and the red trace represents the size standard.
Patient
Number
Cell
Type
XCIP result 
at first test
XCIP results for subsequent tests *
1 2 3 4
1 T 27 31 (61m) 25 (74m) 27(85m) 25 (97m)
N 0 0 4 3 6
2 T 52 57 (53m) 50 (55m)
N 1 100 100
3 T 1 59 (54m)
N 91 89
4 T 56 54 (50m)
N 11 26
5 T 66 55 (17m) 58 (23m)
N 21 22 22
6 T 62 71 (24m)
N 100 84
7 T 40 45 (16m)
N 0 0
8 T 71 68 (5m) 68 (19m)
N 100 100 95
Table 4.4 
HUMARA results for ET patients with clonal 
myelopoiesis at first test by XCIP
All results given as percentage expression o f  the smaller allele 
T = T-cells N = Neutrophils 
*Time from first test (months)
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Patient Cell XCIP result XCIP results for subsequent tests ★
Number Type at first test 1 2 3 4 5
9 T 64 35 (48m) NA (74m) NA (87m)
N 74 80 80 80
10 T 45 53 (43m) 51 (67m) NA (84m) NA (102m)
N 51 64 67 66 68
11 T 70 70 (47m)
N 51 76
12 T 47 48 (56m) NA (86m)
N 47 53 53
13 T 38 40 (39m) 40 (60m) NA (72m)
N 26 37 37 38
14 T 31 14 (38m)
N 46 48
15 T 67 65 (23m) 69 (35m) 63 (55m) 64 (71m) 58 (72m)
N 64 59 62 61 60 60
16 T 65 61 (27m)
N 73 74
17 T 58 60 (25m)
N 37 43
18 T 17 35 (20m) 36 (22m) 38 (37m) 37 (50m)
N 36 19 21 31 23
19 T 39 38 (52m) 38 (69m) NA (85m) 41 (102m)
N 38 30 27 32 33
20 T 41 42 (10m)
N 25 25
21 T 25 NA (34m)
N 19 15
22 T 30 36 (87m)
N 26 27
Table 4.5 
HUMARA results for ET patients with polyclonal 
myelopoiesis at first test by XCIP
All results given as percentage expression o f  the smaller allele 
T = T-cells N = Neutrophils NA = Sample not available 
*Time from first test in months
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more likely that this change represents technical variation. The T-cell results for patient 9 
were <20% different from neutrophils throughout the study, confirming that this patient 
was polyclonal.
The neutrophil XCIP results from patient 11 changed from 51 %:49% expression of 
each allele at first test to 76%:24% 47 months later. However, this change was thought to 
be due to age-related skewing as at the time of last test patient 11 was 77 years of age. 
Also, the T-cell result was 70%:30% expression of each allele in both samples so the 
clonality status remained polyclonal in spite of the 25% change in neutrophil result.
The neutrophil XCIP results of patient 18 were less than 25% expression of the 
lower allele in 3 out of 5 samples studied. Neutrophil results of 36%:64%, 19%:81 %, 
21%:79%, 31 %:69% and 23%:77% expression of each allele were obtained over the course 
of 50 months. The largest change in neutrophil result was 17%, and at no time point was 
the T-cell result >20% different from the neutrophil result. Therefore, clonality results from 
patient 10 were polyclonal throughout the course of follow up. It is possible that a handling 
error may have occurred with this sample. The T-cell result at first test was 17%:83% and 
the neutrophil result 36%:67%. Twenty two months later the T-cell result was 35%:65% 
and the neutrophil result was 19%:81%. All other T-cell results were consistent with the 
second sample, suggesting that the original T-cell and neutrophil samples may have been 
mislabelled.
The neutrophil XCIP results of patient 21 were less than 25% expression lower 
allele at both the original test (19%:81 %) and 34 months later (15%:85%). However, the T- 
cell result for patient 21 at first test was 25%:75%. Therefore, patient 21 had a polyclonal 
myelopoiesis at both first test and after 34 months follow up as the T-cell XCIP was 
balanced and the neutrophil XCIP was less than 20% different from T-cell results.
All other patients with polyclonal myelopoiesis at first test had a balanced XCIP in 
both T-cells and neutrophils throughout the course of the study.
4.3.3 Comparison o f RNA and DNA data
RNA clonality data was obtained from 10 patients with follow-up samples. Of the 
10 patients, 4 were clonal and 6 were polyclonal at first test (Table 4.6). Five of the 10 
patients were analysed at more than one time point resulting in a total of 18 samples being 
analysed by both DNA and RNA. Four of the 18 samples were analysed at more than one 
RNA locus. Therefore, a total of 24 samples were analysed in T-cells and neutrophils by
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(a) Polyclonal
Patient Number Cell Type DNA 1 RNA 1a RNA1b RNA1c DNA 2 RNA 2a RNA2b D N A 3 R N A 3
11 T 70 58 66 70 57 54
N 51 57 55 76 70 77
P 61 48 59 36
12 T 48 49 58 58
' N 53 49 56 56
P 53 65 50
14 T 14 14
N 48 14
P 0
15 T 69 62 62 58
N 62 68 61 69
P 58 41 55
16 T 65 87 61 66
N 73 93 74 75
P 96 86
18 T 17 19 35 25 36 24
N 36 22 19 14 21 12
P 9
(b) Clonal
Patient Number Cell Type DNA 1 RNA 1 D N A 2 R N A 2 DNA 3 RNA 3
1 T 27 2 31 31 25 28
N 0 3 0 0 4 0
P 6 0
3 T 59 98
N 89 88
P 93
5 T 66 15 55 20 58 19
N 21 21 22 20 22 27
P 5 1 4
7 T 45 4
N 0 0
P 4
Table 4.6
Comparison of XCIP results using DNA and RNA clonality assays 
from patients with (a) polyclonal m yelopoiesis and (b) clonal myelopoiesis
All results are given as percentage expression o f the smaller allele 
T = T-cells N = Neutrophils P = platelets
Samples collected at different times from the same patients are numbered 1, 2 or 3 
Samples from one patient assesed by one or more RNA assays are indicated by a, b or c 
The RNA assay used to asses clonality is colour coded:
Green = p55 Red = IDS Blue = BTK Purple = G6PD
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both HUMARA and RNA analysis, giving a total number of DNA:RNA comparisons of 
48. Overall, DNA and RNA results were similar, with correlation coefficients for XCIP 
results of r= 0.87 and i^= 0.76. The median difference between DNA and RNA results was 
6.5% (range 0-34), mean difference was 8.3% and modal difference 1%.
Sixteen T-cell and 16 neutrophil results were obtained from DNA and RNA from 
the 6 polyclonal patients. Only 2 of the 32 DNA verses RNA comparisons were greater 
than 20% different. Neutrophils from patient 14 had a balanced XCIP of 48%:52% 
expression of each allele by DNA analysis, but by RNA analysis the XCIP was imbalanced 
at 14%:86% (BTK assay), a change of 34%. The T-cell sample also had an XCIP of 
14%:86% so the patient was considered to be uninterpretable by RNA analysis due to a 
constitutively imbalanced XCIP. T-cell and neutrophil XCIP results from the first sample 
from patient 16 assayed by HUMARA were 65%:35% and 73%:27% expression of each 
allele respectively, but by RNA (p55) analysis were 87%: 13% and 93%:7% respectively. 
This would alter the clonality status of this patient from polyclonal by DNA analysis to 
uninterpretable by RNA analysis. However, the RNA results from the follow up sample 
from patient 16 were less than 5% different from DNA results for both T-cell and 
neutrophils (Table 4.6a), suggesting that the original RNA result may have been incorrect, 
although the reason for this is unknown.
Four ET patients with clonal myelopoiesis by DNA analysis were investigated by 
RNA analysis; 8 T-cell and 8 neutrophil results were obtained (Table 4.6b). The RNA 
neutrophil results were less than 5% different from DNA neutrophil results in all samples 
tested. However, 6 of the 8 T-cell samples tested had RNA results that were more than 20% 
different to DNA results. For patient 1, 3 RNA results were obtained using the IDS assay at 
3 different time points. All RNA results were equivalent to DNA results except the T-cell 
result from the initial sample, where the XCIP was 27%:73% expression of each allele by 
DNA assay, but 2%:98% by RNA. This was probably due to platelet contamination of the 
T-cell fraction as cytospins of T-cells from the first sample showed large numbers of 
platelets adhered to the T-cells. As the XCIP obtained from the platelet sample was 
6%:94%, contaminating RNA from platelets could account for the discrepancy between 
DNA and RNA results in patient 1.
Patients 3 and 7 were informative for BTK. DNA and RNA neutrophil XCIP results 
were comparable, but T-cells results were not: XCIPs from T-cells from patient 3 were 
59%:41% expression of each allele by DNA and 98%:2% by RNA, XCIPs from T-cells
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from patient 7 were 45%:55% by DNA and 4%:96% by RNA. However, as the T-cell 
XCIP results from RNA were similar to neutrophil and platelet results from both RNA and 
DNA, this suggests that contamination of the purified T-cell fraction by platelets may be 
the cause of the aberrant T-cell results.
Patient 5 was informative for the p55 RNA clonality assay. Results were obtained 
from three samples for patient 5 and in each case the neutrophil results from DNA and 
RNA were similar. However, T-cell XCIP results obtained from the p55 assay were 
imbalanced and did not match the balanced XCIP results obtained from T-cells by 
HUMARA. T-cell XCIP results from p55 were 15%:85%, 20%:80%, and 19%:81 % 
expression of each allele, and T-cell XCIP results from HUMARA were 66%:34%, 
55%:45% and 58%:42% expression of each allele. The T-cell results did, however, closely 
match results from the myeloid lineage, the neutrophil XCIP results by RNA assay were 
21 %:79%, 20%:80% and 27%:73% expression of each allele and by HUMARA were 
21%:79%, 22%:78% and 22%:78%. Again this suggests contamination of the T-cell 
fraction with cells of the myeloid lineage.
In this small cohort of ET patients clonal by DNA analysis, 6 out of the 8 RNA 
XCIP results were uninterpretable due to imbalanced T-cell XCIPs. This was thought to be 
due to contamination of the polyclonal T-cell fraction by clonal platelets.
4.3.4 HUMARA in male ET  patients
To test directly whether hypermethylation at the human androgen receptor locus 
affected HUMARA results, male ET patients were assayed. As males only posses one X- 
chromosome, it is always active and therefore should be unmethylated. This allele should 
be completely digested by HpaW leading to the absence of any sample peaks in the HpaW 
digested aliquot. Hypermethylation of the CpG island located in the recognition sequence 
of HpaW in the HUMARA PCR product would lead to a peak in the HpaW positive fraction. 
HUMARA was carried out on DNA obtained from the neutrophils of 11 male ET patients. 
No measurable product peak was present in the HpaW positive aliquot in 10 (89%) samples 
(Figure 4.7A). In one sample a peak was observed in the HpaW positive aliquot. The peak 
was very small compared to the aliquot with no HpaW, representing approximately 4% of 
the height of the peak in the HpaW negative fraction (Figure 4.7B). If hypermethylation 
does occur in the human androgen receptor in ET patients, it is at a very low level which 
would have little or no effect on clonality results.
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E lectrop h oretogram s o f  H U M A R A  P C R  carried  out on neutroph il D N A  from  m ale  
ET patients, w ith  or w ith ou t p re-incubation  w ith  HpaW
(A) -  Representative electrophoretograms o f  the 10 male ET patient samples in which no PCR 
product was obtained from the H pall digested aliquot.
(B) -  Electrophoretograms o f  the male ET patient sample in which PCR product was obtained in the 
H pall digested aliquot.
The blue trace represents PCR product, and the red trace represents the size standard.
4.4 Discussion
Use of XCIPs to indirectly assess clonality in ET patients has shown that 
approximately 40% of patients have polyclonal myelopoiesis. Those patients with 
polyclonal myelopoiesis appear to be at a lower risk of thrombotic events than ET patients 
with clonal myelopoiesis (Harrison et al, 1999a; Chiusolo et ah 2001; Shih et al, 2002; 
Vannucchi et al, 2004). Follow-up samples from ET patients previously tested for clonality 
were obtained and XCIPs determined by HUMARA (and RNA assay where informative) to 
investigate whether clonality is stable in this cohort of patients.
Samples were collected from 22 ET patients who had previously been tested for 
clonality, 8 patients had clonal myelopoiesis at their original test and 14 patients had 
polyclonal myelopoiesis at original test. No significant change in T-cell or neutrophil XCIP 
was found between the first test and any subsequent test, using the DNA-based clonality 
assay HUMARA. Median follow up of the polyclonal cohort was 61 months (range 10 -  
102), showing that clonality status was stable in these patients. Diagnosis dates were 
available for 11 of the polyclonal patients, the latest samples for this cohort were median 78 
months (range 45 -  188) post diagnosis, indicating that clonality status can remain stable in 
ET patients for up to at least 16 years.
It has been suggested that the high incidence of ET patients with polyclonal 
myelopoiesis may be due to technical artifact related to hypermethylated DNA at the 
HUMARA locus. Only XCIP results from DNA assays would be affected, since digestion 
of the active allele would be prevented by hypermethylation (Figure 4.1). This may lead to 
a falsely balanced XCIP, even though the patient may have an underlying clonal disorder. 
As RNA assays directly measure the amount of each allele that is transcribed, while 
expression levels may be reduced with hyper-methylation, relative expression of the two 
alleles should remain unchanged.
All ET patients in the cohort polyclonal by DNA assay were also polyclonal by 
RNA assay. This suggests that hypermethylation does not affect XCIPs obtained from 
DNA clonality assays. In clonal patients, RNA results from neutrophils were similar to 
DNA results. However, 6 out of 8 T-cells results which were balanced by DNA analysis 
were imbalanced by RNA analysis. Many patients with ET have activated platelets which 
are more sticky than non-activated platelets. This can lead to the formation of platelet
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clumps and cause platelets to adhere to leukocytes. These platelet/leukocyte interactions 
can lead to contamination o f purified T-cell and neutrophil fractions by large numbers of 
platelets (Griesshammer et al, 1999; Villmow et al, 2002; Falanga et al, 2000). This does 
not affect the DNA assay as platelets are anucleate, or the neutrophil fraction of RNA 
assays as platelet and neutrophil fractions are both of the myeloid lineage and would 
therefore be expected to have the same XCIP. However, the T-cell fraction of clonal 
patients has a different XCIP to platelets, so platelets in the purified T-cell fraction may 
lead to an imbalanced XCIP in T-cells from clonal patients.
Expression levels o f a specific gene may vary between cell types. Therefore, low 
level contamination of a purified cell lineage by cells from a second lineage can have a 
large effect on clonality results. One study has shown that the number of IDS gene 
transcripts from one T-cell were equivalent to those from 6 neutrophils or 800 platelets 
(Harrison et al, 1998a). For the BTK gene, expression in T-cells is less than 1% of that seen 
in B-cells (Smith et al, 1994). As B-cells in clonal ET patients are also clonal (Raskind et 
al, 1985), a small level o f B-cell contamination in purified T-cell samples may account for 
the imbalance in XCIP obtained by BTK. RNA clonality assays should therefore be 
interpreted with caution, as incorrect results can occur due to contamination from other cell 
lineages.
To further analyse hypermethylation in ET patients at the HUMARA locus, male 
ET patients was investigated for methylation status at the human androgen receptor gene. 
As males only have one X-chromosome, which will be active, incubation with HpaW 
should digest all X-chromosomal DNA between the primer annealing sites, preventing PCR 
product formation. Any PCR product formation would be suggestive of hypermethylation. 
After HpaW digestion and PCR of neutrophil DNA from the 11 male ET patients, only one 
had sufficient PCR product to be detected. In this patient the PCR product represented 
approximately 4% o f the amount of product measured without HpaW digestion. It is 
possible that this is a result of incomplete digestion by HpaW in this specific sample, but if 
this is not the case then this suggests that any hypermethylation at the HUMARA locus in 
ET is rare and of a low level and is unlikely to be sufficient to alter clonality results. 
Therefore, HUMARA data is usually similar to RNA data, especially in polyclonal patients, 
and where differences occur this is often due to technical problems, frequently caused by 
sample contamination by different cell lineages.
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In summary, these data demonstrate that the high proportion of ET patients reported 
with polyclonal myelopoiesis is not due to technical artifact and HUMARA accurately 
reflects the biological situation. Clonality status in polyclonal and clonal ET patients 
appears stable during long term follow up by XCIP. This suggests that ET can be divided 
into at least 2 subgroups: a group with clonal myelopoiesis - at higher risk of developing 
thrombotic complications, and a group with polyclonal myelopoiesis, which remains 
polyclonal throughout the clinical course of the disease and is at a lower risk of thrombotic 
complications than clonal patients. It may be an advantage to investigate clonality status in 
all female ET patients as clonality status, considered in combination with other indicators 
o f risk, may influence a treatment regimen. In fact, in a retrospective study of 27 ET 
patients, one centre has shown that the 8 polyclonal ET patients received less cytoreductive 
treatment than the 19 clonal patients, supporting the view that clonality testing should be 
used more widely (Briere et al, 1999).
The molecular basis of polyclonal ET may be due to stimulation of the MK lineage 
by proliferation and/or survival factors from external sources, such as an increase in TPO 
expression (see Chapter 5). However, clonal ET would be expected to arise by one or more 
acquired alterations in a stem cell or early myeloid progenitor cell. Therefore it would be 
helpful for studies investigating the molecular basis of ET to asses clonality status in their 
patient cohort to enable investigators to study ET both as one single disease and as two 
distinct clinical entities based on clonality status.
121
Chapter 5
Mutation screen of the 5’ UTR of the thrombopoietin gene in ET patients
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5.1 Introduction
5.1.1 Historical perspective
The name TPO was first coined in 1958 to describe the humoral regulator of platelet 
production. However, 36 years passed before the TPO protein was isolated and the gene 
cloned. The isolation of TPO was made possible by the discovery of an acute 
leukaemogenic retrovirus (MPLV) which induced a myeloproliferative syndrome in mice 
(Wendling et al, 1986). The molecular cloning of MPLV showed it to be a truncated form 
of a new member of the haemopoietic growth factor receptor superfamily (Souyri et al, 
1990). The murine and human forms of the receptor, termed Mpl, were subsequently cloned 
(Vigon et al, 1993) and were shown to contain characteristic features of members o f the 
superfamily, i.e. organisation of the cytoplasmic domain into 200 amino acid cytokine 
receptor homology domains (CRH) containing four distinctive cysteine residues at their N- 
terminal end. Each CRH can be subdivided into two modules of 100 amino acids with the 
C-terminal domain containing 2 sets o f 7 anti-parallel p strands flanking a Trp Ser X Trp 
Ser (WSXWS) box close to the transmembrane domain (Cosman, 1993; Kishimoto et al,
1994). The extracellular portion o f Mpl consists of 2 CRHs.
Mpl was left as an orphan receptor, as the Mpl ligand was still to be identified. 
Subsequent experiments identified Mpl as important in promoting MK development. RT- 
PCR analysis showed that c-mpl transcripts (the gene coding Mpl protein is called c-mpl) 
were limited to groups o f cells that contained MKs or their precursors, and to cell lines that 
could be induced to display MK characteristics (UT-7, M07e, TF-1, HEL, DAMI and KU- 
812) (Methia et al, 1993). Chimeric proteins, formed by fusing the cytoplasmic portion of 
Mpl to the extracellular portion of IL-4 or G-CSF, demonstrated that the cytoplasmic 
portion of Mpl could transmit a proliferative signal in haematopoietic cells (Skoda et al, 
1993; Vigon et al, 1993). Also, CFU-MK derived from human BM CD34+ cells were 
selectively inhibited by addition o f c-mpl antisense oligonucleotides to CD34+ cells in vitro 
(54-81% inhibition) (Methia et al, 1993). The expression of Mpl decreased by 50-70%. 
However, erythroid, granulocytic and monocytic colony formation was unaffected, 
demonstrating the specificity of signalling via Mpl.
In 1994, four separate groups independently reported the isolation and cloning of 
TPO, also termed Mpl ligand or MK growth and development factor (MGDF), using three
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different techniques. Two groups used Mpl to purify TPO (Bartley et al, 1994; de Sauvage 
et al, 1994). Affinity chromatography was used, based on immobilized recombinant Mpl, to 
purify TPO from porcine and canine plasma respectively. Another group identified TPO by 
constructing a Mpl ligand dependent cell line and screening a cDNA expression library 
(Lok et al, 1994). Finally, using a model of thrombocytopenia in sheep as a source of TPO- 
enriched plasma, conventional protein fractionation methods were used to purify a protein 
which was capable of promoting MK differentiation (Kuter et al, 1994).
5.1.2. Location, structure and expression patterns of the TPO gene
The TPO gene locus was mapped to the long arm of chromosome 3 at 3q26-27 by 
fluorescent in situ hybridisation (Chang et al, 1995; Foster et al, 1994; Gurney et al, 1995; 
Sohma et al, 1994). The TPO polypeptide contains 353 amino acids. The first 22 amino 
acids are a signal peptide and the remainder of the peptide can be divided into two domains: 
a 155 amino acid EPO-like domain, which shares 46% overall sequence similarity with 
EPO and which binds c-mpl (Bartley et al, 1994), and a 177 amino acid carboxy-terminal 
domain which is unique to TPO (Figure 5.1). The removal of the carboxy-terminal domain 
does not affect the activity o f the protein but does reduce bioavailability (Hokom et al, 
1995).
The TPO gene contains 2 non-coding exons and 5 coding exons. The gene promoter 
contains no TATA box and there are no other regulatory domains present (Chang et al,
1995). TPO expression is therefore thought to be constitutive. The 2 non-coding exons both 
contain promoter regions. The beginning of exon 1 contains a promoter (PI), which 
produces a full length TPO transcript. The second promoter (P2) lies within exon 2 and a 
shorter transcript is produced which lacks all of exon 1 and part of exon 2. The transcript 
produced from P2 is more efficiently translated than that produced from PI due to the lack 
of transcription initiation sites (AUGs) from exon 1 (see below). The most common 
transcript found in liver is produced from P2, with only 10% of transcripts produced by PI 
(Ghilardi et al, 1998) (Figure 5.1). Expression of TPO occurs primarily in the liver, but it is 
also produced in kidney and smooth muscle, as shown by northern blot and RT-PCR, and 
to a lesser extent in the spleen and bone marrow.
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As well as TPO mRNA being constitutively expressed, production of TPO protein 
is highly suppressed at the translational level. The 5’ UTR of the full-length mRNA 
transcript contains eight potential AUGs and the shorter transcript from P2 contains 4 
AUGs (Figure 5.1). Of these AUGs only the most 3’ site in exon 3 (AUG 8) produces 
functional TPO, all the others appear to suppress access to the physiological start site. 
AUGs 1 to 7 produce small peptides from a short open reading frame (ORF). These 
peptides have no known function, but their production causes competition for the 
translation initiation machinery, thereby reducing availability for AUG 8 (Kozak, 1989). 
Inhibition is particularly strong from start site seven where the ORF extends beyond the 
physiological start site. This completely blocks access to AUG 8 while the ORF from AUG 
7 is being transcribed. Removal of all upstream AUGs, thus removing all inhibition to 
AUG 8, results in a large increase in TPO expression (Wiestner et al, 1998).
5.1.3 Functional studies of TPO
5.1.3.1 In vitro studies
As originally defined, TPO is the primary regulator of MK proliferation and 
differentiation. A number o f groups investigated the effects of the newly discovered protein 
on murine BM cells to ensure its properties matched this definition. Using 
acetylcholinesterase (AChE) staining as a marker for late stage MKs (the first identified 
MK marker (Long & Williams, 1981), very low levels of TPO (750pg/ml) were better at 
promoting AChE activity after 6 days o f serum free culture than 5000pg/ml IL-6 or IL-11, 
either alone or in the presence of co-stimulatory molecules IL-3 or KL (Kaushansky et al,
1994). IL-6 and IL-11 were used for comparison in these studies as they had previously 
been shown to stimulate MK growth and development and were, themselves, candidate 
proteins for TPO. The use of 50ng/ml was needed for either IL-6 or IL-11 to approach the 
level of activity induced by the low dose TPO, demonstrating the potency of TPO on 
megakaryocytopoiesis. Individual AChE-stained cells were assessed and it was shown that 
both the number and the size of MKs were greater in the presence of TPO than IL-6 or IL- 
11. TPO induced a higher level of ploidy than IL-6 or IL-11 when measured by FACS 
analysis, with modal ploidy levels of 32 or 64N for TPO-induced cells, but only 
approximately 8-16N for IL-11-induced cells. TPO was also shown to be a potent colony- 
stimulating factor. Cell culture of murine BM cells in 10% horse serum demonstrated that 
recombinant TPO could support CFU-MK growth in a dose-dependent fashion, and the
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ploidy level of 30-35% of those MKs was greater than or equal to 64N (Broudy et al,
1995). These studies demonstrated that TPO is a potent proliferation and maturation factor 
during megakaryocytopoiesis.
TPO also stimulates end stage maturation and platelet formation. Expression of 
platelet-specific membrane proteins can be stimulated by TPO, including Gplb and 
GpIIb/lIIa (Bartley et al, 1994; de Sauvage et al, 1994). Electron micrograph studies of 
murine BM cells have shown that TPO induced the formation of a mature peripheral zone 
in MKs which was devoid of organelles and a well-developed demarcation zone. TPO 
stimulated the fragmentation of the demarcation zone into platelets (Kaushansky, 1995).
5.1.3.2 In vivo studies
TPO can also stimulate MK proliferation and maturation in vivo as measured by 
platelet counts. Administration of 50ng TPO to wild type BALB/c mice led to greater than 
fourfold increase in platelet production (Lok et al, 1994). Also, in healthy human 
volunteers, a single subcutaneous injection of 3pg/kg pegylated recombinant human MGDF 
(PEG-rHuMGDF) led to an increase in platelet counts from normal levels o f 237±41 
x l03/pl to peak counts o f 522±90 x l0 3/pl (p<.0001) by day 12. The platelet counts 
normalised at 28 days in response to a decrease in serum TPO levels during the course of 
the experiment (Harker et al, 2000).
Thrombocytopenia can be abrogated by the administration of TPO. In a murine 
model, made thrombocytopenic by lethal irradiation prior to BM transplant (BMT), 
administration of 50pg/kg/d PEG-rHuMGDF over 17 days caused accelerated platelet 
recovery. Treated mice recovered sooner than control mice injected with a PBS carrier 
solution containing 0.1% BSA, with platelet counts reaching 300x103/pl by day 9 and over 
1000xl03/pl by day 12 compared to day 11 and day 16 respectively in control mice 
(Molineux et al, 1996). The severity of platelet nadir was also decreased with TPO 
treatment. Mice treated with 30jig/kg/d of PEG-rHuMGDF had a platelet nadir at 8% of 
pre-treatment levels compared to 4% in untreated animals (Kabaya et al, 1996).
In patients with thrombocytopenia, TPO administration can also lead to an increase 
in platelet counts. A phase one study of rhTPO administered after autologous BMT showed 
an average time to platelet recovery of 18 days, this was significantly quicker than 
historical studies where platelet recovery took 40 days on average (Wolff et al, 2001).
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Breast cancer patients undergoing autologous BMT have also been studied in randomised, 
double blind trials of PEG-rHuMGDF (Schuster et al, 2002). Seventy five patients were 
randomised to receive placebo or PEG-rHuMGDF. Platelet recovery to 20x109/l, and 
platelet transfusion requirements were significantly reduced in patients receiving PEG- 
rHuMGDF (18-19 days) compared to placebo (22 days).
Thus TPO stimulates the proliferation and maturation of MKs and the production of 
platelets both in vitro and in vivo, demonstrating that TPO is the primary regulator of 
megakaryocyte proliferation and differentiation.
5.1.4 Regulation of TPO levels in the circulation
As TPO expression is thought to be constitutive, there must be other regulatory 
mechanisms which control its circulating levels. However, these control mechanisms are 
not yet fully understood. The binding of TPO to Mpl on the surface of MKs and platelets 
removes TPO from the circulation (Li et al, 1999), thus an increase in MK and platelet 
mass leads to an increase in available Mpl and circulating TPO levels decrease. This is 
known as the sponge theory, and forms a negative feedback mechanism controlling 
circulating TPO levels in response to alterations in platelet numbers. It was first 
demonstrated by measurement of TPO levels in plasma from rabbits treated with busulphan 
to induce thrombocytopenia (Kuter & Rosenberg, 1995). TPO plasma levels increased after 
busulphan treatment as the platelet mass declined. The plasma levels o f TPO increased 
inversely and proportionally to platelet levels, peaked as the platelet counts reached nadir, 
and decreased as platelet counts returned to normal. Transfusion of platelets into 
thrombocytopenic rabbits around the platelet nadir also caused the elevated TPO levels to 
decrease, suggesting that TPO was removed from the circulation by the increased platelet 
mass acting like a sponge. This effect has also been demonstrated in patients during 
chemotherapy, where serum TPO levels changed reciprocally with platelet counts. 
Transfusion of platelets around the time of platelet nadir caused an immediate drop in 
serum TPO levels as the platelet count increased (Shinjo et al, 1998). This effect was only 
temporary, and as the platelet counts reduced the TPO levels rose. Platelets obtained from 
these patients post-transplant, i.e. in a thrombocytopenic state, showed lower binding of 
biotinylated TPO than donor platelets prior to transfusion. This indicated that the TPO 
receptors were saturated by the excess endogenous TPO in patients with high serum levels.
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A number o f factors may also be involved in the control of TPO regulation which 
are unrelated to the sponge theory.
IL-6 stimulates the differentiation of MKs in vitro and in vivo which leads to an 
increase in platelet counts (Chapter 6.1.3). However, IL-6 may augment platelet production 
via its interaction with TPO. In the hepatoma cell line HepG2, addition of lpg/ml to lng/ml 
IL-6 resulted in an increase of TPO mRNA expression in a dose-dependent manner. Mice 
treated with IL-6 developed thrombocytosis, with platelet counts at their peak 2.5 fold 
higher than untreated mice, and this was accompanied by an increase in hepatic TPO 
mRNA expression. Neutralization of TPO by rabbit anti-TPO polyclonal antibody prior to 
IL-6 treatment, abrogated the thrombocytosis. Also, cancer patients treated with 30mg/kg/d 
IL-6 for 5 days showed an increase in plasma TPO levels, from undetectable before 
treatment to 630±110pg/ml on day 6 (Kaser et al, 2001). These studies suggest that 
circulating TPO levels may be influenced by IL-6.
As well as IL-6, proteins contained in the a-granules have been shown to affect 
TPO expression. Platelet derived growth factor (PDGF) and fibroblast growth factor-2 
(FGF-2) increased the expression of TPO mRNA in cultures of normal BM stromal cells by 
2 and 1.5 fold respectively in a dose dependent manner. However, the opposite was shown 
for platelet factor 4 (PF4), TSP and TGFpl. One to 2 pg/ml PF4 and TSP significantly 
inhibited TPO mRNA and protein expression compared to controls, as did 50 to lOOng/ml 
TGFpi (Sungaran et al, 2000). Whole platelet lysates suppressed TPO expression, 
suggesting that the negative effect o f the complete contents of the platelet a-granules is 
greater that the positive, and that platelets may play a negative role in their own 
proliferation and maturation by modulating TPO expression.
Contrary to the evidence described above using high concentrations of TGFpl, 
lower concentrations may lead to up-regulation of TPO mRNA in BM stromal cells. 
TGFpl is a potent inhibitor of megakaryocytopoiesis and is discussed at length in chapter 6 
(6.1.1). Addition of 0.1-2ng/ml TGFpl to cultured BM stromal cells from normal 
individuals led to a dose-dependent increase in TPO mRNA up to 7 times normal levels as 
measured by quantitative RT-PCR. Media from cultures containing TGFpl-treated cells 
contained more TPO (37.4±4.6pg/ml and 162.7±25.4pg/ml at 24 and 48 hours respectively) 
than untreated cells (18.3±2.4 and 30.4±3.7pg/ml), showing that the increase in TPO 
mRNA led to a higher level o f TPO protein expression. This effect could be blocked by
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addition of a TGFp blocking antibody prior to treatment, showing that the effect was due to 
TGFpi alone (Sakamaki et al, 1999). This evidence suggests that TGFpl can up-regulate 
TPO expression in BM stromal cells. As TGFpl is a potent inhibitor of 
megakaryocytopoiesis, a negative feedback loop has been suggested whereby TGFpl 
stimulates TPO expression in BM stromal cells. This in turn stimulates the expression of 
TGFp receptors (TGFpR) I and II on the surface of maturing BM MKs. Bioavailability of 
TGFpRI and II is increased facilitating TGFpi binding to MKs which leads to inhibition of 
megakaryocytopoiesis.
Clearly a number o f mechanisms may be involved in TPO regulation. The sponge 
theory accounts for most of the changes in TPO circulating levels, but other regulatory 
mechanisms may be important in controlling TPO expression and ultimately platelet 
number, particularly in the BM micro-environment.
5,1.5 TPO levels in Thrombocytosis
The sponge theory accounts for the changes in serum/plasma TPO levels in the 
normal and thrombocytopenic state. However, in patients with thrombocytosis this is not 
always seen. Several diseases characterised by a thrombocytosis show a normal or elevated 
circulating TPO level.
Kawasaki disease (KD) is an acute febrile vasculitic syndrome seen in children and 
is accompanied by a thrombocytosis. TPO was detected in 26 out of 31 patients (mean 
173pg/ml, range 89-249pg/ml) using an ELISA-based technique that was not sensitive 
enough to pick up TPO in haematologically normal individuals, thus TPO was elevated in 
the majority of KD patients with thrombocytosis (Miura et al, 1998). Patients with the 
cMPD agnogenic myeloid metaplasia (AMM), a disease characterised by BM MK 
hyperplasia and atypical MK clusters, have also been reported to have elevated TPO levels 
of 693.2±82.66pg/ml compared to normal levels of 185.80±26.62pg/ml (pO.OOOl) (Wang 
etal, 1997).
A number o f major studies have reported circulating TPO levels in patients with ET 
and their results are summarised in Table 5.1. All reports showed that circulating TPO 
levels in ET patients are equal to or higher than levels in normal individuals. Eight of the
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Reference Diagnosis n= Mean ( ± SD) Median Range Source(units)
Harrison et al 
(1999)
N
ET
RT
12
18
8
122 ±69 
162 ±138 
140 ±137
110
118
69
39-242
<15-483
22-375
Plasma
(pg/ml)
Cerruti et al 
(1997)
N
cMPD
RT
32
32
70
156.7
246.2
287
62.2-352.7
93.5-4596
82.7-1960
Serum
(pg/ml)
Karakus et al 
(2002)
N
cMPD
RT
16
24
21
62.65
467
100.5
Plasma
(pg/ml)
Pitcher et al 
(1997)
N
ET
RT&NEM
96
25
16
80.1 ±5 
203.9 ±56.5
237.1 ±46.7
64.4
127.2
77.1
22.2-255.9
77.5-1551.9
39.1-1660.1
Plasma
(pg/ml)
el-Kasser et al 
(1998)
N
ET
RT
28
48
3
245±117 
287 ±233 
123 ±7
Plasma
(pg/ml)
N
ET
RT
28
48
3
259 ±177 
692 ±1129 
151 ±17
Serum
(pg/ml)
Tahara et al 
(1996)
N(Female)
N(Male)
ET
21
29
6
0.70 ±0.26 
0.79 ±0.35 
2.8 ±1.55
Serum
(fmol/ml)
Usuki et al 
(1996)
N
cMPD
15
12
0.84 ±0.40 
1.99 ±1.47
Serum
(fmol/ml)
Horikawa et al 
(1997)
N
ET
21
17
0.76 ±0.21 
1.31 ±1.64 0.22-5.20
Serum
(fmol/ml)
Espanol et al 
(1999)
N
ET
RT
43
15
50
121 ±58 
120 ±28 
149 ±58
Serum
(pg/ml)
Griesshammer 
et al (1998) NET
11
7
25
95.3 ±54 
545 ±853
Serum
(pg/ml)
Hou et al (1998) N
ET
RT
11
12
13
21.1 ±11.0 
44.1 ±45.2 
16.4 ±8.6
Plasma
(pg/ml)
Tomita etal 
(2000)
N
ET
29
59
0.83 ±0.36 
2.70 ±2.74
Serum
(fmol/ml)
Randi et al 
(2004)
N
ET
58
7
25.8 ±14.4 
29.6 ±16.1
Plasma
(pg/ml)
Wang et al 
(1998)
N
ET
RT
17
20
34
201±112 
505 ±459 
290 ±133
Serum
(pg/ml)
Table 5.1
Circulating TPO levels reported in ET patients
N=normal control, RT=reactive thrombocytosis, cMPD=non-specified 
myeloproliferative disorder, NEM=non-ET cMPD
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studies demonstrated at least a two-fold increase (Griesshammer et al, 1998; Hou et al, 
1998; Abgrall et al, 1992; Karakus et al, 2002; Pitcher et al, 1997; Tahara et al, 1996; 
Tomita et al, 2000; Usuki et al, 1996; Wang et al, 1998). No difference between TPO 
levels in ET and normal controls was shown in 2 studies (Randi et al, 2004; Espanol et al, 
1999). No difference in TPO levels was seen between males and females (Tahara et al,
1996). Only one study investigated both serum and plasma TPO levels. They found that 
TPO levels in plasma samples from normal controls were 287 ±233 pg/ml, similar to the 
levels found in plasma samples from ET patients of 245 ±117 pg/ml. However, in serum 
samples, TPO levels were dramatically increased from 259 ±177 pg/ml in normal controls 
to 692 ±1129pg/ml in ET patients (el Kassar et al, 1998). Differences in TPO levels 
between serum and plasma may occur because serum samples have platelets removed by 
clot formation, thus platelet contents can be released and this may affect TPO levels. 
However, of the 5 studies which used only plasma as the sample material, TPO levels were 
raised in ET and other cMPDs in comparison to normal controls in 4 studies (Harrison et al, 
1999c; Hou et al, 1998; Karakus et al, 2002; Pitcher et al, 1997) and were the same as 
normal controls in only one study (Randi et al, 2004). This was similar to the 8 studies 
which used only serum as the sample material, 7 studies showed raised TPO levels in ET 
and other cMPDs (Cerutti et al, 1997; Espanol et al, 1999; Griesshammer et al, 1998; 
Horikawa et al, 1997; Tahara et al, 1996; Tomita et al, 2000; Usuki et al, 1996; Wang et al, 
1998) and only one showed similar levels (Espanol et al, 1999) compared to 
haematologically normal controls. Thus the overwhelming consensus from these studies is 
that TPO levels are elevated in ET patients compared to normal controls.
However, TPO circulating levels in all categories were very variable. The widest 
range of values for ET patients was 39.1-1660.1 pg/ml (Pitcher et al, 1997), and the mean 
for ET patients from another study, 692 pg/ml, had a standard deviation of 1129 (el Kassar 
et al, 1998). Thus the range of results obtained for ET patients overlap with that of other 
groups and many ET patients have higher circulating TPO levels than normal controls.
The studies were also unable to distinguish ET patients from patients with RT or 
other MPDs. TPO levels in RT were similar to those in ET in three of the studies (Espanol 
et al, 1999; Harrison et al, 1999c; Pitcher et al, 1997), and while TPO levels were not 
raised to the same degree as in ET patients in two further studies, they were raised 
compared to normal controls (el Kassar et al, 1998; Wang et al, 1998). TPO levels in other 
MPDs were also equal or raised compared to haematologically normal controls as
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demonstrated by the studies which did not separate ET from other MPDs (Karakus et al, 
2002; Cerutti et al, 1997; Usuki et al, 1996). The increase in TPO circulating levels in these 
studies were similar to increases seen in ET patient groups.
Whilst circulating levels of TPO cannot be used diagnostically in ET because of the 
large overlap between cMPD, RT and normal cohorts, the question as to why TPO levels 
are high remains. The sponge theory suggests that the increased platelet mass of the 
thrombocytosis should remove TPO from the circulation leading to subnormal TPO levels, 
but this is not the case in ET. The high level of TPO may be caused by up-regulation of 
factors which modulate TPO expression, and this would be important for ET pathogenesis.
5.1.6 Hereditary Thrombocytosis Studies
Hereditary thrombocytosis (HT) is an inherited condition which shares many 
features with ET. Patients with HT fulfil the diagnostic criteria for ET laid down by the 
PVSG (Ghilardi & Skoda, 1999). Both diseases are characterised by elevated platelet 
counts due to sustained over-proliferation of MKs, and frequently lead to thrombotic and 
haemorrhagic complications. HT is often inherited in an autosomal dominant fashion, 
although one family has been identified in which inheritance is probably in an X-linked 
fashion (Stuhrmann et al, 2001). To date, four point mutations have been identified in the 
5’UTR of the TPO gene in HT families. All four mutations lead to a reduction in the 
suppression of transcription initiation from AUG 7.
The first mutation described in the TPO 5’UTR was a G to C substitution at 
nucleotide 3916 (Wiestner et al, 1998). It was identified in a cohort of four generations of 
the affected family. All affected individuals had elevated platelet counts (880-1280xl09/L) 
and serum TPO levels (74-1180pg/ml) compared to unaffected family members (220-330 
x 109/L and <62pg/ml respectively). The mutation was present in all affected individuals 
and was shown to disrupt the splice donor site of intron 3 by replacing the 5’ G with a C. 
The splice donor site on intron 4 was used instead and an mRNA transcript missing exon 3 
was produced (Figure 5.2A). This led to removal of the two most significant start sites, 
AUG 7 and 8, from the transcript, and brought AUG 5 and 6 into frame with the normal 
coding sequence. Thus, the suppressive effect on translation from AUGs 5, 6 and 7 was 
removed, but functional protein is still produced. A TPO construct containing the mutation 
was transfected into a rat hepatoma cell line (HTC). TPO levels in supernatants taken from
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these cell lines were significantly increased (210±6pg/ml) compared to cells transfected 
with vector only and untransfected controls (<62pg/ml). A G to A substitution at nucleotide 
3920 was described in all four affected members of another family with HT (Jorgensen et 
al, 1998). Platelet counts (700-1000xl09/L) and serum TPO levels (430-980pg/ml) were 
elevated in affected individuals compared to controls (control TPO levels 85pg/ml). The 
substitution results in a change from G to C at the 5th position from the 5’ end of intron 3, 
disrupting the splice donor sequence in intron 3 and was presumed to lead to an 
alternatively spliced mRNA lacking exon 3. This would lead to removal of the two most 
significant start sites, AUG 7 and 8, from the transcript as described above (Figure 5.2A).
Two other mutations have been described in HT that remove the suppression on 
TPO translation by AUG 7. A G to T substitution at nucleotide 3872 has been described in 
a Japanese family (Ghilardi et al, 1999). Three generations of affected individuals were 
shown to have increased platelet counts (1095-1380x 109/l) and high serum TPO levels (5.6- 
8.0fmol/ml) compared to unaffected family members (189-274x 109/l and <1.3fmol/ml 
respectively). In this instance the mutation affects translation from AUG 7 by introducing a 
stop site between AUGs 7 and 8 (Figure 5.2B). This shortens ORF 7 by 42 nucleotides, 
which now terminates 31 nucleotides upstream of AUG 8, reducing the suppressive effect 
from AUG 7. This mutation led to an increase in TPO expression in rat HTC cells 
transfected with constructs containing the mutation. An 8-fold increase in TPO levels was 
seen for mutant-containing cells compared to cells transfected with vector only (Ghilardi et 
al, 1999).
Finally, a family has been described where affected individuals were shown to carry 
a deleted G in a run of 4 Gs beginning at position 3853 (Ghilardi et al, 1999; Kondo et al, 
1998). This frame shift mutation brings ORF 7 in frame with ORF 8 (Figure 5.2C), 
extending the N-terminus of the TPO signal peptide by 23 amino acids, and removing 
suppression from AUG 7 (Ghilardi & Skoda, 1999). COS cells transfected with a construct 
containing the mutation secreted 7-fold more TPO than cells transfected with wild type 
TPO. This indicated that not only does the mutation improve efficiency of TPO translation, 
but also that the alteration to the signal peptide does not prevent secretion of TPO protein.
The 4 mutations appear solely responsible for the increase in circulating TPO levels 
associated with the HT disease phenotype in the families studied. Since the phenotype of 
ET matches that of HT it is possible that some ET patients may have acquired one of the 
described mutations, or a similar alteration with the same effect on suppression of TPO
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translation. This may be more significant in polyclonal patients where there is no clonal 
expansion of a megakaryocytic progenitor and factors derived from outside the MK 
progenitor could be of greater importance. It has been demonstrated that the G3916C 
mutation, which leads to the exon skipping of exon 3 and removal of AUGs 7 and 8, was 
not present in 51 ET patients (Harrison et al, 1998b). However, none of the other mutations 
have yet been examined in ET patients, nor have novel mutations been sought.
5.1.7 A IM
The aim of the work detailed in this chapter was to establish whether any of the 
three HT mutations, not yet investigated in ET, were present in a cohort of 50 ET patients 
using restriction enzyme analysis, and to analyse for any novel mutations in the TPO 
5’UTR which may affect TPO expression levels using PCR-SSCP.
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5.2 Materials and methods
5.2.1 Patients and Samples
Peripheral blood samples were collected from 50 female patients with a diagnosis of 
ET according to the PVSG criteria and 100 haematologically normal controls. Patient 
characteristics are outlined in Table 5.2. DNA was prepared from purified neutrophils as 
detailed in chapter 2 (2.2.1 and 2.2.2).
5.2.2 PCR
Approximately lOOng o f DNA was used for 30 cycles of PCR using Bioline 
reagents as outlined in chapter 2 (2.2.7). The primers and annealing temperatures used are 
listed in Table 5.3.
5.2.3 Analysis o f known HT mutations
PCR was carried out on DNA from patient neutrophils as outline above. The 
G3872T substitution (Ghilardi et al, 1999) was investigated with Bsll digestion of 3F/3R 
PCR products. The full length PCR product of 365bp was digested into fragments of 28, 
149 and 188bp for WT alleles and 149 and 216bp for mutant alleles (Figure 5.3A). The 
G3920A mutation (Jorgensen et al, 1998) was investigated with primer 3F and a mismatch 
primer MM3920 followed by digestion with Mbol (Figure 5.3B), which would give 
fragments of 28 and 227bp for WT alleles and remain undigested for mutant alleles 
(255bp). The AG mutation at nucleotide 3853 (Kondo et al, 1998) was investigated using 
mismatch primers MM3852 and MM3920 to allow a suitable size PCR product for 
digestion. SacII digestion would give fragments of 29 and 203bp for WT alleles and mutant 
alleles remain undigested (232bp) (Figure 5.3C).
5.2.4 Single Stranded Conformational Polymorphism (SSCP) Analysis
As the size of the 5’UTR of the TPO gene is large (over 1200bp), and 50 patients 
being investigated, direct sequencing was considered too impractical and expensive to be 
used as a method of mutation detection. To detect sequence changes quickly and efficiently 
a screening method was used. SSCP is a relatively rapid screening technique sensitive 
enough to detect single base pair substitutions and previously has been used successfully in
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Age at Diagnosis (years) Median = 53.5
Platelet Count at Diagnosis(x 109/l) Median = 837
Follow up at Test (months) Median = 38
Range 10-89 
Range 600-1917 
Range 0-240
Karyotype Normal 27
+8,+9 1
20q- 1
Not known 21
Clinical Symptoms at Test Hepatosplenomegaly 12
Haemorrhage 6
Thrombosis 22
None 20
Treatment at Test 32p 2
Chemotherapy* 34
None 16
Clonality Monoclonal 10
Polyclonal 15
Uninterpretable 22
Not Tested 3
Table 5.2
Clinical details of the 50 ET patients
♦includes Busulphan, Hydroxyurea, Interferon-a, Anagrelide
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Fragment Annealing
Fragment Forward primer (5'—>3') Reverse primer (5*—►3') Nucleotides* Size (bp) Temp (°C)
1 GTCGGTGTCCAGCCCAGGAAG CACTGCCTAGCCTGCCTCCCT 428-654 226 64
2A CCTCTGTGCTTCTTCCCCAGC GTATGACCTGCTGCTGTGGAG 1702-1992 290 60
2B GTGTGTGTGGGTGGAGGAGTG AG AAAT GGGCTCCC AGCT GGG 1841-2158 317 60
3 ACCCTGCCAGGCAGTCTCTTC G AGGGGT GG ATTCCCT GGGTT 3695-4057 362 60
4 AGAGAAAGGAGACACGCTGCA TCCGCGTAACTGGTAAGACAC 3969-4323 354 60
MM3920+ ATC AC ACCT G AGGGGCT AGGGCC AT AT GG A (Down Primer) 3768-3797 64
MM3852+ CGCCTCCATGGCCCCAGGAAGGATTCCGCG (Up Primer) 3921-3951 64
MM3767+ TCAGAATTGGCCCGCCTTTGCCCCACCCTA (Down Primer) 3826-3855 68
 ^ Mismatch primers with mismatched bases underlined 
* Numbered according to Chang et al 1995
Table 5.3
PCR primers used to investigate the 5’UTR of the TPO gene
The PCR fragment sizes and the annealing temperature used for each primer pair are also shown
u> 
VO
(A)
G3872T (Ghilardi 1998) 
Using primers 3F and 3R 
and digested with Bsl I
WT | < --------  149  > |  28 | < --------  188  > |
MUT | < --------  149---------  > | < --------  216  >\
(B)
G3920A (Jorgensson et al 1998) 
Using primers 3F and MM3920 
and digested with Mbo I
WT \< ---------------  227  > |  28 |
MUT |< ---------------  255  > |
(C)
AG at 3852 (Kondo et a/1999)
Using primers MM3920 and MM3852
and digested with Sac II
6  Sacll
WT | 29 |< ---------------------  203  > |
MUT |< ---------------  232  > |
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the laboratory. Under non-denaturing conditions single stranded DNA has a folded 
conformation dependent on intra-strand interactions, and the folding is sequence specific. 
Changes to the sequence thus influence folding and, in suitable experimental conditions, the 
rate of migration through non-denaturing polyacrylamide gels is altered leading to band 
shifts and the appearance or disappearance of bands. Factors affecting mobility include 
temperature, ionic strength, pH and gel composition. A number of gel conditions were 
therefore used to increase the likelihood of detecting sequence changes, as outlined below. 
Previous studies have shown that the optimal PCR fragment size for SSCP is between 200 
and 400bp (Glavac et al, 1994; Hayashi, 1991). Therefore, primers were designed to create 
five PCR fragments of less than 400bp covering the first four exons of the TPO gene 
(Figure 5.4, Table 5.3). Twenty cycles of PCR were performed as above with the addition 
of 0.2pl a -32P-dCTP (0.37MBq/pl) per 20pl PCR mix. A 2pl aliquot of radioisotope 
labelled PCR product was added to lOpl 0.1% SDS, lOmM EDTA and 11 pi denaturing 
solution (95% Formamide, 20mM EDTA, 0.05% bromophenol blue and 0.05% xylene 
cyanol). Samples were heated to 95°C for 10 minutes and 5pl loaded onto a non-denaturing 
gel (6% polyacrylamide crosslinker 37.5:1, 1 x TBE, with or without 10% glycerol). Each 
sample was electrophoresed under three different conditions: (A) 0% glycerol, room 
temperature, 15W for 5 hours, (B) 0% glycerol, 4°C, either 23mA for 4 hours (fragments 3 
and 4), 5mA for 17 hours (fragments 2A and 2B) or 4mA for 17 hours (fragment 1) and (C) 
10% glycerol, room temperature, 30W for 5 hours.
5.2.5 Sequence Analysis
Samples with an altered SSCP pattern were sequenced using the ABI 310 genetic 
analyser to characterise the alteration. Cycle sequencing was carried out using BigDye™ 
Terminator Cycle Sequencing Ready Reaction, 310 Genetic Analyser Kit, as outlined in 
Chapter 2 (2.2.9) in both the 5’ and 3’ direction. Sequence alterations were then confirmed 
using restriction enzyme digestion.
5.2.6 Mutation-sensitive R E  analysis
PCR products were digested as described in chapter 2 (2.2.11), electrophoresed 
through agarose gels and visualized by ethidium bromide staining.
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5.3 Results
5.3.1 Analysis o f  known H T  mutations
Fifty ET patients were analysed for the mutations described in HT at nucleotides 
3852, 3872 and 3920 using PCR and restriction enzyme digestion (Figure 5.3, Table 5.3). 
The mutation at 3872 was analysed by BslI digestion of PCR fragment 3. All 50 patients 
studied showed only WT alleles. An enzyme whose cutting site enabled the detection of the 
mutations at 3852 or 3920 was not available, therefore two mismatch primers were 
designed. A mismatch primer is so called because one or more of the primers nucleotides 
are altered from the published sequence to introduce an enzyme-cutting site into the PCR 
product. During the PCR reaction these alterations are introduced into every fragment 
produced, thus altering the sequence of the PCR product. In this instance, enzyme-cutting 
sites were introduced by the mismatch primer to allow the detection of wild type alleles at 
positions 3852 or 3920. The mismatch primer MM3920 was used with primer 3F to 
produce a PCR fragment containing an Mbol cutting site which would cut WT alleles at 
nucleotide 3920. All 50 patients studied showed only WT alleles. Similarly, the mutation at 
position 3852 was investigated using a mismatch primer, MM3852. This primer was used 
with mismatch primer MM3920 to generate a PCR product of a suitable size for 
visualisation on ethidium bromide stained agarose gels. The PCR fragment produced 
contained a cutting site for Sac\I, generated by the MM3852 mismatch primer, that would 
cut WT alleles at position 3852. All 50 patients studied showed only WT alleles.
5.3.2 SSCP
In order to determine whether novel alterations were present in the 5’UTR of the 
TPO gene, PCR-SSCP analysis was carried out using neutrophil DNA from 50 ET patients, 
and the patterns compared to DNA from the haemopoietic cell lines HL60 and TF-1. Five 
PCR fragments were designed to cover the first four exons and flanking regions of the TPO 
gene (Figure 5.4). The fragments therefore encompassed the 5’UTR and the first 47 amino 
acids of the coding sequence. No abnormal patterns were detected in fragments 1, 2A, 2B 
or 4. However, three different patterns were observed in fragment 3 (Figure 5.5A). In 12 
patients and the HL60 control, pattern 1 was observed in condition C; three equally spaced 
bands were seen with the upper two bands more intense than the third lower band. Fourteen
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patients and the TF-1 control shared pattern 2; three bands could again be seen, two with a 
higher intensity than a lower third band. However, the mobility of each band was slightly 
different when compared to pattern 1. Pattern 3 was found in 24 patients; the bands were 
less clearly resolved, but appeared to contain all the bands present in patterns 1 and 2.
5.3.3 Sequencing and Genotyping
A representative sample o f each PCR-SSCP pattern described above was sequenced 
to characterise the sequence alteration. As shown in Figure 5.5B, an alteration to the 
published genomic sequence was identified at position 3767 in two of the samples. The 
published sequence carries a C at this position. HL-60 was found to be homozygous for C 
at 3767, TF-1 was shown to be homozygous for T, and the patient sample with SSCP 
pattern 3 was heterozygous CT.
A mismatch primer MM3767 (Table 5.3) was created which introduced a DdeI 
cutting site in T-containing alleles. Digestion of 3F/MM3767 PCR products confirmed 
results for the patients, HL60 and TF-1. C-containing alleles remained uncut at 102bp, T- 
containing alleles digested to 76 and 26bp (Figure 5.5C). A complete correlation was 
shown between digest pattern and SSCP pattern in the ET patients. To establish whether 
this alteration was a common polymorphism, or a mutation possibly relating to ET, 100 
haematologically normal control samples were also investigated for the alteration at 3767. 
The genotypes of the ET group were 24% homozygous C, 48% heterozygous CT, and 28% 
homozygous T. The genotypes for normal controls were 20% homozygous C, 52% 
heterozygous CT and 28% homozygous T. The allele frequency for C at position 3767 was 
0.48 and 0.46 for ET patients and normal controls respectively. There was no significant 
difference between ET patients and the cohort of 100 controls at either the genotypic or 
allele frequency levels. Twenty five of the ET patients were interpretable for clonality 
status by XCIP, 10 had clonal myelopoiesis and 15 had polyclonal myelopoiesis. Of the 10 
clonal patients, 30% were C homozygous, 60% heterozygous CT, and 10% were 
homozygous T. The genotypes of the 15 polyclonal patients were 40% homozygous C, 
47% heterozygous CT, and 13% homozygous T (Figure 5.6). These data gave an allele 
frequency for the C allele of 0.60 for clonal patients and 0.64 for polyclonal patients. No 
correlation between clonality status and genotype at position 3767 could be established 
(p>0.5). There was also no significant difference between the clonal patients and normal 
controls (p>0.4) nor between the polyclonal patients and normal controls (p=0.1) at the
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5.4 Discussion
TPO is the prime regulator of megakaryocytopoiesis, and as such the circulating 
levels of TPO play a major role in controlling peripheral blood platelet counts. TPO is 
expressed constitutively in the liver and other organs, and circulating levels are regulated 
mainly by MK and platelet mass. However, serum and plasma concentrations of TPO in ET 
patients are equal to or higher than normal control subjects, in spite of the increase in 
platelet mass.
Four mutations have been identified in the 5’ UTR of the TPO gene in families with 
HT, which decrease suppression of TPO translation. If they were present in ET patients 
they could account for the elevated TPO levels described, as well as the disease phenotype. 
PCR and restriction enzyme analysis were used to investigate whether any of these 
mutations were present in ET. However, only wild type alleles were identified in the 50 ET 
patients studied, suggesting that none of the previously described HT mutations are 
responsible for the pathogenesis ET.
SSCP of the complete 5’ UTR of TPO mRNA was then carried out to analyse for 
novel alterations which may have a similar effect on TPO expression as the HT mutations. 
A single alteration was identified, a C3767T substitution. The alteration is lObp 
downstream from the 5’ end of exon 3, 65 bp upstream of AUG 7. While this substitution 
could affect translation from AUGs 5 and 6, which have been shown to have some 
inhibitory effect in vitro, inhibition from AUG7, the major inhibitory start site, would be 
unaffected. As the region does not code for TPO, no alteration to its protein sequence 
occurs. No start or stop sequence is generated by the substitution.
An allele frequency for the C allele at position 3767 of 0.48 was determined in ET 
patients and 0.46 for haematologically normal control subjects. The difference between the 
two groups was not statistically significant and it is therefore unlikely that either allele 
alone has any effect on disease pathogenesis. At the genotypic level, no significant 
differences could be demonstrated. The genotype CC was present in 28% of patients, CT
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48% and TT 28%. Normal control genotypes were similar at CC 20%, CT 52% and TT 
28% and again no significant differences could be shown. Only 25 patients in the group had 
known clonality status, and although there were some small differences probably due to 
small sample size, there was no significant bias towards a particular allele frequency or 
genotype in either clonal or polyclonal patients. The different alleles at this locus are 
therefore unlikely to have any effect on efficiency of TPO translation and are probably a 
naturally occurring single nucleotide polymorphism with no affect on disease pathogenesis.
The lack of acquired or inherited mutations in the 5’UTR of TPO in ET patients 
does not rule out the presence o f mutations or polymorphisms in the coding region o f the 
TPO gene. Genetic alterations may affect TPO transcript or protein stability which could 
lead to an increase in circulating levels if TPO is less readily degraded. Also, alterations 
affecting the binding efficiency o f TPO to Mpl could lead to less efficient removal from the 
circulation leading to an abnormally high TPO level. However, alterations to the coding 
sequence of TPO have yet to be investigated in ET.
Two promoters in the TPO gene, PI and P2, give rise to 2 mRNA isoforms by 
alternative promoter usage. A full length isoform is produce from PI and a truncated 
mRNA, missing exon 1 and part o f exon 2, is produced from P2. The isoform produced 
from P2 is more efficiently translated than the full-length transcript due to the absence of 
AUGs 1-4 and the subsequent loss o f their suppressive effect on translation. In liver, the 
major site of TPO production, 90% of transcripts are generated from P2 (Ghilardi & Skoda, 
1999). A increase in promoter P2 usage in ET could lead to a small, but significant increase 
in TPO expression. Also, promoter usage may vary between cell types which may be 
important for local effects. If promoter P2 usage is less in liver than in BM stromal cells 
then TPO would be less efficiently expressed in BM. An increase in the proportion of TPO 
transcripts generated from P2 in ET patients may than lead to a large increase in BM TPO 
levels. However, as liver biopsies are not taken in ET patients and BM samples are difficult 
to obtain, studies o f isoform usage in ET are difficult.
Other isoforms affecting TPO at the protein level may contribute to the 
pathogenesis of ET. Six different TPO protein isoforms have been identified in carcinoma 
cell lines: the full length TPO mRNA, four deletions in exon 6 of sizes 12bp, 116bp, 128bp 
and 197bp (TPO-1 to TPO-5 respectively) and a 60bp insertion of intron 5 coupled with the 
116bp deletion of exon 6 (TPO-6). Twenty seven carcinoma cell lines were tested and 24 
were found to contain TPO-1 mRNA with one or more of the other isoforms. The
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biological activities of TPO-5 and TPO-6 were studied and neither was able to promote the 
proliferation o f TPO-responsive FDCP-hMpl5 cells, whereas TPO-1 was able to, in a dose- 
dependent fashion. These non-biologically active isoforms could compete with TPO-1 for 
access to the TPO receptor, possibly preventing TPO internalisation and subsequent 
degradation. While this would not be expected to lead to a proliferative or survival 
advantage for the MK lineage, it may lead to an increase in circulating TPO levels 
secondary to another underlying defect.
While the mutations described in the families with HT were causative of their 
disease, not all HT patients carry mutations in the 5’UTR of their TPO gene. Two reports 
document two families where TPO mutations were not present. Affected individuals had 
normal TPO circulating levels, compared to raised levels in the families with TPO 
mutations. Linkage analysis was used to exclude TPO in one family, direct sequencing in 
the other (Wiestner et al, 2000; Tonelli et al, 2000). As TPO is not involved in these two 
families, other factors must be contributing to the disease phenotype.
One such candidate is Mpl. TPO binds to Mpl on the surface of MKs and platelets 
causing downstream signalling events as outlined in chapter 1. Once binding has occurred, 
the receptor, with TPO still bound, is internalised and TPO degraded (Fielder et al, 1997). 
Levels of Mpl in the HT family carrying the C to G mutation at nucleotide 3916 were 
decreased in 7 out of 8 affected individuals, despite having normal mRNA expression of c- 
mpl (Kralovics et al, 2003), and there is increasing evidence that Mpl levels are reduced in 
ET patients.
A marked reduction o f the level o f Mpl on the surface of platelets, and a reduction 
in total Mpl protein was seen in 14 ET patients compared to 5 normal controls using flow 
cytometry and western blot analysis (Horikawa et al, 1997). A decrease in the level of c- 
mpl mRNA was also shown by northern blot and semi-quantitative PCR. A significant 
decrease in the surface expression of Mpl on 18 ET platelets was demonstrated using 125I- 
labelled antibodies bound to purified platelet preparations (Harrison et al, 1999c). Surface 
c-mpl levels in ET patients ranged from 0%-63% of control values (p<0.001). However, 
while a significant difference in c-mpl surface expression was shown between these ET 
patients and 8 RT patients (p=0.0015), no significant difference could be shown between 
the ET cohort and 8 patients with other MPDs, nor did Mpl surface expression differentiate 
patients with clonal or polyclonal haemopoiesis. A decrease in protein levels was also 
shown by western blotting.
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A similar study using flow cytometry showed that there was a 10 fold decrease in 
the number of TPO binding sites on platelets from 23 ET patients compared to 19 normal 
controls (Li et al, 2000). ET patients had 5.6 ±5.5 TPO binding sites per platelet and normal 
controls 56±17. From this data the clearance rate of TPO from the circulation could be 
established as 0.30±0.14ml/hr/109 platelets in ET patients compared to 1.24±0.38ml/hr/109 
platelets in normal controls.
Immunohistochemical studies have also show a reduction in Mpl levels in ET 
patients compared to control samples, and this is combined with a more heterogeneous 
staining pattern than controls (Duensing et al, 1999; Teofili et al, 2002b; Yoon et al, 2000). 
The decrease in platelet c-mpl expression could lead to platelet c-mpl becoming saturated, 
preventing further uptake o f TPO from the circulation, and this may account for the rise in 
circulating TPO levels seen in ET.
Mutations in the c-mpl gene may also lead to a decrease in TPO clearance from the 
circulation by preventing c-mpl translocation to the cell surface, disrupting TPO binding or 
preventing TPO internalisation. This may result in elevated circulating levels. A large 
proportion of congenital amegakaryocytic thrombocytopenia (CAMT) patients have a 
mutation in the c-mpl gene. A 10-year-old girl with CAMT was described who had 
inherited two c-mpl mutations, one from each parent (Ihara et al, 1999). Each mutation 
caused truncation of the Mpl protein to produce a peptide lacking all intracellular domains 
essential for signal transduction. Another study analysed the c-mpl sequence o f 5 CAMT 
children and found that 4 of the 5 patients had c-mpl mutations, 3 caused an amino acid 
change or led to a premature stop codon, while the fourth resulted in loss of a splice site 
(van den Oudenrijn S. et al, 2000). Another study found c-mpl mutations in 8 out of the 8 
CAMT patients they studied (Germeshausen et al, 2001).
A single nucleotide polymorphism, a G to T at nucleotide 1238 of the c-mpl gene, 
has been identified in approximately 7% of African Americans which changes a lysine to 
an asparagine at codon 39 (Molitemo et al, 2004). Individuals with an asparagine at codon 
39 had a slight, but significant thrombocytosis (p<0.001). This was associated with a 
marked decrease in c-mpl expression in two patients, as assayed by western blot and Q-RT- 
PCR of 32D cells transformed with mutant or wild type c-mpl. However, circulating TPO 
levels were not investigated in the study.
A c-mpl mutation has also been identified in a family with HT (Ding et al, 2004). 
The activating point mutation, G to A at nucleotide 1073 of the c-mpl gene was identified
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in 8 affected family members, but was not present in 8 unaffected family members. The 
mutation led to replacement o f a serine residue at codon 505 with an asparagine. It was 
shown to confer IL-3 independence on Ba/F3 cells transfected with the mutant c-mpl, and 
random mutagenesis had previously shown that this mutation led to an increase in 
sensitivity to TPO in mice (Onishi et al, 1996). However, none of the 19 ET patients 
screened had the mutation.
Mutations in the c-mpl gene have not yet been described in ET patients. Two 
alterations to the c-mpl sequence were found in 2 out of 4 ET patients sequenced in one 
study. However, these were also found to be present in normal controls and assumed to be 
common polymorphisms (Kiladjian et al, 1997). A second study sequenced the whole 
coding region of c-mpl in 9 ET patients and found no alterations (Taksin et al, 1999). 
Another study detailed 7 young ET patients where no alterations to the c-mpl gene could be 
identified by direct sequencing (Randi et al, 2004). The number of ET patients investigated 
for c-mpl mutations is still small, so mutations to c-mpl in ET patients cannot be ruled out. 
However, as disease-specific mutations have not been identified in the 20 ET patients 
studied so far, it is unlikely that they are a major factor in the pathogenesis of ET.
In conclusion, the increased or normal circulating TPO levels in ET patients is not 
due to mutations in the 5’ UTR of the TPO gene. The evidence for the involvement of 
disregulated Mpl expression in the high serum/plasma TPO levels is strong, but further 
study of TPO regulation is necessary to determine whether altered TPO levels can be 
implicated in the pathogenesis of ET.
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Chapter 6
Polymorphisms in the TGFB1 and IL-6 genes in essential 
thrombocvthaemia patients
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6.1 Introduction
6.1,1 Transforming growth factor p i
The transforming growth factor family of proteins, originally isolated from Maloney 
MuSV transformed 3T3 fibroblasts, are involved in most processes concerned with somatic 
tissue development and renewal (De Larco & Todaro, 1978). Virtually every cell in the 
body, including haemopoietic cells, produces and has receptors for TGFp, although the 
main storage site of TGFp 1 is in the a-granules o f MKs and platelets (Assoian et al, 1983). 
In-situ hybridization using a TGFpl specific probe has demonstrated the presence of 
TGFpl mRNA in MKs indicating that TGFpi is synthesised in MKs, and 
immunohistochemical studies have directly shown storage of TGFpl in a-granules (Fava et 
al, 1990). Three highly similar isoforms o f TGFp have been identified in mammals, TGFpi, 
II and III (de Martin et al, 1987; Derynck et al, 1985; ten Dijke et al, 1988), and while the 
most studied isoform in haemopoietic tissue is TGFpi, all three isoforms have some 
involvement in the regulation o f haemopoiesis.
TGFp is generated by the production o f a primary translation product (Figure 6.1), 
which consists of three regions, a pre region (aa l-2 9 ) which forms a short signal peptide, a 
pro region (aa30-278) and active TGFp (aa279-390) (Gentry et al, 1988). The pro region, 
once cleaved, forms a homodimer termed latency associated protein (LAP) which non- 
covalently binds with TGFp dimers to form the ‘small complex’. This small complex 
therefore contains ‘latent’ TGFp which is prevented from reaching target cells (Miyazono 
et al, 1988). Latent TGFp binding proteins (LTBP) then bind the small complex to form the 
large complex, which can associate with the extra cellular matrix and act as a store of 
readily available TGFp (Wakefield et al, 1988).
Release of latent TGFp may occur in vivo by proteolytic cleavage by plasmin or 
transglutaminase, or conformational modification of LAP by thrombospondin. The in vitro 
release of latent TGFp is achieved by acidification, and therefore measured TGFp levels 
are often quoted as a combination o f active and acid inducible latent TGFp ((a+1) TGFp).
Once released, TGFp binds to TGFp receptor II which then recruits TGFp receptor 
I, both of which are serine/threonine kinase receptor family members. This leads to 
formation of a protein complex at the cell surface containing one TGFp dimer bound to a
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tetrameric TGFp receptor complex consisting of two TGFp receptor I and two TGFp 
receptor II molecules (Wrana et al, 1994). TGFp receptor I is then phosphorylated by the 
constitutively active TGFp receptor II and downstream signalling occurs via the Smad 
family of proteins (Massague, 1998).
6.1.2 TGFpl regulation o f  megakaryocytopoiesis
Regulation of haemopoiesis by TGFpl is complex, and TGFpl can have a positive 
or negative effect on proliferation and maturation depending on the lineage and/or 
developmental stage of the target cell. However, in the MK lineage, TGFpi acts as an 
inhibitor of both proliferation and maturation.
Proliferation assays using human BM CD34+ cells cultured in human plasma 
demonstrated that the percentage of MK cells produced was reduced 3-4 fold compared to 
serum free cultures supplemented with a standard cytokine cocktail (IL-3, IL-6 and IL-11). 
Addition of a neutralising TGFpi monoclonal antibody to the cultures containing plasma 
restored MK growth to the level of the serum free cultures, indicating that TGFpi was the 
factor inhibiting proliferation of the MK lineage (Berthier et al, 1993). Formation of HPP- 
CFU-MK in cultures o f murine BM cells was completely abrogated in the presence of 
TGFpi (Jackson et al, 1994b). Also, murine BM cells grown in liquid culture in the 
presence of TGFpi showed a 50% decrease in AChE activity, a marker of MK maturity, 
and only 20% of single MKs in culture showed a size increase compared to 68% without 
TGFpl demonstrating inhibition o f MK maturation (Ishibashi et al, 1987).
TGFpi inhibition of the MK lineage may occur, at least in part, through the IL-3 
and/or TPO signalling pathways. IL-3 promoted MK colony formation was inhibited by 10- 
200 pg/ml TGFpl in cultures of murine BM progenitor cells. However, inhibition could not 
be demonstrated in cultures stimulated by IL-6, even using 200-500 pg/ml TGFpl, 
implying specific suppression of IL-3 stimulation (Han et al, 1992). Inhibition of IL-3 
induced MK formation occurs at the CFU-MK stage of differentiation as CFU-MK 
expansion stimulated by IL-3 is inhibited by TGFpl, but not CFU-MK expansion 
stimulated by IL-1 or IL-6 (Jackson et al, 1994b). Formation of the less mature colony 
forming unit HPP-CFU-MK is inhibited by TGFpi whether stimulated by IL-1, IL-3 or IL- 
6 .
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As well as the specific inhibition of IL-3 mediated MK proliferation and 
differentiation, TGFpi inhibits MK growth mediated by TPO. Cultures of the TPO 
responsive cell line Mo-7e containing lOOng/ml of either TPO, TGFp 1 or both were 
analysed for proliferation by 3H thymidine incorporation. Cultures stimulated with TPO 
showed a dose-dependent 6 fold increase in thymidine incorporation compared to 
unstimulated control, but thymidine incorporation in cultures containing TGFpi were not 
significantly different to unstimulated control. When both TGFpi and TPO were added to 
cultures of Mo-7e cells, the growth enhancing effect of TPO was completely abrogated and 
no significant difference in thymidine incorporation could be demonstrated compared to 
unstimulated control cultures (Kalina et al, 2001). Inhibition of TPO stimulated 
megakaryocytopoiesis may occur by modulation of TPO expression as human BM stromal 
cells cultured with TGFpi have been shown to decrease significantly the expression of 
TPO mRNA in a dose-dependent fashion (Sungaran et al, 2000). However, TPO expression 
can also be up-regulated by low dose TGFpl in the BM microenvironment as discussed 
more fully in Chapter 5 (5.1.4)
Platelets from gray platelet syndrome patients, a condition where platelets have little 
or no granules, showed only minor inhibition of MK growth in human BM cultures, further 
suggesting that TGFpl inhibits MK growth (Mitjavila et al, 1988).
6.1.3 TGFpl in cMPDs
TGFpl levels may be dysregulated in cMPD. The mean level of (a+1) TGFpi from 
10 healthy controls was 320 ±52 ng/109 platelets, but was raised to between 420-900 ng/109 
platelets in 7 patients with cIMF (p<0.003) (Martyre et al, 1991). This raised TGFpl level 
was confirmed in platelet lysates from 4 cIMF patients by a second group (Zauli et al, 
1993). Expression of TGFpl mRNA was elevated in PBMNC of 7 out of 8 patients with 
cIMF compared to healthy controls by northern blot analysis (Martyre et al, 1994). An 
increase in secreted peptide was also identified, and immunohistochemistry demonstrated 
co-localisation of antibodies to TGFpl and gpllbllla indicating localisation of the TGFpl to 
MKs. However, BM biopsies from 11 cIMF patients showed no difference in MK staining 
intensity using an antibody to TGFpi (Chou et al, 2003). Also, no difference in TGFpi 
expression levels could be detected in BM CD34+ cells from 8 cIMF patients by RT-PCR 
analysis (Bousse-Kerdiles et al, 1996). This suggests that TGFpi regulation between the
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BM microenvironment and circulating platelets may be disrupted, and this may be 
important in the pathogenesis o f cIMF.
Four groups have reported TGFpl levels in ET. In one study, levels of (a+1) TGFpi 
in platelet lysates from 7 ET patients were similar to normal controls (Zauli et al, 1993). 
However, other studies have shown that circulating TGFpl levels in ET patients were 
raised in comparison to normal controls.
TGFpi levels were measured from serum samples obtained from 16 normal 
controls, 10 clonal ET patients and 12 polyclonal ET patients. The level of TGFpl in 
normal controls was 34.4ng/ml (range 22.8-56.0), 44.4ng/ml in clonal ET patients (range 
23-108.1) and 46.4ng/ml (range 4.8-71) in polyclonal ET patients. While there was no 
significant difference between the three cohorts, and the range of results was large and 
overlapping, there was a trend towards higher serum TGFpi levels in ET (Harrison et al, 
1999b). Because in vitro release o f TGFpl from platelets may affect results from serum 
samples, plasma TGFpl levels were also measured. Plasma TGFpi levels for normal 
controls were 5.1ng/ml (range 1.6-5.8), 8ng/ml (range 4.3-11.4) for 5 clonal ET patients, 
14ng/ml (range 4.4-22.6) for 5 polyclonal ET patients and 5.6ng/ml (range 5.6-11.9) for 5 
RT patients. The plasma data showed a more pronounced increase in TGFpi levels in ET 
patients compared to controls, although a significant difference was still not reached, 
probably due to small patient numbers (Harrison et al, 1999b). In a second study mean 
plasma levels of both active (371.14 ±205.35 pg/ml) and latent (17.07 ±7.13 ng/ml) TGFpi 
in 10 ET patients were shown to be significantly higher than those in 6 healthy volunteers 
(95.50 ±4.95 pg/ml and 6.57 ±2.68 ng/ml respectively) (Kuroda et al, 2004). A third study 
also showed that plasma TGFpl levels o f 1,405 pg/ml (range 852-1,851.4) in 14 ET 
patients were significantly higher (p<0.0001) than 606.9pg/ml (range 286.5-858) for 
controls (Lev et al, 2002). However, no significant difference in TGFpi levels from platelet 
lysates could be demonstrated between ET patients and normal controls in this third study.
When taken together these studies suggest that levels of TGFpi in platelets from ET 
patients may be normal, but circulating levels appear to be increased. While this appears 
counter intuitive in ET patients, since increased levels o f an inhibitor of 
megakaryocytopoiesis would be expected to lead to a decrease in MK proliferation, ET 
patients may be resistant to the inhibitory effects of TGFpl.
In 8 ET patients, CFU-MK derived from BM CD34+ cells were significantly 
(p<0.05) less responsive to the inhibitory activity of platelet lysates than CFU-MK derived
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from BM CD34+ cells from 8 normal controls. A 10 fold higher platelet lysate 
concentration was required to inhibit CFU-MK derived from ET BM CD34+ cells than that 
needed for CFU-MK derived from normal BM CD34+ cells (Zauli et al, 1993). Reversal of 
all inhibition occurred by addition o f anti-TGFpi antibodies, suggesting that TGFpl was 
the main factor responsible for the inhibition.
This data has been confirmed in a second cohort of 10 ET patients. The percentage 
suppression of 1 ng/ml TGFpi on CFU-MK derived from BM CD34+ cells from 5 normal 
controls was 95 ±2.6%, but this was reduced to 56 ±11.8% for CFU-MK derived from BM 
CD34+ cells from ET patients (Kuroda et al, 2004). This reduced inhibition was associated 
with low level expression of Smad4, a down stream effector molecule in TGFpl signalling, 
in 5 patients studied from the ET cohort. Transfection of the Smad4 gene into BM MNC 
from ET patients restored the inhibitory effects o f TGFpl. Thus ET MK progenitors may 
not be inhibited by TGFpl to the same extent as normal MK progenitors, and this may be 
due to decreased expression o f Smad4.
6.1.4 TGFpl Polymorphisms
A number of polymorphisms have been described at the TGFpl gene locus. Using 
RT-PCR-SSCP a single group described 5 SNPs in TGFpl (Awad et al, 1998). Four of 
these polymorphisms occur either in the promoter or coding regions of the gene and may 
affect TGFpl expression. A G to A and a C to T substitution occur 800bp and 509bp 
upstream of the AUG respectively, in the promoter region of the gene. The other two 
polymorphisms, a T to C substitution at nucleotide 869 and a G to C substitution at 
nucleotide 915, occur within the signal peptide. A number of studies investigating the 
effects of these polymorphisms have demonstrated their involvement in disease.
The polymorphisms in the promoter region of TGFp 1 were both identified in lung 
carcinoma patients, but were not thought to be linked to disease (Awad et al, 1998). 
However, in 170 pairs o f twins a T allele at position -509 of the TGFpl gene led to an 
increase in serum concentration of (a+1) TGFpl as measured by ELISA. The mean TGFpl 
level in CC homozygous subjects was 3.83 ng/ml, in TC heterozygous individuals 
5.06ng/ml, and in homozygous TT individuals 7.62 ng/ml, suggesting that TGFpl 
expression may be influenced by the genotype at the TGFpl locus (Grainger et al, 1999).
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At codon 10 a T869C polymorphism, which changes a leucine to a proline, is linked 
to osteoporosis (Yamada et al, 1999). Possessing the C allele (the higher producer allele) 
was shown to confer resistance against osteoporosis. In a study of 356 healthy Japanese 
students a 5-6% increase in bone mineral density was measured in subjects homozygous for 
the C allele compared to those homozygous for T alleles, with a 2% increase for 
heterozygous individuals. This was thought to occur due to a local increase of TGFpl in the 
bone marrow leading to higher proliferation of osteoclasts for which TGFpi is a promoter 
of proliferation.
The G915C substitution in codon 25 converts an arginine, a large charged polar 
amino acid, to a proline, a small nonpolar amino acid, at codon 25 of the preproTGFpi 
translation product and is associated with inter individual variation in plasma TGFpi 
concentration. This polymorphism falls in the signal sequence of the protein, and may alter 
the efficiency with which TGFpl processing can occur, thus changing its rate o f release. 
Stimulated lymphocytes cultured from homozygous G individuals produced 10,037 ± 745 
pg/ml TGFpl compared to 6,729 ± 883 pg/ml (p<0.02) for heterozygous individuals. This 
has also been linked to disease pathology. Lung transplant patients with the G allele 
demonstrate higher levels o f fibrosis post transplant than other patients (Awad et al, 1998).
A shift to the higher producer allele at any of these polymorphic loci could lead to 
the increase in the circulating levels o f TGFpi described in ET patients.
6.1.5 IL-6
Originally described as B-cell stimulating factor because it induces maturation in B- 
cells, IL-6 is the founder member o f the IL-6 cytokine family (Hirano et al, 1986). A 26 
KDa protein, IL-6 consists o f 212 amino acids, the first 28 being the signal peptide. Its 
specific interaction with the IL-6 receptor (IL-6R) leads to signal transduction via gpl30 
dimerisation and tyrosine phosphorylation (Hibi et al, 1996; Hirano et al, 1997).
IL-6 has been shown to stimulate platelet production. IL-6 administered to mice led 
to a dose-dependent increase in platelet count. A 50-60% increase in platelet number was 
seen at plateau, associated with an increase in megakaryocyte size, but not number 
(Ishibashi et al, 1989a). This size increase was associated with an increase in average 
ploidy from 16N to 32N, indicating that IL-6 is important for MK differentiation but does 
not appear to affect proliferation (Ishibashi et al, 1989a; Hill et al, 1991). IL-6 alone did not
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influence CFU-MK formation from murine BM cells, but did augment the number of 
colonies produced when IL-3 was added (Ishibashi et al, 1989b). Also, cultures o f murine 
BM cells treated with IL-6, G-CSF, GM-CSF and/or IL-3 in various combinations 
demonstrated that other cytokines augment the action of IL-6 in either a synergistic or 
additive fashion (Quesenberry et al, 1991). Therefore, IL-6 can stimulate proliferation as 
well as maturation, but only in the presence o f other factors.
Studies using human BM or MK cells have similarly shown that IL-6 alone can 
stimulate the maturation of MKs and works in synergy or addition with other growth 
factors on proliferation. No increase in CFU-MK was demonstrated in cultured human BM 
or cord blood cells stimulated by IL-6 alone, but an increase in size and DNA content up to 
16N was recorded (Imai et al, 1991; Kimura et al, 1990). However, by introducing other 
cytokines into culture mixtures, IL-6 did have an effect on human MK proliferation. The 
addition of IL-6 to cultures o f human MKs containing IL-3 led to a 2 fold increase o f the 
proliferation seen with IL-3 alone (Bruno & Hoffman, 1989). Also, human BM cells 
enriched for MKs gave no colony growth with IL-6 or IL-1 a  alone, but cultures containing 
both cytokines did proliferate (Bruno et al, 1991b). Thus IL-6 is able to stimulate 
proliferation and maturation of human MKs in vitro. In fact the combination of SCF, IL-3 
and IL-6 has been shown to be as potent as TPO for MK growth in cultures of CD34+ cells, 
although the number o f platelets produced was 10 fold lower than with TPO alone, 
suggesting that IL-6 can stimulate an increase in number, size and DNA content in MK, but 
is not involved in platelet shedding (Bruno et al, 1991b; Norol et al, 1998).
Administration of IL-6 to patients with chemotherapy-induced thrombocytopenia 
led to significant increases in platelet counts in vivo. However, it is not in common use as a 
therapeutic agent due to a high level o f systemic toxicity (D'Hondt et al, 1995; Gordon et 
al, 1995; Schrezenmeier et al, 1995; van Gameren et al, 1994).
Platelet counts in the IL-6 knockout mouse were within the normal range at 
approximately 900x106/ml and mice developed normally, suggesting that while IL-6 can 
augment platelet production, it is not essential for normal thrombopoiesis (Gainsford et al, 
2000; Kopf et al, 1994). In mpl knockout mice, which have platelet counts of around 
100xl06/ml, the platelet production is not due to the action of IL-6, as mpl/IL-6 double 
knockouts have comparable platelet counts (Gainsford et al, 2000). Thus, while increasing 
availability of IL-6 in vivo can increase platelet counts, reducing IL-6 levels does not lead
160
to decreased platelet counts, suggesting that normal thrombopoiesis is not reliant on 
stimulation from IL-6.
IL-6 may affect thrombopoiesis in vivo via stimulation of TPO expression. As the in 
vitro experiments demonstrated no increase in platelet numbers with the addition of IL-6, 
but in vivo administration in mice and humans has resulted in platelet count increases, it is 
clear that other factors are involved in augmentation of platelet numbers by IL-6. Upon 
administration o f 30 pg/kg/d IL-6 to cancer patients, plasma TPO levels increased from 
basal levels o f 152 ±35 pg/ml to 630 ±110 pg/ml. Platelet counts in normal mice increased 
with IL-6 administration from 1,025 ±80 x l0 6/L to 1,492 ±70 x l06/L, and this increase was 
accompanied by TPO plasma level increases of >2.5 fold (Kaser et al, 2001). Neutralising 
antibodies to TPO severely abrogated the thrombopoietic effect of IL-6, suggesting that the 
increase in platelet counts caused by IL-6 administration was due to increased TPO 
signalling.
A number of groups have measured IL-6 levels in ET patients with conflicting 
results. Serum IL-6 levels in samples from 13 ET patients were 1.56 U/ml ±1.2, which was 
not significantly different from levels measured in 71 control samples, 2.19 U/ml ±1.08 
(Hollen et al, 1991; Hollen et al, 1992). Similar results have been reported in plasma 
samples where a mean value of 0.33 ±0.12 fmol/ml was recorded in 45 samples from ET 
patients and 0.31 ±0.19 in 25 normal control samples (Alexandrakis et al, 2003). Median 
IL-6 levels in plasma samples from 10 clonal ET patients were 4 pg/ml (range 0-14) which 
was not significantly different from 12 polyclonal patients, median 3.8 (range 0-12) or 16 
normal controls, median 6 (range 0-19) suggesting that the levels o f IL-6 in plasma from 
ET patients is not related to clonality status (Harrison et al, 1999b).
However, elevated IL-6 levels have been reported in a cohort o f 37 patients with 
cMPD containing 16 ET, 10 cIMF, 8 CML and 3 PV patients. Mean IL-6 levels in serum 
samples from the 37 patients with cMPD were 1.6 ±0.4 pg/ml, significantly raised in 
comparison to 0.2 ±0.1 pg/ml for normal controls (p<0.02) (Uppenkamp et al, 1998). Only 
8 of the 37 cMPD patients had IL-6 levels above the normal range, and the diagnosis of 
these 8 patients is not documented, however, this result indicates that elevated IL-6 levels 
may be involved in the pathogenesis of ET in at least a small number of cases.
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6,1,6 IL-6 polymorphisms
Since administration o f exogenous IL-6 can lead to an increase in platelet count, a 
polymorphism resulting in an intrinsic increase in circulating IL-6 levels may have a 
similar effect and could contribute to the pathogenesis of ET. A single nucleotide 
polymorphism, a G to C at nucleotide -174 in the promoter region of the IL-6 gene has been 
identified which affects plasma levels of IL-6. A study o f fasting plasma IL-6 levels in 
samples from 102 healthy Caucasians measured median IL-6 levels for individuals 
homozygous GG as 2.74 pg/ml (95% Cl 2.43-3.10), heterozygous GC 2.64 pg/ml (95% Cl 
2.35-2.97) and homozygous CC 1.63 (95% Cl 1.44-1.86) showing that G at position -174 is 
the higher producer allele (Fishman et al, 1998).
The G-174C polymorphism is a risk factor in a number of disorders. Following BM 
transplantation, patients can develop a systemic toxicity to the donor cells termed graft 
verses host disease (GVHD) which is caused by repopulating donor immune cells reacting 
to host antigen. Circulating IL-6 levels are elevated in both chronic (cGVHD) and acute 
GVHD (aGVHD) and in aGVHD, IL-6 levels correlate with severity and prognosis. In a 
study of 80 patients BM transplanted for haematological malignancy, patients with a G 
allele at nucleotide -174 had a tendency to higher grades of aGVHD and patients 
homozygous for the G allele had an increased incidence of chronic GVHD compared to 
patients homozygous for the C allele (Cavet et al, 2001). This suggests that the G allele can 
directly influence disease.
A number of HIV patients suffer with Kaposi sarcoma (K-S), an angioproliferative 
disorder associated with lesions containing high levels of IL-6, and which may progress to 
malignancy. In a cohort of 115 HIV patients, homozygotes for the G allele were over 
represented in the K-S group, and homozygous C patients under represented, compared to 
125 HIV patients without K-S (Foster et al, 2000), suggesting that carrying the G allele 
may be a risk factor for K-S.
A disorder associated with changes in IL-6 levels is systemic juvenile chronic 
arthritis (sJCA). One of the main symptoms of sJCA is a spiking fever which correlates 
with spikes in IL-6 serum levels. In a study of 97 sJCA patients less severe symptoms 
occurred in those with the CC genotype compared to other genotypes (Fishman et al, 
1998), suggesting that a G allele at nucleotide -174 is an important modulator of disease 
severity for sJCA.
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6.1.7 Aim
The aim of the work detailed in this chapter was to analyse the four polymorphisms 
previously reported in the TGFpl gene, and the G-174C polymorphism described in the IL- 
6 gene, in a cohort o f ET patients and haematologically normal controls, using PCR and 
restriction enzyme analysis.
6.2 Materials and Methods
6.2.1 Patients and Samples
Peripheral blood samples were collected from 75 patients with a sustained 
thrombocytosis, 66 with a diagnosis o f ET according to the PVSG criteria and 9 with a 
provisional diagnosis o f ET but with the PVSG criteria yet to be confirmed, and 100 
haematologically normal controls. O f the 75 patients, 11 were clonal and 24 were 
polyclonal by XCIP analysis, the other 40 samples were uninterpretable due to age or a 
constitutively imbalanced XCIP, or were male. DNA was prepared from purified 
neutrophils as described in chapter 2 (2.2.1,2.2.2).
6.2.2 PCR
Approximately lOOng o f DNA was used for 35 cycles of PCR using the primers 
listed in Table 6.1, at an annealing temperature of 64°C. The location of the PCR primers 
and the polymorphisms in the TGFpi and IL-6 genes are shown in Figure 6.2.
6.2.3 Analysis of polymorphisms
PCR was carried out as described above using neutrophil DNA. All TGFpi 
restriction digests contained 3pi of PCR product with BSA and appropriate buffer in a final 
volume of 6pl. The polymorphisms at -800 and -509 were investigated using the product of 
primers TB1/F and TB1/R, the G-800C polymorphism was analysed using BsaH\, and the 
C-509T polymorphism with AJR\. Polymorphisms at 869 and 915 were investigated with 
primers TB2/F and TB2/R, the T869C polymorphism was analysed using MspAl, and the 
G915C polymorphism using Sau96 I. The IL-6 polymorphism at nucleotide -174 was 
analysed using primers IL-6/F and IL-6/R with Hinfi digestion. The Hinfl digestion
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Primer Name Primer Sequence 5’—>3’
TB1/F CGTGGAGTGCTGAGGGACTCTGCCTCCGAC
TB1/R AGTGGGAGGAGGGGGCAACAGGACACCTTA
TB2/F CCACCCACCTTCTGGTACCAG
TB2/R TCTTGCAGGTGGATAGTCCCG
IL-6F GGCTGCGATGGAGTCAGAGGA
IL-6R a a g a t t g t g c a a t g t g a c g t c c t t t a g a a t
Table 6.1
Table of Primers used to study the TGFpi and IL-6 polymorphisms
Primer names and sequences, with mismatched bases underlined.
(A) TGFpl gene locus Promoter Sequence Coding Sequence
Polymorphic loci -800 -509 869 915
11 11
DNA ------------------------------------ 1 1 H 2 H 3 ~ -----------
,  TB1 TB2PCR fragments ^ ^  ^ p
352bp 339bp
(B) IL-6 gene locus Promoter Sequence Coding Sequence
Polymorphic locus
DNA
-174
1
1 — 2 — 3 — 4 — 5 —
PCR fragment
IL-6 
<4---------- ►
353bp
Figure 6.2 
Gene structure of the TGFpi and IL-6 loci
Location of the (A) TGFpl and (B) IL-6 polymorphisms and the PCR 
fragments used to analyse them. The boxes represent exons and the 
solid lines represent introns
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contained lOpl of PCR product and lx  buffer 2 in a final volume of 12pl without BSA. All 
PCR products were digested overnight at 37°C according to manufacturers instructions 
(NEB). The samples were then electrophoresed through agarose gels and visualized by 
ethidium bromide staining. Sizes of fragments expected from the digestions are shown in 
Figure 6.3 and Figure 6.4 shows the digestion patterns for each genotype visualised by 
ethidium bromide staining o f agarose gels.
6.2.4 Confirmation of Digests
Inconsistencies in the intensity o f the 108bp band were observed in the digestion 
patterns obtained during analysis o f the polymorphism in the IL-6 gene. Therefore, a small 
number of samples were sequenced to confirm the results. A 50pl PCR using the IL-6 
primers was prepared, cleaned using Wizard PCR clean-up kit (Promega) and eluted into 
50pl of distilled water. Cycle sequencing was then carried out as described in chapter 2 
(2.2.9) using 20ng of PCR product, the IL-6/F primer and BigDye Terminator Ready 
Reaction Mix (Applied Biosystems).
6.2.5 Statistics
X2 analysis was carried out using Microsoft Excel XP.
6.3 Results
6.3.1 Polymorphism analysis of TGFpl
The G to C polymorphism at nucleotide -800 of the TGFpl gene was analysed in 75 
ET patients and 100 normal controls. The ET patient cohort had a gene frequency for G of 
0.93, normal controls had a gene frequency for G of 0.94 (Figure 6.5A). The percentages of 
the three genotypes in the ET patients were 87% homozygous GG, 12 percent were 
heterozygous GC and 1% were homozygous for the CC allele. The percentages o f each 
genotype were similar in normal control samples, 87% were homozygous GG, 13% were 
heterozygous GC and none were homozygous for CC alleles. No difference in genotype or 
gene frequency could be demonstrated between clonal and polyclonal patients either. The 
gene frequency for G in 11 clonal patients was 1.0 and in 24 polyclonal patients was 0.9.
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(A) TB1 PCR product
BsaH I  digestion +/_ A = 352 
(G-800A) I 0  = 323 + 29
PCR product |---------------------------------------   r -1 352 bP
Afl II digestion t  = 32^ + 31 J/
(C-509T) +A
(B) TB2 PCR product
MspA I  digestion 
(T869C)
PCR product
+
Sau961 digestion 
(G915C)
T = 278+40+21 
C = 266+40+21+12
+ +
+ /- +
t t t t
+
i 1
t
+  + /-  
G =165+67+47+40+20 
C =132+67+47+40+33+20
339 bp
(C) IL-6 PCR product
+ +  + /-
PCR product I— ^ ^ ---------1 353 bp
H inf I  digestion G = 204+108+30+11
(G-174C) C = 204+138+11
Figure 6.3 
Restriction enzyme digests for the TGFpi and IL-6 
polymorphisms.
Diagram showing the three PCR fragment sizes, enzyme cutting sites 
and digested product sizes for each of the five polymorphisms
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TGFpl TGFpl TGFpi
G-800A C-509T T869C
a— 352 <+- 352
^— 323 +— 321
GA GG AA CT TT CC TC TT CC
278
266
TGFpi
G915C
GC CC
IL-6
G-174C
^— 165
< 132 138
108
GC CC GG
Figure 6.4  
R estriction enzym e digest patterns for the T G F p i and IL-6  
polym orphism s
On
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Genotype Allele frequency
(A) 100
80
60
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GG GA AA
I | ET Patients (n = 75)
I I Normal Controls (n = 100)
I | Clonal ET Patients (n = 11)
□  Polyclonal ET patients (n = 24)
■
GG GA AA o  A
Figure 6.5
The genotypes and allele frequencies for the G -800A  T G F pi prom oter  
polym orphism  in
(A) All ET patients and norm al controls
(B) C lonal and polyclonal ET patients.
All clonal patients were homozygous GG, polyclonal patients were 83% GG, 13% 
heterozygous GA and 4% homozygous AA (Figure 6.5B).
At nucleotide -509 a C to T polymorphism was analysed in 75 ET patients and 100 
normal controls. The gene frequency of the CC allele was 0.71 for ET patients, and 0.70 for 
normal controls (Figure 6.6A). The percentage of patients with each genotype was 52% for 
homozygous CC patients, 39% for heterozygous CT patients and 9% for patients 
homozygous for the TT allele. The percentages of each genotype in normal control subjects 
were homozygous CC 48%, heterozygous CT 44% and homozygous TT 8%. No significant 
difference in genotype or gene frequency could be demonstrated between clonal and 
polyclonal patients either. The gene frequency for C in 11 clonal patients was 0.78 and in 
24 polyclonal patients was 0.65. Clonal patients were homozygous CC 64%, heterozygous 
CT 27% and homozygous TT 2%. Polyclonal patients were 38% CC, 54% heterozygous 
CT and 8% homozygous TT (Figure 6.6B). While clonal and polyclonal patient genotypes 
were slightly different, this is most likely due to the small size of each patient cohort rather 
than disease specificity, although investigation of this polymorphism in a larger cohort 
would be useful.
These data suggest that there are no significant differences in allele frequency or 
genotype between ET patients and normal controls, or between clonal and polyclonal ET 
patients, at either of the polymorphic loci in the promoter region of TGFpl gene.
The T to C polymorphism at nucleotide 869 of the TGFpi gene was analysed in 67 
ET patients and 100 normal control subjects. The allele frequency of T alleles in ET 
patients was 0.68 and in normal controls was 0.62 (Figure 6.7A). The percentages of the 
three genotypes in the ET patients were 45% homozygous T, 46% heterozygous TC and 
9% homozygous C. The percentages of each genotype were similar in normal control 
samples, 36% were homozygous T, 51% were heterozygous TC and 13% were 
homozygous for C alleles. The gene frequency for C in 11 clonal patients was 0.37 and in 
24 polyclonal patients was 0.3. 9% of clonal patients were homozygous CC, 55% 
heterozygous CT and 36% homozygous TT. Polyclonal patients were 4% CC, 52% 
heterozygous CT and 43% homozygous TT (Figure 6.7B).
At nucleotide 915 the G to C polymorphism was analysed in 75 ET patients and 100 
normal controls. The allele frequency for the G allele was 0.93 for ET patients and 0.94 for 
normal controls. The percentages of each genotype in ET patients were GG 85%, CG 15% 
and CC 0%, and the percentages in normal control subjects were very similar, GG 88%, GC
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Genotype Allele frequency
(A)
m n
I | ET Patients (n = 75)
CH Normal Controls (n =  100)
(B) 100
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CC CT TT T
I | Clonal ET Patients (n = 11)
I I Polyclonal ET patients (n = 24)
Figure 6.6
The genotypes and allele frequencies for the C -509T  T G F p l prom oter  
polym orphism  in
(A) A ll ET patients and norm al controls
(B) C lonal and polyclonal ET patients.
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Figure 6.7
The genotypes and allele frequencies for the C 869T T G F pi coding  
sequence polym orphism  in
(A) All ET patients and norm al controls
(B) C lonal and polyclonal ET patients.
12%  and  C C  0 %  (F ig u re  6 .8 A ). C lo n a l p a tie n ts  had  a gen e  freq u en cy  o f  0 .8 6  fo r G a lle le s  
and  p o ly c lo n a l p a tie n ts  0 .9 6 . T h e  p e rc e n ta g e s  o f  each  g en o ty p e  a t 915  o f  th e  T G F p i gen e  
in c lo n a l p a tien ts  w ere  0 %  h o m o z y g o u s  C C , 2 7 %  h e te ro z y g o u s  C G  and  7 3 %  h o m o z y g o u s  
G G . P o ly c lo n a l p a tien ts  w e re  no t s ig n if ic a n tly  d iffe ren t w ith  0%  h o m o z y g o u s  C C , 8%  
h e te ro zy g o u s  C G  and  9 2 %  h o m o z y g o u s  G G  (F ig u re  6 .8B ).
T h u s  no  s ig n if ic a n t d iffe re n c e s  in a lle le  freq u en cy  o r  g e n o ty p e  b e tw een  E T  p a tien ts  
and  n o rm al co n tro ls  c o u ld  be d e m o n s tra te d  at e ith e r  o f  th e  p o ly m o rp h ic  loci in th e  co d in g  
reg ion  o f T G F p l  gene.
6.3.2 Polymorphism analysis o f  IL-6
T he G -1 7 4 C  p o ly m o rp h ism  in th e  p ro m o te r  reg io n  o f  th e  IL -6 g e n e  w as  a n a ly sed  in
75 E T  p a tien ts  and  100 n o rm a l c o n tro ls . T h e  a lle le  f req u en cy  in E T  p a tie n ts  fo r th e  G  a lle le
w as 0 .65  and  in n o rm al c o n tro ls  w a s  0.61 (F ig u re  6 .9 A ). T h e  p e rc e n ta g es  fo r each  g en o ty p e
in ET  p a tien ts  w ere  3 9 %  h o m o z y g o u s  G G , 5 2 %  h e te ro z y g o u s  G C  and  9 %  h o m o z y g o u s
C C . In n o rm al co n tro ls  th e  p e rc e n ta g e s  w e re  4 5 %  h o m o z y g o u s  G G , 3 3 %  h e te ro z y g o u s  G C
and  2 2 %  o f  co n tro ls  w ere  h o m o z y g o u s  fo r  th e  C a lle le . T h ere  a re  m in o r d iffe re n c es  in the
p e rcen tag es  o f  each  g e n o ty p e  b e tw e e n  E T  p a tie n ts  and  no rm al co n tro ls . H o w ev er, th e  gen e
freq u en cy  o f  each  a lle le  is th e  sam e  in E T  p a tie n ts  as no rm al co n tro ls  an d  th e  sam p le  size  is
sm all. 55%  o f  c lonal p a tie n ts  w e re  h e te ro z y g o u s  C G  and  4 5 %  w ere  h o m o z y g o u s  G G ,
po ly c lo n a l p a tien ts  w ere  5 0 %  C G  an d  5 0 %  G G . N o  C C  h o m o zy g o te s  w ere  p re sen t in e ith e r
c lonal o r p o ly c lo n a l c o h o rts  (F ig u re  6 .9 B ). A s  th e re  is n o  d iffe ren ce  b e tw een  th e  re su lts  fo r 
o r  n o rm a l c o n tro ls
c lonal and  p o ly c lo n a l p a tie n ts ^ it  is um iK ely th a t th e  G -1 7 4 C  p o ly m o rp h ism  in th e  p ro m o te r  
reg io n  o f  th e  IL -6 g en e  is im p o rta n t fo r th e  p a th o g e n e s is  o f  ET.
6.3.3 Sequencing o f  the IL-6 gene
A n a ly s is  o f  th e  IL -6  p o ly m o rp h ism  w a s  c o m p lica ted  by p ro b le m s w ith  th e  d ig est 
p a tte rn . A lle le s  w ith  a G a t n u c le o tid e  -1 7 4  w o u ld  p ro d u ce  ban d s at 2 0 4 b p , 108bp, 30bp  
and  1 lb p  upon  d ig es tio n  o f  th e  IL -6  P C R  p ro d u c t w ith  H infl, and  d ig es tio n  o f  C co n ta in in g  
a lle le s  w o u ld  p ro d u ce  b a n d s  o f  2 0 4 b p , 138bp and  1 lb p . T he  h e te ro zy g o te  co u ld  be d ifficu lt 
to  d e te rm in e  d u e  to  v a ria tio n  in th e  in ten s ity  o f  th e  108bp band . T o  te s t th e  acc u ra cy  o f  the  
d ig es t re su lts , four sa m p le s  w ere  p rep a red  fo r seq u en c in g . T w o  h e te ro z y g o u s  in d iv id u a ls  
w ere  in v es tig a ted , o n e  w ith  a h ig h  in ten s ity  b an d  a t 108bp and  an o th e r w ith  a low  in ten sity
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Figure 6.8
The genotypes and allele frequencies for the C 915G  T G F p i coding  
sequence polym orphism  in
(A) A ll ET patients and norm al controls
(B) C lonal and polyclonal ET patients.
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Figure 6.9
The genotypes and allele frequencies for the C -174G  IL-6 prom oter  
polym orphism s in
(A) All ET patients and norm al controls
(B) C lonal and polyclonal ET patients.
band at 108bp. Two other individuals were sequenced, a GG homozygote and a CC 
homozygote, to confirm the results (Figure 6.10). Both the individuals heterozygous by 
restriction enzyme analysis were shown to have both C and G alleles. The sample with a 
more intense band at 108bp (Figure 6.10A) also had a larger G peak at nucleotide -174 
compared to the sample with a less intense band at 108bp (Figure 6.1 OB). However, this is 
likely to be technical variation relating to the sequencing analysis. The size of the G peak at 
nucleotide -173 is also significantly different between the two samples and it is likely that 
this is affecting the height of the G peaks at nucleotide -174.
6.4 Discussion
TGFpl and IL-6 are able to alter platelet production in vitro and in vivo. TGFpl is 
a negative regulator of thrombopoiesis, and IL-6 is a positive regulator of thrombopoiesis. 
Polymorphisms have been identified in the TGFpi and IL-6 genes which can affect protein 
expression. Two polymorphisms are in the promoter region of the TGFpl gene, two are in 
the signal peptide encoding region of the TGFpl gene and one polymorphism is in the 
promoter of the IL-6 gene. The work described in this chapter has investigated both the 
allele frequency and genotype at each of these five polymorphic loci to establish whether 
they might have a role in the pathogenesis of ET. All polymorphisms were analysed using 
PCR and restriction enzyme digestion of DNA extracted from neutrophils obtained from a 
cohort of ET patients and 100 haematologically normal individuals.
Two polymorphisms in the promoter region of the TGFpi gene (G-800A and C- 
509T) were analysed. These polymorphisms may alter the rate of transcription by affecting 
the binding efficiency of transcription factor complexes. Nucleotide -800 of the TGFpi 
gene is located in a consensus sequence for the cAMP response element binding protein 
(CREB) family of transcription factors. An A at nucleotide -800 of the TGFpi gene, the 
lower producer allele, would be expected to decrease the DNA binding affinity of CREB 
family proteins, which may lead to a decrease in TGFpl expression (Kim et al, 1992). 
However, no significant differences in either genotype or gene frequency could be detected 
between ET patients and normal controls for either polymorphism, suggesting that the two 
promoter polymorphisms in the TGFpi gene do not have a role in the pathogenesis of ET.
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C C G G
(C ) | (D) |
Figure 6.10  
Sequences o f tw o heterozygotes and each hom ozygote at nucleotide -174  
o f the IL-6 gene.
(A) is a heterozygote GC patient with a low intensity band at 108bp on ethidium 
bromide stained agarose gels, (B) is a heterozygote GC patient with a high intensity 
band at 108bp. (C) and (D) are homozygotes for CC and GG respectively.
Black trace represents C, blue trace represents G. Arrows indicate nucleotide -174
- ' j
Two polymorphisms in the coding region of the TGFpl gene (T869C and G915C) 
were studied. Coding region polymorphisms may alter protein expression by mechanisms 
acting at the RNA or protein level. A sequence change may cause the mRNA to adopt a 
stem loop configuration, which would be expected to reduce the efficiency of translation. A 
less stable mRNA secondary structure may be produced which is more readily degraded, 
decreasing the availability of message which would lead to a decrease in protein 
expression. At the protein level, amino acid changes can lead to inefficient post- 
translational modification or disruption of signal sequence recognition which may reduce 
protein secretion rates from the cell, as can alterations in the signal cleavage site. However, 
the allele frequency and the percentage of each genotype in the ET patients and normal 
controls were not significantly different, suggesting that the two polymorphisms in the 
signal peptide encoding region of TGFpl are not involved in the pathogenesis of ET.
Undescribed polymorphisms or mutations may exist in the TGFpl coding or non­
coding regions which may affect TGFpi release into the circulation. However, as the major 
store of TGFpl is the a-granules of MK and platelets, it may be that normal release of 
TGFpi from the increased MK and platelet load in ET patients accounts for the increase in 
serum/plasma TGFpl.
In the promoter region of the IL-6 gene a G-174C polymorphism has been identified 
which affects plasma IL-6 levels. Alleles containing G are higher producer alleles and lead 
to increased circulating IL-6 compared to C containing alleles (Fishman et al, 1998). 
Binding of the glucocorticoid receptor, which is a transcriptional repressor, occurs around 
nucleotide -201 of the IL-6 gene (Ray et al, 1990). The G-174C polymorphism is close 
enough to nucleotide -201 to potentially influence binding efficiency of the glucocorticoid 
receptor. Also, a C at position -174 of the IL-6 gene creates a binding site for NF-1 in the 
gene promoter (Fishman et al, 1998). NF-1 has been shown to be a general repressor of 
transcription in HeLa cells and could therefore account for the decreased expression 
reported for C containing alleles (Rein et al, 1995).
No difference in allele frequency could be detected between ET patients and 
haematologically normal controls suggesting that the IL-6 polymorphism is not involved in 
ET. While the genotypes of the two groups were slightly different, this is probably due to 
small sample size rather than disease specificity. If the polymorphism was involved in ET it 
would be more likely to be involved in polyclonal pathogenesis. However, there was also
178
no correlation between genotype and clonality status in the ET patients, further suggesting 
that the G-174C polymorphism in the IL-6 gene in not involved in the pathogenesis of ET.
In conclusion, analysis of the G-800A, C-509T, T869C and G915C polymorphisms 
in the TGFpl gene and the G-174C polymorphism in the IL-6 gene has been unable to 
demonstrate any relationship between these polymorphisms and the pathophysiology of ET.
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Chapter 7
Analysis of differential mRNA expression between platelets from 
an ET patient with monoclonal myelopoiesis and a haematologicallv 
normal control using representational difference analysis
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7,1 Introduction
7.L I  Investigating differential m RN A expression
The pathogenesis o f ET may be extremely complex and could involve a number of 
genes, both known and/or previously undescribed. Mutations which affect gene function 
are likely to be important in disease pathology, but changes in gene expression levels, either 
gross or more subtle alterations, may also have a major role in disease pathology. A global 
approach was therefore adopted to study differences in gene expression between platelet 
mRNA obtained from ET patients and haematologically normal controls. A number of 
approaches are available to investigate differential gene expression, but 2 o f the most 
frequently used are representational difference analysis (RDA) and microarrays. 
Microarrays utilize a vast number o f defined oligonucleotide probes bound to a solid 
support medium which is then probed with fluorescently labelled cDNA. This technology is 
very powerful and able to identify large numbers o f differentially expressed genes. 
However, results can be complex and array technology is unable to identify novel 
sequences. RDA is able to detect changes in mRNA expression between two populations 
without prior knowledge o f sequence or specific genes. It is also extremely sensitive and 
has been able to identify known transcripts spiked into an RDA reaction which made up as 
little as 0.0005% o f total mRNA (O'Neill & Sinclair, 1997).
In its original form RDA was used to identify differences between genomic DNA 
populations by a series o f hybridization reactions and selective PCR amplification (Lisitsyn 
et al, 1993; Lisitsyn, 1995). This process was extensively modified to enable the analysis of 
differences in expressed mRNA populations (Hubank & Schatz, 1994) and further 
optimised to streamline the procedure and reduce the incidence o f false positive results 
(Pastorian et al, 2000).
Two populations o f RNA are prepared for an RDA procedure, the RNA population 
o f interest is used as tester and the control RNA population is used as driver. Successive 
rounds o f hybridization with an excess o f driver, followed by selective PCR, amplify and 
enrich for differentially expressed genes, and dilution o f the PCR products between rounds 
o f hybridization subtracts non-dififerentially expressed genes (Figure 7.1). At the end o f the 
process subtracted RDA products can easily be isolated by cloning, and identified by 
sequence analysis.
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Figure 7.1 
The RDA hybridisation and am plification  procedure
Amplification can only occur when sequences are only, or more highly, expressed in tester. This leads 
to enrichment for these sequences in the difference products (Modified from Hubank and Schatz 1994).
RDA has been used extensively in cell lines to assess gene expression. For example, 
RDA was used to compare RNA from U937 cells transduced with the AML/ETO fusion 
protein, generated from the t(8;21) translocation in AML, to vector only transduced control 
cells. 26 novel genes whose expression levels were significantly modulated by AML/ETO 
induction were identified (Fliegauf et al, 2004). The effects of cytokine stimulation have 
also been investigated by RDA in cell lines. The myeloblastic cell line 32Dcl3 was used to 
study the effect on RNA expression of IL-3 stimulation. Two aliquots of cells were 
prepared, one aliquot was starved for 24 hours without growth factors, the other aliquot was 
actively proliferating due to stimulation with 10% WEHI (conditioned media containing 
IL-3). A novel gene termed the small unstable apoptotic protein was shown to be up- 
regulated during apoptotic death due to IL-3 deprivation (Baker, 2003).
The differences between the starting populations of mRNA from cell lines should be 
solely due to how they have been manipulated for the experimental procedure. However, in 
primary cells the situation is more complex due to biological variation, which could cause 
non-disease related, inter-individual differences in gene expression. While the technique is 
optimised to minimise artefact, it is impossible to eradicate all technical problems, therefore 
the number of false positive clones would be expected to increase. Genes expressed at a 
very high level may not be sufficiently subtracted during the RDA procedure. Because of 
these problems, a number of screening steps are required to confirm that genes identified by 
RDA are truly differentially expressed and are disease specific. These screening methods 
are described in section 7.3.
However, RDA has been used successfully to identify disease-specific changes in 
mRNA levels in patient material. A commercially available variation of RDA (PCR 
SelectIM cDNA subtraction kit, CLONTECH), which uses a single round of hybridisation 
and amplification rather than the multiple rounds used by Hubank and Schatz (1994), was 
successfully used to isolate the PRV-1 gene from pools of granulocyte mRNA obtained 
from 5 PV patients and compared to normal controls (Temerinac et al, 2000). After 
extensive screening of the RDA products, the PRV-1 gene was identified and shown to be 
overexpressed in the granulocytes of PV patients compared to normal controls, secondary 
erythrocytoses and some ET patients.
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7.1.2 Aim
The aim of the work described in this chapter was to compare global gene 
expression in platelet mRNA obtained from an ET patient and a normal control subject in 
order to identify genes which may be involved in the pathogenesis of ET, or which may be 
useful as a diagnostic marker for ET. After initial screening of the RDA products, the 
expression levels of one gene that was shown to be differentially expressed were quantified 
in platelet mRNA from a cohort of ET patients compared to a number of normal controls, 
patients with other cMPDs and patients with reactive thrombocytosis.
7.2 Overview of the generation of difference products (DP)
The RDA procedure used to produce clones for screening was carried out by Dr. R. 
Gale and is summarised in Figure 7.2 (A and B). Platelet RNA was obtained from one ET 
patient with monoclonal myelopoiesis (XCIP result by HUMARA; T-cells 50%:50% 
expression of the 2 alleles, neutrophils 100%:0%) and one normal control. The SMART™ 
PCR cDNA synthesis kit (CLONTECH) was used to initially amplify polyA+ mRNA to 
enrich for full length cDNAs (Figure 7.3). Representations were prepared from cDNA from 
each sample (Mrep = representation prepared from platelet RNA obtained from one ET 
patient with monoclonal myelopoiesis, Nrep = representation prepared from platelet RNA 
from one normal control) by DpnW digestion of the double stranded cDNA followed by 
PCR amplification. The representations were then used either as driver or tester in the 
initial hybridization reaction at a driver to tester ratio of 4:1. Two difference products 
(DPI) were generated by selective PCR: the forward reaction nMl (Nrep driver, Mrep tester 
-  enriched for sequences only, or more highly expressed, in the monoclonal ET patient 
sample) and the reverse reaction mNl (Mrep driver, Nrep tester -  enriched for sequences 
only, or more highly expressed, in normal control sample). During the PCR step only 
differentially expressed sequences should have been exponentially amplified (Figure 7.1). 
A second round of hybridization was carried out to further enrich for differentially 
expressed genes. DP2 products were generated by hybridizing driver to DPI products at a 
ratio of 16:1 (Figure 7.4). After the final PCR of the RDA process, the DP2 products were 
cloned into the TOPO-2 vector (Invitrogen) and 48 clones isolated for both the forward
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polyA+ RNA prepared (Qiagen Oligotex Kit)
2nd strand synthesis by dC tailing with 
SMART™ II oligo (CLONTECH)
20 cycles of long distance PCR with PCR primer (CLONTECH)
1st strand synthesis with MMLV RT (Superscript II, 
Gibco BRL) using CDS primer (CLONTECH)
Platelet RNA from:
1 Normal control and 1 ET patient with monoclonal myelopoiesis
- f t
Ligated with R oligos
Digested with Dpn II
| Large scale PCR with R o ligos|------------------- ► Mrep and Nrep
Driver Tester
Driver : Tester = 4 
(mN and nM)
-► DPI
Diluted 1/20
Ligated with J oligos
Digested with Dpn IIDigested with Dpn II
7 cycles PCR with J oligos
20 cycles PCR with J oligos
Hybridized 4pg driver with 1 jig tester, 20 -  48 hours at 67°C
(mNl and nM l)
Figure 7.2A
G eneration  o f  double stranded  cD N A , representations and  
difference product 1 (D P I). Mrep = monoclonal ET representation, 
N rep = normal control representation, m = monoclonal ET driver, M = 
monoclonal ET tester, n = normal control driver, N = normal control 
tester. 185
DP 1 products
Digested with Dpn II
(mN 1 and nM 1)
Ligated with N oligos
 _____________________
Hybridized 4pg driver (original Dpn II
digested R) with 250ng N-ligated tester (DPI)
___________20 -  48 hours at 67°C__________
i l
7 cycles PCR with N oligos
Driver : Tester = 16:1 
(m:mNl andn:nM l)
Diluted 1/20
20 cycles PCR with N oligos ------------------- ► DP2
I (mN2 and nM2)
Shotgun cloning o f DP2 products into 
_______ TOPO-2 (Invitrogen)_______
V
48 clones for each hybridization selected
Figure 7.2B
G eneration  o f  d ifferen ce product 2 (D P2) and cloning o f  
DP2 products, m = monoclonal ET driver, M = monoclonal ET 
tester, n = normal control driver, N = normal control tester. 
Protocol based on CLONTECH SMART™ PCR, Hubank and Schatz 
(1994) and Pastorian et a l (2000)
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RNA
5’ \ / > / \ / v r v y v \ / v \ / \ / v r v pofyA 3’
BD SMART II™ A 
Oligonucleotide
S
go
s'
BO SMART™
CDS primer II A
First-strand 
synthesis by RT
5' v \ / > y > y \ / \ / v \ / v A ^  polyA
dC tailing by RT
5' v \ / > y > y \ / v \ / v r v / v ^  polyA
Template sw itch ing  
and extension  by RT
,GGGLcCO
Amplify cDNA by LD PCR 
with PCR primer
Double-stranded cDNA
F igure 7.3
S M A R T ™  P C R  cD N A  synthesis
(From SMART™ PCR cDNA synthesis kit user 
manual 2001, CLONTECH)
Single
step
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Representations
1353 -
603 -  
310 -
DPI DP2
■ P H
1353 - ■ ■#|
603 - 1■1 310 - 1 su
M NAT*rep AVep D river:T ester 4:1 16:1
i
DP2 products cloned
Figure 7.4 
Gel im ages o f  driver, tester and d ifference products
Mrep is unsubtracted representation produced from an ET patient with monoclonal 
myelopoiesis, N rep is unsubtracted representation produced from normal control. Driver : 
Tester ratios are given for DPI and DP2.
(Produced by Dr R. Gale)
(nM2) and reverse (mN2) RDA reaction. All work in this chapter was carried out from 
these 96 clones.
7.3 Screening of PP2 Products
7.3.1 Dot blots
Principle Each clone produced by the RDA procedure was screened by hybridizing to 
both the unsubtracted representations and to the subtracted difference products produced by 
the forward and reverse reactions. The likelihood that any clone represents a differentially 
expressed gene can then be estimated from the binding patterns produced. For nM2 
products, the forward subtraction is nM2, the reverse subtraction is mN2, and tester and 
driver are Mrep and Nrep respectively. All clones which represent differentially expressed 
genes should hybridize with the forward subtraction probe (i.e. nM2 clones must be 
positive with the nM2 probe). Most clones which are also negative with the reverse 
subtraction, positive with tester and negative with driver are likely to be fragments of 
differentially expressed mRNAs (Table 7.1 A). Clones which are negative with the reverse 
subtraction and both tester and driver are likely to be good candidates for differential 
expression (Table 7.1 B). Clones which are negative with the reverse reaction and positive 
with both tester and driver may also be from differentially expressed genes, but they may 
be artefact due to high expression in both ET and normal samples (Table 7.1 C). Clones 
which are positive with all probes may be from differentially expressed genes if the degree 
of positivity is higher with the forward subtraction and tester probed membranes (Table 7.1 
D). Any other hybridization patterns are not suggestive of differential expression.
Method PCR products were obtained from the 96 cloned DP2 products using 35 
amplification cycles with the N oligo and Bioline reagents (Chapter 2, 2.2.7) and were 
analysed for size by agarose gel electrophoresis. These products were then individually 
hybridized to 4 probes, the monoclonal representation (Mrep), the normal control 
representation (Nrep), nM2 product and mN2 product. One pi fresh PCR product was mixed 
with 1 pi 0.6M NaOH to denature the DNA and aid binding to the nylon membrane, before 
being spotted onto Hybond N+ nylon membrane (Amersham Pharmacia). Four membranes 
were prepared, each containing 96 dots in a 96 well plate format, 48 from nM2 clones and
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P robe used
Forward Reverse j es e^r Driver Likelihood of being differentially expressed 
Reaction Reaction
A + - + >95% of these clones will be differentially
expressed
B + - - High probability of differential expression
C + + +
D ++ + + +/-
Difficult to interpret, could be differentially 
expressed
Can be differentially expressed, according to 
fold difference of positive clones
+ + + Rarely differentially expressed
Rarely differentially expressed
Table 7.1 
Interpretation of dot blot results.
(Modified from CLONTECH PCR-SelectrM differential screening kit user manual, 2001).
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48 from mN2 clones. The membranes were neutralised for 4 minutes with 1.5M NaCl, 
0.5M TrisHCl pH 7.2 and 0.001 M EDTA (neutralising solution), before being fixed for 20 
minutes in 0.4M NaOH. After fixing, the membranes were rinsed in 5ml 5x SSPE for 45 
seconds (20 x SSPE contains 3M NaCl, 0.2M NaH2P 04.H20 , 20mM EDTA).
To prepare for probe hybridization, the membranes were incubated for 2 hours at 
65°C with 10ml hybridization solution (lOx Denhardt’s solution: 0.25% Ficoll, 0.25% 
polyvinylpyrrolidone, 0.25% BSA, and 4 x SSPE, 0.1% SDS, lOmg/ml denatured, sheared 
single stranded DNA [ssDNA]) to reduce non-specific DNA binding. During this pre­
hybridization, the four probes were prepared.
The random primed DNA labelling kit (Roche) and [a-32P]dCTP (0.37MBq/pl, 
Amersham Pharmacia) were used to label the probes. Fifty ng of Mrep, Nrep, nM2 or mN2 
was incubated with de-ionised water to lOpl final volume at 95°C for 5 minutes and 
transferred directly to ice. Once cooled, 2pl reaction mixture (containing random 
hexanucleotide primers in 10 x reaction buffer), 1 pi Klenow fragment, 1 pi each of dATP, 
dGTP, dTTP and 4pl [a-32P]dCTP were added and the reaction incubated at 37°C for 1 
hour. During this incubation a complementary DNA strand is synthesised by the Klenow 
enzyme from the 3’ terminus of the hexanucleotide primers, incorporating isotope labelled 
cytosine. The probes were then centrifuged through Sephadex G50 columns for 6 minutes 
at 2000rpm to remove unincorporated [a-32P]dCTP. To ensure an equal amount of labelled 
probe was used for each hybridization, probes were counted by mixing lpl probe with 
4.5ml scintillation fluid and the disintegrations per minute (DPM) measured using a 
scintillation counter. One hundred pi ssDNA (2mg) was added to an aliquot containing 
25x105 DPM each probe and incubated at 95°C for 5 minutes, quenched on ice and then 
added to 5ml hybridization solution. Pre-hybridized membranes were then incubated in this 
solution for 17 hours at 65°C.
After incubation the membranes were washed in 500ml 2xSSPE, 0.1% SDS for 15 
minutes at room temperature to remove non-specifically bound probe. This wash was 
repeated and then followed by a further wash for 30 minutes at 65°C. Each membrane was 
then monitored for presence of isotope using a Geiger counter. If isotope levels were in 
excess of approximately 200cpm then a higher stringency wash was carried out using 
0.2xSSPE, 0.1% SDS for 30 minutes at 65°C. The membranes were then covered in Saran 
wrap and exposed to autoradiography film (Hyperfilm, Amersham Pharmacia) for 1 hour at 
-80°C.
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Results The sizes of the clones produced by the RDA reaction ranged from
approximately 200bp to 800bp. To establish which clones were likely to be expressed 
differentially all spots were scored according to dot intensity as either highly positive (++), 
positive (+), difficult to determine positivity (+/-) or negative (-) (Table 7.2). For example, 
of the nM2 products probed with Nrep, D9 was scored +/-, DIO was scored ++, D11 was 
scored + and D12 was scored -  (Figure 7.5). Of the 96 clones from both the forward and 
reverse reactions, 15 were selected which had a high probability of being differentially 
expressed (Table 7.1 A, B), 4 from nM2: A8, B4, C l, and D2 (Figure 7.5) and 11 from 
mN2: A3, A4, A8, B8, B9, BIO, B11, Cl 1, D8, DIO and D ll (Figure 7.6). Eight clones 
were identified which could be differentially expressed but this was less likely than those 
above, all 8 were clones from mN2 (A9, Al l ,  Bl ,  C7, CIO, Cl 2, D9 and D12). Therefore, 
a total of 23 clones were further screened for differential expression using Virtual Northern 
blot analysis, 4 from nM2 and 19 from mN2.
7.3.2 Virtual northern blots
Principle Virtual northern blots are similar to northern blots, but use amplified cDNA 
rather than RNA. In this instance, the Mrep and Nrep were individually probed with the 
cloned DP2 products identified by dot blot as being from differentially expressed genes. 
This allowed a direct comparison of the levels of each clone in the initial representations, 
decreasing the subjectivity o f scoring each clone due to non-specific hybridization in the 
dot blot analysis.
Method The 23 clones selected from dot blot assay were analysed by virtual northern 
blots. Agarose gels (1.5%) were prepared and loaded with 200ng each of Mrep and Nrep, and 
the samples separated by gel electrophoresis. The gels were placed in 100ml denaturation 
buffer (1.5M NaCl, 0.5M NaOFI) for 15 minutes at room temperature to ensure the DNA 
was fully denatured, and then rinsed in de-ionised water for 2 minutes. A capillary transfer 
system was used to transfer the DNA to Hybond N+ nylon membrane (Amersham 
Pharmacia). The membrane was placed on the agarose gel and transfer buffer (1.5M NaCl, 
0.25M NaOH) allowed to pass through them both, by capillary action, over the course of 17 
hours. The membranes were then washed in 100ml 2xSSPE at room temperature for 2 
minutes to remove any adherent agarose and stored in 10ml hybridization solution.
Each of the 23 candidate clones were separately used to probe the membranes. 
Probes were prepared from the original PCR products generated from cloned DP2 products.
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(A )_______________    (B)
A B C D A B C D A B C D A B c D
Al - . - ++ Cl + - - - * Al - - + 4- Cl - - 4- -
A2 - + - + C2 + + - +/- A2 + - + 4- C2 - - +/- -
A3 - - - +/- C3 + +/- - + + A3 + - + - * C3 - 4-4- 4-4- -
A4 + - - +/- C4 + +/- - + A4 ++ - +/- - * C4 4-4- 4-4- 4-4- 4-
A5 4- - +/- +/- C5 - - - + A5 + + + + - C5 4-4- 4- + / - -
A6 - - - - C6 - + - +/- A6 - + + - C6 4- 4-4- +/- 4-
A7 - + - - C7 - - - +/- A l - - + +/- Cl 4- +/- 4- 4- t
A8 +/- - - - * C8 + + - 4- A8 +/- - +/- - * C8 +/- +/- 4- -
A9 - - - + C9 - - - + / - A9 + / - +/- +4- +/- t C9 +/- +/- 4- -
A10 +/- ++ - ++ CIO - + - + A10 - - - - CIO 4- +/- 4-4- - t
A ll - - - +/- C ll - + - ++ A ll +/- +/- +4- +/- t C ll 4- - 4-4- - *
A12 - +/- +/- +/- C12 - - - - A12 - - 4-4- 4- C12 4-4- - 4-4- 4- t
B1 + + - 4-4- D1 + / - - - + B1 + +/- 4- 4- t D1 - 4- 4- -
B2 - - - - D2 +/- - - - * B2 - - - - D2 + / - 4- 4-4- -
B3 - - - - D3 - - - + / - B3 + + +/- - D3 - + / - 4-4- -
B4 +/- - - - * D4 - - - + / - B4 - - - - D4 + / - 4-4- 4-4- + / -
B5 - - - +/- D5 - +/- +/- +/- B5 - - + / - - D5 4-4- 4-4- 4- +/-
B6 +/- + + - D6 - - - +/- B6 - - - - D6 4- - - 4-
B7 - + - - D7 - - - +/- B7 - + - 4- D7 4- +/- 4- 4-
B8 - +/- - - D8 +/- + - + B8 +/- - +/- - * D8 4-4- - 4- - *
B9 - - - +/- D9 - - - +/- B9 +/- - +/- - * D9 4-4- +/- 4- - t
BIO 4" + + ++ DIO +/- 4-4- + / - + + BIO + - 4-4- - * DIO +/- - 4-4- - ★
B ll - - - - D ll - + - + B ll + - 4- - * D ll 4-4- 4-/- 4-4- - *
B12 - - - - D12 - - - - B12 ++ - 4- 4-4- D12 4-4- - 4-4- 4- t
Table 7.2
Dot blot scoring for (A) nM2 clones and (B) mN2 clones
Each set o f  48 clones was probed with: 
A - Forward subtraction, B - Reverse subtraction, C - Tester and D - Driver 
* = High probability o f  differential expression f  = Could be differentially expressed
Probe: nM2 - Forward reaction 
1 2 3 4 5 6 7 8 9 10 11 12
mN2 - Reverse reaction 
1 2 3 4 5 6 7 8 9 10 11 12
A A # #
B B ♦ # ^
c
D
o  •  • C
D O ' •
Probe: Unsubtracted tester (M )
1 2 3 4 5 6
A
B
C
D
rep>
7 8 9 10 11 12
Unsubtracted driver (Nrep)
1 2 3 4 5 6 7 8 9 10 11 12
iib
A
n
•  - •
o BC o  • • •
D •
Figure 7.5 
Dot blots o f  48 nM 2 products
Clones created using the Mrep as tester and the Nrep as driver for generation o f D PI, and the 
N rep as driver for DP2. A good candidate clone is circled: positive for the forward 
subtraction, and negative for all other probes
Probe: mN2 - Forward reaction nM2 - reverse Reaction
1 2 3 4 5 6 7 8 9  10 11 12 1 2 3 4 5 6 7 8 9  10 11 12
A A
B •  *  •  • B
C C •  •  •
D •  « •  •  •  • D •
Probe:
A
B
c
D
Unsubtracted Tester (Nrep) 
1 2 3 4 5 6 7 8 9 10 11 12
Unsubtracted driver (Mrep) 
1 2 3 4 5 6 7 8 9 10 11 12
•  • •  •  • A •  • ;  *m % S •  •  m B •
•  •  • « * • # # C
•  •  •  • #  •  # D
—*••••
Figure 7.6 
Dot blots o f 48 mN2 products
Clones created using the N rep as tester and the Mrep as driver for generation o f D PI, and the 
Mrep as driver for DP2. For the blot probed with unsubtracted driver (M ), C6 (green circle) 
shows a positive result, C9 (red circle) shows a negative result with high background signal
Each PCR product was diluted 1/500 and re-amplified using 30 cycles of PCR with the N 
oligo at an annealing temperature of 64°C as described in chapter 2 (2.2.7). PCR products 
were isotope labelled with a-32P-dCTP by random primed DNA labelling as described in 
section 7.3.1. Probes were cleaned through Sephadex G50 columns and hybridized to the 
membranes as outlined in section 7.3.1. A high stringency wash was required to remove 
non-specifically bound radiolabelled probe, therefore the final wash was carried out using 
500ml 0.1 xSSPE, 0.1 % SDS for 30 minutes at 65°C.
Results For 10 of the 23 clones used as probes in the virtual northerns, the relative
intensity o f the bands in Mrep and Nrep appeared to be equal. Therefore these clones were 
likely to be false positives and were not further studied. Thirteen o f the 23 clones 
investigated by virtual northern analysis appeared to have bands of variable intensity in the 
Mrep and Nrep samples and were therefore likely to be differentially expressed. The band in 
Mrep was of higher intensity than the band in Nrep when all 4 clones selected from nM2 
were used as probes (A8, B4, Cl and D2). This suggested that these clones represented 
genes which had a higher expression level in platelet RNA from the monoclonal ET patient 
than the haematologically normal control. When blots were probed with clones selected 
from mN2, the band in Nrep was of higher intensity than the band in Mrep for 9 clones (A3, 
A4, A8, B8, B9, B11, Cl 1, D8, D12), suggesting that these clones represented genes which 
had a lower expression level in platelet RNA from the monoclonal ET patient than the 
haematologically normal control. Three representative samples are shown in Figure 7.7, 
clone mN2 A3 had a band of lower intensity in the Mrep compared to Nrep, clone nM2 C 1 
had a band of higher intensity in the Mrep compared to Nrep, and clone mN2 D10 had bands 
of similar intensity in both Mrep and Nrep.
7.3.3 Sequencing o f  differentially expressed genes
Method The 13 clones which appeared to be differentially expressed by virtual
northern analysis were sequenced. The DP2 PCR products had the same primer annealing 
sites at both ends of the DNA fragment as a result of the RDA process (the N oligo). 
However, sequencing reactions require unidirectional linear amplification, therefore each 
product was cloned into the TOPO T-Cloning vector as described in chapter 2 (2.2.10) 
using 0.5pl fresh PCR product (prepared as in 7.2.3). The TOPO vector contains M13 
primer sites close to the insertion site, one annealing site for the M13F(-20) primer and one 
annealing site for the -M13R primer Table 7.3. PCR was carried out using these two
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Probe: C lone mN2 A3 C lone nM 2 C l C lone nM 2 DIO
Sam ple: M rep N rep ^rep ^rep ^rep ^rep
Figure 7.7 
V irtual northern analysis o f  mN2 and nM 2 clones
Three representative clones selected from dot blot screening are shown. Bands produced 
with mN2 clone A3 and nM2 clone C 1 were o f  variable intensity between Mrep and N rep. 
Bands produced with nM2 clone DIO were not thought to be o f  variable intensity.
Forward primer Reverse primer
Fragment size 
(bp)
Annealing
Temperature
(°Q _____
RANTES CTGTACTCCTCATTGCTACTG CTACCACACAGCAGCAGTTAC 390 62
FLP TCCAGGACATCAAGAAGCCAG TC AG A AGGCTCTT AGTCGTGC 303 60
CD32 CATCATGCTGAGGTGCCACAG TTGGGCAGCCTTCACAGGATC 360 62
N-arginine dibasic 
convertase I TGCTGTGGTCAAAGCTGACTG
GAAGTACTTCCTCTGGACATG 403 60
Cytochrome C 
Oxidase II TCTGCTTCCT AGTCCTGT ATG
TT AG ACGTCCGGG A ATTGC AT 437 60
12s rRNA ATCCCCGTTCCAGTGAGTTCA TGTTG AGGTTT AGGGCT A AGC 409 60
Cytochrome b AGGAGGCTACTCAGTAGACAG GATCGGAGAATTGTGTAGGCG 353 60
GAPDH GCCGAGCCACATCGCTCAGA GAGGCATTGCTGATGATCTTG 471 62
M 13 primers C AGG A AAC AGCT ATG AC CTGGCCGTCGTTTTAC V 50
R131H primers TCC AG AATGG AA AATCCC AG AA ATTCT AG A GACCTCCATGTAGGCCCATGTG 231 66
Table 7.3
The primer sequences used to screening RDA products
The oligonucleotides used for RDA, screening and polymorphism analysis. All primers shown in 5’—>3’ direction, mismatch primer 
shows altered base underlined. For the Ml 3 PCR reaction -M13R is the reverse primer, M13F(-20) is the forward primer.
V = variable size PCR product.
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primers for 35 amplification cycles using Bioline reagents. The PCR products were cleaned 
using QIAquick PCR purification kit (Qiagen), cycle sequencing carried out using the 
M13F(-20) primer and samples loaded to the ABB 10 genetic analyser as described in 
chapter 2 (2.2.9). Approximately lOObp of the resultant sequence was entered into a 
nucleotide-nucleotide BLAST (blastn) search (http://www.ncbi.nlm.nih. gov/ BLAST/). 
Results The 4 clones identified from nM2 were shown to be fragments from 4
different genes: Clone A8 was a fragment from the Regulated upon Activation Normal T 
cell Expressed and Secreted (RANTES) gene, clone C2 was a fragment from the CD32 
(FcyRIIA) gene, clone C4 was a fragment of the mitochondrial gene 12S rRNA and clone 
D2 was a portion of the Ferritin Light Polypeptide gene (FLP) (Table 7.4). The 9 clones 
selected from mN2 were fragments of 4 different genes: B8 was a fragment from the N- 
arginine dibasic convertase I (NRDI) gene, clones A4, B9, Cl 1, D8 and D12 were 
fragments from the mitochondrial 12S rRNA, previously identified from clone C4 of the 
nM2 forward reaction, clones A3 and B1 were fragments from Cytochrome C Oxidase 
subunit II and clone A8 was from the cytochrome b gene (Table 7.4).
The sequences generated by all 13 clones had >95% homology to previously 
described genes. Of the four clones selected from nM2 products, 3 were fragments from 
genomic genes (RANTES, CD32, FLP) and one was a fragment from a mitochondrial gene 
(12S rRNA). Only one clone selected from the mN2 products was a fragment from a 
genomic gene (NRDI), the other 9 clones were fragments from 3 mitochondrial genes (12S 
rRNA, Cytochrome C Oxidase subunit II and cytochrome b).
7.3.4 Variable cycle number PCR
Principle The 2 major disadvantages with the RDA technique when used in primary 
cells are the propensity to amplify sequences which are expressed at high levels in both 
starting populations, irrespective of differences, and an inability to select only for disease- 
specific differences. As with all techniques used to assay differential expression, inter­
individual differences will generate clones in the same way as disease-specific differences. 
To investigate whether the difference in the expression of the seven genes identified by 
screening RDA products was disease-specific, RT-PCR was carried out on a small number 
of patient and control samples and the expression levels of each gene between the two 
groups compared. The PCR reaction was carried out using a variable number of 
amplification cycles for each gene. This was because it was important that the PCR
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Clone Number of bases entered into search Gene Sequence identifier
Homology
(%)
A8 106 RANTES NM 002985.2 97
nM2
C2 131 CD32 XM 033957.3 94
C4 98 12S rRNA AY 012136.1 97
D2 99 FLP XM 050465.1 98
B8 97 NRDI XM001517.5A4 98
A4
B9
C ll 98-136 12S rRNA AY 012136.1 >95
mN2 D8
D12
A3
124-136
Cytochrome 
C oxidase 
subunit II
NC 001807.3 99
B ll
A8 96 Cytochrome b NC 001807.3 98
Table 7.4 
Sequence inform ation for the 13 clones selected from  screening  
o f the RDA DP2.
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products were obtained from the linear phase of the reaction, and that bands on the agarose 
gels were not saturated, which may lead to overrepresentation of a gene expressed at a low 
level, potentially masking any differential expression.
Method RNA was obtained from purified platelet samples from 3 ET patients with 
clonal myelopoiesis and 3 haematologically normal control subjects as shown in chapter 2 
(2.2.1, 2.2.3). RT reactions were performed using Ipg RNA of each sample (Chapter 2, 
2.2.6). Two pi of the RT products were added to the PCR as cDNA template and a hot start 
was used with Bioline reagents as described in chapter 2 (2.2.7). The FLP, CD32, RANTES 
and Cytochrome b genes were investigated using 22 and 27 cycles of amplification, the 
Cytochrome C Oxidase subunit II gene was investigated using 25 and 30 amplification 
cycles, and the 12S rRNA gene was investigated using 15 and 20 PCR amplification cycles. 
The forward and reverse primers used to investigate the expression of each gene, the 
annealing temperature used and the expected PCR product sizes are detailed in Table 7.3. 
PCR products were electrophoresed through 1.5% agarose gels and visualised with 
ethidium bromide staining.
Results The intensity of the RT-PCR product for each gene in 3 ET patients with
clonal myelopoiesis was visually compared to 3 normal control samples. RANTES PCR 
products appeared more intense in the ET patients than normal controls using 22 cycles 
(Figure 7.8). Differences in intensity were still evident when 27 amplification cycles were 
used but they were less pronounced due to saturation. PCR products for the FLP gene were 
very faint using 22 cycles of amplification and differential expression was difficult to 
determine. However, when 27 amplification cycles were used the bands produced from ET 
patients with clonal myelopoiesis appeared to be more intense than bands from normal 
controls. This was also the case for CD32 PCR products, where only samples amplified for 
27 cycles of PCR were evaluable, and ET patients with clonal myelopoiesis had more 
intense bands than normal controls. None of the 3 mitochondrial genes appeared to be 
differentially expressed between the two groups (Figure 7.8), even where the numbers of 
amplification cycles used was low enough to ensure the absence of saturation which may 
have masked differences in expression.
The NRDI RT-PCR product was of low intensity and had multiple bands. While the 
intensity of the product could be increased by carrying out more amplification cycles, this 
also increased the number of extra bands produced. These bands were still present after 
optimization for magnesium ion concentration and annealing temperature. As these extra
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Differentially expressed genes Non-differentially expressed genes
RANTES
FLP
CD32
30 cycles25 cycles
Cytochrome 
Oxidase 
subunit II
20 cycles15 cycles
12s rRNA
27 cycles22 cycles
Cytochrome
Clonal I Control | Clonal I ControlClonal Control I Clonal Control
Figure 7.8
V ariable cycle num ber R T-PC R
The six genes investigated by variable cycle number RT-PCR are shown for 3 ET patients with 
clonal myelopoiesis and 3 haematologically normal controls. Numbers o f amplification cycles 
are shown for each gene
bands made it difficult to assess expression levels between different samples and may have 
interfered with subsequent quantification, NRDI was not further investigated.
Therefore, while no difference in the expression of the 3 mitochondrial genes was 
apparent between the two groups, 3 somatic genes were identified which appeared to be 
overexpressed in platelet mRNA obtained from ET patients with clonal myelopoiesis 
compared to platelet mRNA from normal control subjects.
7.4 Analysis of CD32
7.4.1 Introduction
Of the three genes with an apparently increased expression in clonal ET patients, 
CD32 was thought to be the most likely to be involved in the pathogenesis of ET and so its 
expression level in platelet mRNA was further investigated. CD32 is an Fey receptor 
expressed on the surface o f platelets and is known to be involved in thrombus formation. 
Immunoglobulin G (IgG) can interact with various membrane receptors via their Fc region. 
These Fc receptors (FcyR) occur in three different groups depending on structural and 
functional criteria. CD32 is a group II FcyR, FcyRIIa, the only FcyR present on platelets 
(Parren et al, 1992; Ravetch & Kinet, 1991). It has been shown to associate with the von 
Willebrand factor (vWF)/Gp!b-IX-V complex and mediate platelet activation and thrombus 
formation (Sullam et al, 1998; Sun et al, 1999).
7.4.2 Method
To assess whether the increased levels of expression of CD32 seen in the 
preliminary RT-PCR experimental data (Section 7.3.4) were reflective of disease-specific 
changes, CD32 expression was investigated in platelet mRNA from 3 patient groups and 
normal controls using a radioactively labelled semi-quantitative multiplex RT-PCR (SQ- 
RT-PCR). Two primer sets were used in a single tube PCR reaction, one primer set to 
amplify a portion of the CD32 gene, the other to amplify a portion of a control gene. The 
relative intensity of the CD32 PCR product was compared to that of the control gene to 
obtain a relative ratio which was then used to assess expression levels between the sample 
cohorts. The choice of control gene was important, as it was desirable that its expression
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levels were constant irrespective of disease and similar to those of CD32, and that an RT- 
PCR product of similar size to that of CD32 could be designed.
Housekeeping genes are often used as control genes. They code for proteins 
involved in the normal maintenance of the cell and their expression level is expected to be 
consistent, for a given cell type, across all samples tested, irrespective of disease. It is 
desirable that the expression level of the housekeeping gene is similar to the expression 
level of the gene of interest. This allows the exposure of both bands on autoradiography 
film to be in the linear phase, preventing over-estimation of the less intense band due to 
saturation of the film by the more intense band.
Pseudogenes of the control gene may be present in the genome and these must not 
be amplified. Pseudogenes are non-allelic genomic copies of normal genes which are 
mutated, preventing functional activity. They often lack intron sequences, and may have 
arisen from viral integration of reverse transcribed mRNA into the host genome, as they 
often have short poly(A) tails (Weaver & Hedrick, 1992). Therefore, if pseudogenes, of 
either test or control gene, are present the PCR primers may amplify the pseudogene from 
contaminating DNA, and the intensity of the band produced may therefore be more a 
reflection of the amount of DNA contamination in the sample rather than the expression 
level of the gene of interest. All primer sequences used in the work presented here were 
designed so that the PCR product spanned at least one exon-intron boundary to prevent 
amplification of contaminating DNA in RNA preparations.
Finally, the PCR product size should be similar between test and control genes. 
Smaller products are preferentially amplified in a PCR reaction and this effect is relative to 
the size difference (Gale et al, 1996), therefore, in a multiplex reaction it is important for 
the size difference between the two PCR products to be the minimum needed for adequate 
separation of the two bands.
The housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was 
chosen as the control gene for these studies as its expression level was similar to those of 
CD32, and while there is a GAPDH pseudogene, the primers have been designed from a 
region of GAPDH which is non-homologous to its pseudogene (Lehmann et al, 2002). 
These primers produce a product of 471 bp which enabled primers to be designed for CD32 
to produce a product of 360bp which crossed exon/intron boundaries.
Reverse transcription and PCR reactions were carried out from platelet RNA 
samples as described in chapter 2 (2.2.6 and 7). PCR reactions were carried out using
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GAPDH primers and CD32 primers (Table 7.4), at an annealing temperature of 62°C. Ten 
pmol of one primer from each primer pair was added to an end-labelling reaction as 
described in chapter 2 (2.2.8). Twenty two cycles of PCR were carried out and samples 
were loaded onto 6% denaturing polyacrylamide gels (32 x 40 x 0.4cm) as described in 
chapter 2 (2.2.5) and electrophoresed at 1500V for 4 hours. Gels were exposed to 
autoradiography film prior to densitometry (GS300 Scanning Densitometer, Hoefer 
Scientific Instruments, San Francisco, CA). The densitometry results for CD32 were 
divided by the result from GAPDH to obtain a ratio. Statistical analysis was performed 
using the non-parametric Wilcoxon signed ranks test with SPSS for windows version 
11.5.0.
7.4.3 Results
Platelet RNA from 52 ET patients, 8 patients with a reactive thrombocytosis, 11 PV 
patients and 10 normal controls was studied by multiplex SQ-RT-PCR. Two bands were 
produced after visualisation on autoradiography film. The GAPDH PCR product was 
471 bp and the CD32 PCR product 360bp. The intensity of the GAPDH PCR product was 
consistent across most samples tested, suggesting that GAPDH expression was similar for 
each sample. The intensity of the CD32 PCR product varied between samples indicating 
that CD32 was differentially expressed in different samples (Figure 7.9). The intensity of 
each band was quantified by densitometry and for each sample a ratio of CD32 to GAPDH 
expression was obtained by dividing results from the CD32 band by the results from the 
GAPDH band and multiplying by 100. Samples were analysed in duplicate and the average 
of the two results used for comparison.
The median CD32:GAPDH ratio from the 10 normal control samples was 1 (range 
<1-3) (Figure 7.10, Table 7.5). The expression of CD32 was often very low in normal 
control samples compared to GAPDH, therefore where the expression of CD32 was too low 
to accurately measure without saturation of the GAPDH band, the expression ratio was 
designated <1. The median CD32:GAPDH ratio for the 52 ET patients was 21 (range 2-73), 
and this was significantly higher than results obtained from haematologically normal 
controls (p=0.005). The CD32:GAPDH ratios obtained from the 2 samples used to generate 
the RDA products were consistent with these results. The normal control used in the RDA 
reaction had a CD32:GAPDH ratio of 1 compared to 12 for the ET patient with monoclonal 
myelopoiesis. Results from the other patient groups studied also showed a statistically
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Figure 7.9
M ultiplex sem i-quantitative, radiolabelled R T-PC R  for analysis o f  
differential gene expression.
Results from six ET patient samples are shown with the corresponding CD32:GAPDH ratio.
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Median CD32/GAPDH 
__________________ n_________ ratio x 100_________Range________ p value
ET 52 21 2-73 0.005
(Clonal ET 15 25 8-60 0.005)
(Polyclonal ET 18 23 2-73 0.007)
RT 8 10 2-25 0.012
PV 11 30 7-63 0.008
Normal controls 10 1 <1-3
Table 7.5 
The CD32:GAPDH ratios for each of the patient groups studied.
p values are for comparisons between the normal control group and each patient group.
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significant difference in CD32:GAPDH ratios compared to that obtained from the normal 
control group. PV patients had a median CD32:GAPDH ratio of 30 (range 7-63), and 
patients with a reactive thrombocytosis had a median ratio of 10 (range 2-25). The p values 
for comparison to the normal control group were 0.008 and 0.012 respectively. Therefore, 
the expression o f CD32 was significantly increased in platelet mRNA obtained from 52 ET 
patients, 11 PV patients and 8 patients with a reactive thrombocytosis compared to 
haematologically normal controls.
Clonality data was available on 33 of the 52 ET patients, the remaining 19 were 
uninterpretable by XC1P analysis due either to a constitutively imbalanced pattern or age- 
related skewing. O f the 33 interpretable patients, 15 had clonal myelopoiesis and 18 had 
polyclonal myelopoiesis. The median CD32:GAPDH ratio for the ET patients with clonal 
myelopoiesis was 25 (range 8-60) and with polyclonal myelopoiesis was 23 (range 2-73). 
There was no significant difference between the clonal and polyclonal groups (p=0.281). 
Neither was there a significant difference when each group was compared to PV patients 
(clonal ET patients compared to PV patients p=0.594, polyclonal ET patients compared to 
PV patients p=0.173). However, the difference between CD32:GAPDH ratio results in 
clonal ET patients and patients with a reactive thrombocytosis did reach statistical 
significance (p=0.025), as did the difference between the CD32:GAPDH ratio with PV 
patients and patients with a reactive thrombocytosis (p=0.036).
7.5 CD32 polymorphism analysis
A G to A nucleotide polymorphism at position 507 of the CD32 gene has been 
shown to correlate with the incidence o f thrombotic complications in heparin-induced 
thrombocytopenia (HIT). A G at position 507 codes for an arginine (R) at codon 131 of the 
CD32 protein, an A at position 507 leads to a histidine (H) at codon 131 (Clark et al, 1989; 
Warmerdam et al, 1990). A low affinity Fey receptor is produced when R is present at 
codon 131 and a high affinity Fey receptor when H is present, as demonstrated by binding 
studies in leucocytes (Warmerdam et al, 1991). The presence of the low affinity receptor 
(R 131) in HIT led to inefficient removal of heparin/PF4/immuno-complexes, which in turn
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led to prolonged activation o f platelets and endothelial cells and caused an increase in 
thrombotic complications (Carlsson et al, 1998).
The RDA studies had identified an increase in CD32 mRNA expression in ET 
patients compared to normal controls, suggesting that CD32 is important in ET 
pathogenesis, and it was therefore o f interest to screen ET patients for the G507A 
polymorphism. Neutrophil DNA obtained from 51 ET patients was analysed by PCR with a 
mismatch primer which created a ifo/UI cutting site in products from G alleles to enable 
restriction fragment length polymorphism analysis. PCR was carried out using 35 
amplification cycles and R131H primers (Table 7.3) at an annealing temperature of 66°C 
using Bioline reagents, as described in chapter 2 (2.2.7). Enzyme digestion reactions 
contained 10|d PCR product and 5U BstVl in buffer 2 (NEB) as described in chapter 2 
(2.2.11). The enzyme digestion reactions were incubated at 60°C for 17 hours before being 
electrophoresed through 3% agarose gels and visualised by ethidium bromide staining. 
Uncut PCR product was 231 bp and the presence of G alleles at position 507 o f the CD32 
gene led to digestion with Bs/UI generating bands of 202bp and 29bp. A alleles remained 
uncut at 231 bp.
Data on a cohort o f 283 normal control samples of UK origin had been reported for 
the G507A polymorphism and the percentage of each genotype was shown to be 32% 
homozygous GG (90/283), 46% heterozygous GA (131/283) and 22% homozygous AA 
(62/283) (Karassa et al, 2003). The percentage of each genotype in the cohort of 51 ET 
patients was 41% homozygous GG (21/51), 41% heterozygous GA (21/51) and 18% 
homozygous AA (9/51). There was therefore, no significant difference between ET patients 
and the published cohort o f normal control samples (p >0.1 by %2 analysis).
O f the 51 ET patients, 15 had clonal myelopoiesis and 18 had polyclonal 
myelopoiesis by XCIP analysis, the remaining 18 patients were uninterpretable by XCIP 
analysis due to either a constitutively imbalanced XCIP or due to age-related skewing. The 
percentage of each genotype for the 15 patients with clonal myelopoiesis was 47% 
homozygous GG (7/15), 53% heterozygous GA (8/15) and 0% were homozygous AA. Of 
the 18 patients with polyclonal myelopoiesis 41% were homozygous GG (9/18), 36% were 
heterozygous GA (8/18) and 23% were homozygous AA (5/18) (Figure 7.11). Allele 
frequencies for the G allele in normal controls, all ET patients, clonal ET patients and 
polyclonal ET patients were 0.55, 0.62, 0.73 and 0.60 respectively (Figure 7.11).
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□  GG genotype □  AA Genotype ■  GA genotype
Figure 7.11 
G enotype and allele frequencies o f  the G 507A  polym orphism  in the CD32 gene in 
ET patients and norm al controls.
Results for the 283 normal controls used were taken from Karassa et al (2003). 51 ET patients were 
screened, and o f these 15 had clonal myelopoiesis and 18 had polyclonal myelopoiesis by XCIP.
No difference in genotype or allele frequency could therefore be demonstrated 
between normal controls and ET patients with polyclonal myelopoiesis. However, in ET 
patients with clonal myelopoiesis the A allele appears to be under-represented as none of 
this group were homozygous for the A allele. Also, the percentage of GG homozygotes was 
increased in the clonal group compared to normal controls (47% and 32% respectively). 
However, this difference did not reach significance by %2 analysis (p>0.05).
7.6 Discussion
RDA allows a global approach to be adopted to investigate differences in gene 
expression. It can identify both rare and novel genes which are differentially expressed 
between two groups, unlike other strategies which may only identify expression differences 
in known genes or gross changes in expression levels. In terms of platelet count, ET is 
defined by counts in excess of 600x106/ml, which represents just one doubling of normal 
platelet levels, therefore subtle differences in expression levels of key genes may be 
important in its pathogenesis. RDA is highly sensitive and can therefore potentially identify 
subtle changes in gene expression levels, making it appropriate for investigating ET.
Platelet mRNA from an ET patient with monoclonal myelopoiesis and a 
haematologically normal control was used to create tester and driver for the RDA 
procedure. Driver and tester were hybridized using an excess of driver and amplified by 
selective PCR to produce selected difference products. These difference products were then 
hybridised with a greater excess driver to produce DP2 products. The RDA technique can 
produce false positive clones, and a number of screening procedures are required prior to 
establishing differential expression between patient groups. The RDA procedure and 
cloning of DP2 products was carried out by Dr. R. E. Gale and therefore only the screening 
of these clones is discussed within this section.
The 48 clones from the forward nM2 and reverse mN2 reactions were hybridized to 
nM2, mN2, Mrep and Nrep to establish the likelihood that each clone was differentially 
expressed. This was necessary because false positive clones could be generated because 
genes which are expressed at a very high level in both tester and driver may not be 
adequately removed by dilution between each round of differential amplification. From the
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dot blot analysis, 23 clones were selected that appeared likely to be from genes 
differentially expressed between the monoclonal ET patient and the normal control sample.
Virtual northern blot analysis was used to screen the clones selected by dot blot by 
hybridization o f PCR products from candidate clones to Mrep and Nrep. A problem with the 
dot blot technique is the difficulty of accurately scoring each clone, as non-specific binding 
of probes to dots can lead to all dots having a background level o f positivity. Figure 7.6 
demonstrates this problem by highlighting a positive and negative result in a probed blot 
with high background levels. Virtual northern analysis identified 13 o f the 23 candidate 
clones as being differentially expressed between Mrep and Nrep. Sequencing was then 
carried out on these 13 clones to identify which genes they were fragments from.
Nine of the 13 clones were fragments from 3 mitochondrial genes (12S rRNA, 
Cytochrome C oxidase subunit II and Cytochrome b) and 4 clones were fragments of 4 
genomic genes (RANTES, CD32, FLP and NRDI). The high number o f mitochondrial 
RNA (mtRNA) transcripts identified in DP2 probably represent false positives due to high 
levels o f mtRNA in circulating platelets. In a gene profile analysis of normal platelet, using 
serial analysis o f gene expression (SAGE) tags to identify expressed sequences, 89% of 
SAGE tags represented mtRNA transcripts, and these were enriched for 16S and 12S rRNA 
(Gnatenko et al, 2003). Six o f the 9 clones identified as fragments from mtRNAs were 12S 
rRNA. The high level o f mitochondrial transcripts in platelets probably reflects persistent 
transcription from the mitochondrial genome in the absence of nuclear-derived transcripts.
As the starting material for RDA was platelet mRNA from one clonal ET patient 
and one normal control, it was likely that some genes would be expressed at different levels 
due to biological variation rather than disease specificity. This problem may be reduced by 
using pooled RNA from patients and controls, but it is unlikely to be eradicated completely. 
To screen for inter-individual differences in gene expression, platelet RNA from 3 ET 
patients with clonal myelopoiesis and 3 normal control samples was used for variable cycle 
number RT-PCR. More PCR product was obtained for RANTES, CD32 and FLP from ET 
patients than normal controls by visual examination of bands on agarose gels. However, no 
difference in the intensity of the bands was observed for the mitochondrial genes, further 
suggesting that they were false positives due to the high levels of mitochondrial transcripts 
in platelets.
Of the three genes shown to be overexpressed in ET patients by variable cycle 
number RT-PCR, CD32 appeared to be the most likely to be involved in ET pathogenesis.
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CD32 is the only Fey receptor present on platelets (Ravetch & Kinet, 1991) and is involved 
in signal transduction via its immune receptor tyrosine activation motif (ITAM). It has been 
implicated in platelet activation via a number o f pathways. The most well characterised of 
these is the association between CD32 and the vWF/GpIb-IX-V activation pathway. CD32 
has been shown to physically associate with the vWF/GpIb-IX-V complex using co- 
immunoprecipitation in yeast two-hybrid experiments (Sullam et al, 1998), and anti-GpIb 
antibodies could completely inhibit platelet aggregation in viridans group streptococci 
known to induce aggregation via CD32 (Sullam et al, 1998; Sun et al, 1999). Also, platelets 
stimulated with vWF showed tyrosine phosphorylation of CD32 whereas unstimulated 
platelets did not (Canobbio et al, 2001). These data suggest that vWF/GpIb-IX-V 
dependent platelet activation involves CD32 mediation. Using flow cytometric analysis, 
increased platelet activation has been described in all MPDs, with a significant increase o f 
surface CD62p (p-selectin, which migrates from the a-granules to the platelet surface 
during activation) and platelet-leucocyte conjugations in comparison to haematologically 
normal controls, suggesting that activation may be important for disease pathology, 
although this may be a secondary event leading to an increase in complications (Villmow et 
al, 2002).
CD32 was shown to have an approximately 20 fold increase in transcript level in 
platelets from ET patients compared to platelets from normal controls. Transcript levels in 
clonal ET patients were also significantly higher than reactive thrombocytosis patients. 
However, transcript levels were not significantly different between ET and PV patients, or 
between the whole ET cohort and patients with a reactive thrombocytosis. The range of 
results for each patient group was relatively wide (the widest range was 2-73 in ET 
patients), resulting in a large overlap of results between groups. This makes drawing 
conclusions regarding the significance o f differences between groups difficult, as the 
number of patients used in this study was relatively small. However, the range of results 
was narrow for the normal control group (<l-3), suggesting that CD32 expression is under 
tight regulation in the normal situation. In ET and PV patients, a disease related variable 
increase in platelet activation may account for the wide range of results observed. Whilst 
the differences between some patient groups were statistically significant, this may be a 
reflection of the low number o f patients in each group. This is illustrated by the finding that 
whilst no difference could be demonstrated between results from polyclonal patients 
compared to either clonal patients or those with a reactive thrombocytosis, clonal patients
214
were significantly different from those with a reactive thrombocytosis. Therefore, whilst it 
is evident that ET patients have raised CD32 transcript levels compared to normal 
individuals, it is unlikely that a raised CD32 level could be used to distinguish ET patients 
from other cMPDs or patients with a reactive thrombocytosis. As no significant difference 
in CD32 levels could be demonstrated between clonal ET patients at higher risk of 
thrombotic complications, and polyclonal patients at lower risk of thrombosis, this data 
alone does not support the hypothesis that thrombotic events in ET may be due to a general 
increase in platelet activation caused by an increase in CD32 expression.
CD32 has been implicated in increased thrombotic risk in relation to a 
polymorphism in the coding region of the gene. A G509A polymorphism, which leads to an 
arginine to histidine amino acid change at codon 131, has been correlated to thrombotic 
complications in HIT. G alleles lead to the build-up of immune complexes in the circulation 
and ultimately thrombotic events. No significant change in genotype or allele frequency 
could be demonstrated between 51 ET patients and the reported levels o f 283 normal 
controls from a UK population (Karassa et al, 2003). However, clonal patients appeared to 
have an increase prevalence o f G alleles with an allele frequency of 0.73 compared to 0.55 
for controls. At the genotype level, no AA homozygotes were present in the clonal cohort. 
Although this could indicate that at least some of the increase in thrombosis seen in patients 
with clonal myelopoiesis may be partly due to the R131H polymorphism in CD32 and 
platelets from these patients may be primed for activation, the clonal cohort is small, 
containing only 15 patients, and the altered genotype compared to normal controls did not 
reach statistical significance. Further studies with a larger cohort of clonal and polyclonal 
patients is necessary to establish the significance of the R131H polymorphism in 
thrombotic complications associated with ET.
In conclusion, RDA has successfully identified 3 genes which appear to be 
differentially expressed between platelet mRNA obtained from ET patients with clonal 
XCIP and haematologically normal controls, RANTES, FLP, and CD32. After further 
investigation, the CD32 gene was shown to be expressed at a significantly higher level in 
ET patients, where a median increase in expression levels of approximately 20 fold was 
observed. However, platelet mRNA CD32 expression levels were not significantly different 
between ET, PV and patients with a reactive thrombocytosis, nor between ET patients with 
clonal or polyclonal myelopoiesis, suggesting that CD32 levels are not useful as a 
diagnostic marker. Further investigation o f the other genes which were shown to be
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differentially expressed between platelets from ET patients with clonal myelopoiesis and 
normal controls (RANTES and FLP) in larger patient groups is required as they may be 
important in the pathogenesis o f ET.
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Chapter 8
Conclusions
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The chronic myeloproliferative disorder ET is a heterogeneous disorder with 
unknown aetiology. It is characterized by sustained thrombocytosis and MK hyperplasia, 
and diagnosis requires exclusion o f other cMPDs and reactive thrombocytosis. While the 
clinical course of ET is benign and often includes long asymptomatic periods, these periods 
can be punctuated with life-threatening haemorrhagic or thrombotic complications. Risk 
factors for these complications are poorly understood and only old age (>65 years), 
excessive platelet counts (>1500xl06/ml) and a previous history of thrombotic or 
haemorrhagic complications are well defined risk factors (Cortelazzo et al, 1990; van 
Genderen et al, 1994). As some platelet lowering agents such as hydroxyurea and 
busulphan may be leukaemogenic, and others such as anagrelide may not influence long­
term thrombotic rates and induce transformation to clMF (Sterkers et al, 1998; Green et al, 
2004; Randi et al, 1999), it is important to establish risk for these complications to enable 
better assessment of the need for platelet lowering treatment. In this thesis the 
pathophysiology of ET has been investigated by longitudinal assessment of clonality in 
female ET patients by XCIP, the examination o f specific candidate genes for mutations or 
polymorphisms which may be used as molecular markers, and an evaluation of global gene 
expression in platelet mRNA to try to identify genes which may have a role in the disease.
As no disease-specific markers have been conclusively identified for ET, clonality 
cannot be measured directly. However, an indirect PCR-based method using X- 
chromosome inactivation patterns has allowed clonality to be assessed in a number of 
female ET patients. It has been shown by several groups that ET patients can have either 
clonal or polyclonal myelopoiesis, and that ET patients with clonal myelopoiesis are at 
greater risk o f thrombosis than those with polyclonal myelopoiesis (Harrison et al, 1999a; 
Chiusolo et al, 2001; Shih et al, 2002; Vannucchi et al, 2004). However, it is not known 
whether clonality can change during the course of the disease, and the question remains 
whether patients with polyclonal myelopoiesis progress to a clonal disorder with an 
associated increase in thrombotic risk. To address this question, sequential samples were 
collected from ET patients to investigate changes to clonality status over time.
Some of the initial patient samples had been collected and assayed for clonality 
status previously in the laboratory, using radiolabelled XCIP assays. It was desirable to 
avoid the use of radioactivity in the laboratory as the 32P radioisotope used in this assay is a 
mutagen requiring specialist handling techniques and highly regulated disposal and also 
requires the use of a Geiger counter for detection. It has a short shelf life due to its 14.5 day
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half-life and the visualization and densitometry required for quantitative analysis are time 
consuming and labour intensive. A fluorescent primer label was therefore investigated for 
reproducibility and comparison to previous clonality results, as fluorescent labels overcome 
most o f the problems associated with radioactive isotopes.
Basic conditions for the DNA-based HUMARA XCIP assay were established and 
results from 25 DNA samples, with previous radioactive data which covered the whole 
range o f possible XCIP results, were compared with fluorescent data. The median 
difference between radioactive and fluorescent results was 1% (range 0-4%). Having 
established reproducibility and reliability for the fluorescent HUMARA, XCIP results from 
purified neutrophils and T-cells obtained from 18 ET samples were compared with previous 
radioactive data and the median difference was 3.1% (range 0-22%) with correlation 
coefficients r=0.980 and r*=0.960. The IDS RNA XCIP assay was also investigated and 
basic conditions established. As the IDS assay does not use methylation sensitive restriction 
enzymes the digest is carried out after the PCR amplification and it was found that the salt 
concentration of the digest reaction inhibited loading of DNA onto the capillary o f the 
genetic analyser used to visualize and quantify the results. Therefore, the excess salt was 
remove from the reaction using a DNA clean-up kit. Results from RNA obtained from 
neutrophils, T-cells and platelets from 10 ET patients were compared with previous 
radioactive data and the median difference between results was 2% (range 0-10%). Results 
obtained using the fluorescent DNA HUMARA and RNA IDS assays were also compared. 
The median difference between results was 6% (range 0-22%) and correlation coefficients 
were r=0.95 and ^=0.90. This demonstrated that the fluorescent primer label gave 
equivalent results to the radioactive primer label for both DNA and RNA assays, and that 
clonality results were similar irrespective of whether DNA or RNA was used for the assay.
The fluorescent XCIP assays were used to study clonality status during the 
course of disease in 22 ET patients. O f these patients, 8 had clonal myelopoiesis at the time 
of first test, had a median age of 55 years, and up to 4 samples were collected from each 
patient over a median of 52 months (range 5-97 months). Neutrophil results changed by a 
median o f 1.5% (range 0-16%) and all patients remained clonal by HUMARA at the end of 
the follow-up period. The 14 polyclonal patients had a median age o f 49 years, and up to 5 
samples were collected from each patient over a median of 54 months (range 10-102 
months). Neutrophil results varied by a median of 6% (range 0-25%) from first test results 
and all polyclonal patients remained polyclonal by HUMARA after a median 54 months
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(range 10-102 months). The first test samples were not necessarily at diagnosis in these 
patients and the median time since diagnosis for the polyclonal group was 78 months (range 
45-188 months). This data shows that in this cohort of ET patients with polyclonal 
myelopoiesis, clonality is stable and can remain unchanged for up to at least 188 months.
Polyclonal ET has been confirmed in this study and also by a number of other 
groups (Chiusolo et al, 2001; Harrison et al, 1999a; Shih et al, 2002; Vannucchi et al,
2004), but it is possible that ET patients may have polyclonal myelopoiesis, but clonal 
thrombopoiesis with the clonal population therefore being restricted to the platelet lineage. 
EL Kasser et al (1997) reported that XCIPs from 3 out of 31 ET patients showed 
monoclonal pattern o f expression by RNA analysis of platelet samples, but polyclonal 
pattern with neutrophils. This suggested that the clonal population derived from an altered 
stem cell can be restricted to the MK lineage. As platelets are anucleate RNA assays are 
required for studying their clonality.
In this study, 9 patients were investigated for XCIPs of their T-cells, neutrophils and 
platelets by RNA assay and T-cells and neutrophils by DNA HUMARA. The mean 
difference between HUMARA and IDS assay results from T-cells and neutrophils of this 
initial test cohort was 7.2%, and the median difference was 6% (range 0-22%). While the 
difference between platelet RNA duplicates was greater than 10% in 3 cases all patients 
investigate had either balanced XCIPs in neutrophils and platelets or imbalanced XCIPs in 
neutrophils and platelets. The only difference between RNA and DNA results sufficient to 
affect the clonality result was seen with T-cells from patients in the follow-up study. Three 
out of 4 patients with a balanced T-cell XCIP by DNA HUMARA had an imbalanced XCIP 
using RNA assays. This was probably due to contamination of the purified T-cell 
population by clonal platelets. However, all patients polyclonal by DNA or RNA neutrophil 
assay were also polyclonal by platelet RNA assay. Therefore, it is unlikely that lineage 
restriction affects a significant proportion of clonality results for ET patients, and while 
RNA assays may provide more information about clonality status, particularly where 
patients are uninformative for DNA assays, if an imbalanced XCIP is evident in purified T- 
cell samples, contamination from platelets should be ruled out before excluding the sample 
due to a constitutively imbalanced XCIP.
This longitudinal study of clonality shows that ET with polyclonal myelopoiesis is a 
stable subgroup of ET patients using XCIP analysis with either RNA or DNA. It may 
therefore, be useful to routinely assess clonality status in ET patients as polyclonal patients
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have a lower risk of thrombotic events. It may be possible to restrict the amount o f platelet 
reducing drugs received by polyclonal patients on this basis, and a retrospective analysis of 
patients from one centre has shown that their polyclonal patients did receive less 
cytoreductive therapy (Briere et al, 1999). However, this data can never be used in 
isolation, and all factors must be taken into account before such a decision is taken.
Polyclonal ET is likely to be due to mutations that lead to an excessive external 
drive to megakaryocytopoiesis. Mutations or polymorphisms in cytokines or growth factors 
that regulate thrombopoiesis may be important for disease pathogenesis, therefore the 
cytokines TPO, TGFpl and IL-6 were investigated for previously described or novel 
mutations/polymorphisms.
The possible role of TPO in the pathogenesis of ET was investigated by mutation 
analysis of its 5’UTR. TPO is the prime regulator of thrombopoiesis and interacts 
specifically with its receptor Mpl on the surface of all cells of the MK lineage to promote 
proliferation, differentiation and, ultimately, platelet production. TPO production is thought 
to be constitutive and circulating levels in normal individuals controlled by TPO binding to 
Mpl and internalization in MK and platelets. Therefore, circulating TPO levels are 
regulated by, and inversely proportional to, platelet mass (Kuter & Rosenberg, 1995). 
However, TPO levels are normal or elevated in ET, suggesting dysregulation of either TPO 
production or TPO removal. The 5’UTR of the TPO gene contains 8 AUG transcription 
initiation sites, the first 7 o f these cause suppression of transcription initiation from the 
physiological start site, AUG 8, by production of peptides from short ORFs. The most 
significant initiation site is AUG 7 as the ORF from this site extends beyond the 
physiological start site, blocking access to AUG 8. Four mutations have been described in 
HT which reduce this transcriptional suppression leading to an increase in TPO expression 
and subsequent thrombocytosis, all four mutations affect suppression from AUG 7 
(Ghilardi & Skoda, 1999; Jorgensen et al, 1998; Kondo et al, 1998; Wiestner et al, 1998; 
Ghilardi et al, 1999). As the mutation described by Weistner et al (1998) had previously 
been investigated in ET patients, the remaining 3 mutations were investigated by RFLP 
analysis of neutrophil DNA from 50 ET patients. None of the mutations described in HT 
were present in the TPO 5’UTR of ET patients. To further investigate the 5’UTR, SSCP 
was carried out to screen for previously undescribed mutations. While an alteration was 
identified, lObp downstream from the 5’ end of exon 3 and 65 bp upstream of AUG 7, it 
was considered to be a common polymorphism as it did not appear to alter splicing of the
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5’UTR, did not introduce a start site or stop site and was present in normal controls at a 
similar gene frequency and with similar genotype percentages.
This data does not rule out a role for TPO in the pathogenesis o f ET. Only the 
5’UTR of the TPO gene was investigated for mutations. Other mutations may be present, 
either in the TPO gene promoter sequences which may lead to an increase in gene 
expression, or in the coding region of the TPO gene which may increase the half-life of the 
mRNA transcript or the protein. Both these instances would be expected to lead to an 
increase in the circulating levels o f TPO and may be worth further investigation. Also, 
mutations have been described in c-Mpl which may affect circulating TPO levels by 
reducing the binding efficiency o f Mpl to TPO, thereby reducing the removal of TPO from 
the circulation (Molitemo et al, 2004; Ding et al, 2004). However, no c-mpl mutations have 
yet been shown to be present in ET patients (Kiladjian et al, 1997; Taksin et al, 1999; 
Randi et al, 2004). These studies were small and only included a total of 20 ET patients, 
therefore investigations in a larger cohort may be worthwhile.
TGFjM is a negative regulator o f thrombopoiesis, but its circulating levels are 
elevated in ET (Harrison et al, 1999b; Kuroda et al, 2004; Lev et al, 2002). Four 
polymorphisms in the TGFpl gene, which affect its level of expression have been 
described and shown to be risk factors in disease and for severity of disease (Grainger et al, 
1999; Yamada et al, 1999). Two o f these mutations are in the gene promoter and 2 are in 
the coding region which encodes the signal peptide and are likely to effect protein 
trafficking to the cell surface. A shift in the gene frequency or genotype o f the 
polymorphisms in ET patients could account for the reported increase in TGFpi levels. 
Seventy five patients were investigated for the four TGFpl polymorphisms by RFLP 
analysis. However, no significant difference could be shown between patients and 100 
normal control subjects in either genotypes or gene frequencies.
Undescribed polymorphisms or mutations may be present in the TGFpl gene 
coding or non-coding regions which may affect its release into the circulation. Therefore, a 
mutation screen of the entire promoter and coding regions of the TGFpl gene may be of 
value. However, as the major store of TGFpl is the a-granules of MK and platelets, it may 
simply be that the increased MK and platelet mass in ET patients accounts for the increase 
in serum/plasma TGFpl.
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ET patients may be resistant to the inhibitory effects of TGFpi. A 10 fold higher 
platelet lysate concentration was required to inhibit CFU-MK derived from ET BM CD34+ 
cells than that needed for CFU-MK derived from normal BM CD34+ cells (Zauli et al, 
1993). Reversal of all inhibition occurred by addition of anti-TGFpl antibodies, suggesting 
that TGFpl was the main factor responsible for the inhibition. This data was confirmed by 
a second group, which linked insensitivity to TGFpl to a decrease in the expression of the 
downstream effector molecule Smad4 (Kuroda et al, 2004). It would be of value to 
investigate Smad4 in some detail, by a full investigation of expression levels at both the 
mRNA and protein levels in BM MK or platelets, and by mutation analysis o f both the 
promoter and coding gene sequences in a large cohort of ET patients and controls.
IL-6 is able to stimulate the production of platelets and can augment their 
maturation and proliferation in combination with other factors, and IL-6 levels have been 
shown to be dysregulated in ET by a number of groups (Alexandrakis et al, 2003; 
Uppenkamp et al, 1998; Harrison et al, 1999c). A polymorphism is present in the promoter 
region o f the IL-6 gene, a G to C at nucleotide -174, and presence o f the G allele (the 
higher producer allele) has been shown to be a risk factor for GVHD after BM transplant 
and other disorders associated with high levels of IL-6 (Cavet et al, 2001; Foster et al, 
2000; Fishman et al, 1998). If G alleles were more prevalent in ET patients, this would 
suggest that IL-6 may be involved in augmenting the platelet product in these patients. 
However, using RFLP analysis to investigate the genotype and allele frequency for the IL-6 
polymorphism in 75 patients and 100 normal controls, no significant difference could be 
demonstrated between the two cohorts, therefore this polymorphism is unlikely to be 
significant in the pathogenesis o f ET. Other alterations to the promoter or coding regions of 
IL-6 may be important in ET and therefore it might be useful to screen the entire gene for 
novel mutations or polymorphisms.
Unfortunately, this study has been unable to demonstrate a link between ET 
pathogenesis and mutations or polymorphisms in either TPO, TGFpl or IL-6. These 
cytokines may still have a role in ET and their further investigation could help to 
understand the biology o f ET.
As the pathogenesis of ET may be extremely complex an attempt was made to 
identify genes which were differentially expressed between ET patients and normal
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controls. RDA was used because it can identify gross and subtle changes in mRNA levels 
without any sequence information, therefore both known and undescribed genes can be 
identified. The procedure was carried out on platelet mRNA from an ET patient with 
monoclonal myelopoiesis and a haematologically normal control sample.
Representations were prepared from cDNA from each sample by Dpnll digestion of 
the double stranded cDNA followed by PCR amplification. The representations were then 
used either as driver or tester in the hybridization which was carried out in an excess of 
driver. Two difference products (DPI) were generated by selective PCR: the forward 
reaction nMl (Nrep driver, Mrep tester -  enriched for sequences only, or more highly 
expressed, in the monoclonal ET patient sample) and the reverse reaction mN 1 (Mrep driver, 
NrCp tester -  enriched for sequences only, or more highly expressed, in normal control 
sample). A second round of hybridization was carried out to further enrich for differentially 
expressed genes using DPI products and a greater excess of driver. DP2 products were then 
cloned into the TOPO-2 vector (Invitrogen) and 48 clones isolated for both the forward 
(nM2) and reverse (mN2) RDA reaction. The RDA DP2 clones were provided by Dr R. E. 
Gale.
As the rate of false positives produced by RDA is high, the clones were screened by 
hybridization to both initial representations and both forward and reverse subtractions using 
dot blot analysis. O f the 96 clones screened, 23 appeared likely to be from differentially 
expressed genes. Each clone selected from the dot blots was further screened by 
hybridization to each representation using virtual northern analysis. Thirteen of the 23 
clones were selected for sequencing as they appeared to be present in the representations at 
variable levels. These 13 clones were fragments from 4 genomic genes: RANTES, CD32, 
FLP, NRD1, and three mitochondrial genes: 12S rRNA, Cytochrome C Oxidase subunit II 
and cytochrome b. Using variable cycle number RT-PCR, RANTES, CD32 and FLP 
appeared differentially expressed between ET patients with clonal myelopoiesis and normal 
controls. The mitochondrial genes were shown to be false positives as they did not appear 
differentially expressed. NRD1 was not further investigated as a quantifiable PCR product 
could not be produced. CD32 (FcylIRA) is the only FcyR molecule expressed by platelets. 
It has been shown to associate with the vWF/GpIb-IX-V complex and mediate platelet 
activation and thrombus formation (Sullam et al, 1998; Sun et al, 1999). It was, therefore 
further investigated because it was thought to be the gene identified by the RDA procedure
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which was most likely to be involved in ET pathogenesis or complications associated with 
ET.
Platelet RNA from 52 ET patients, 8 patients with a reactive thrombocytosis, 11 PV 
patients and 10 normal controls was studied by multiplex SQ-RT-PCR and comparison of 
CD32 mRNA levels to those of the housekeeping gene GAPDH. All patient groups were 
shown to have significantly increased CD32 mRNA expression compared to normal 
controls (p<0.012). O f the patient groups studied, patients with a reactive thrombocytosis 
had the lowest CD32 mRNA expression levels (median CD32 to GAPDH expression ratio 
10, range 2-25), although this was not significantly different from the entire ET patient 
cohort, which had a median CD32 to GAPDH expression ratio of 21 (range 2-73). No 
significant difference was demonstrable between ET patients with a clonal myelopoiesis 
(median CD32 to GAPDH expression ratio 25, range 8-60) or those with a polyclonal 
myelopoiesis (median CD32 to GAPDH expression ratio 23, range 2-73), p=0.281. CD32 
mRNA levels were also high in PV patients, which had a median CD32 to GAPDH 
expression ratio 30, range 7-63. CD32 mRNA expression was, therefore able to 
differentiate ET patients from normal controls (normal control median CD32 to GAPDH 
expression ratio was 1, range <1-3), and this may be useful in a clinical setting, however, 
while patients with a reactive thrombocytosis had lower levels of CD32 platelet mRNA 
than ET patients, in this small cohort the difference was not significant. Assessing the 
platelet CD32 mRNA expression levels in a larger cohort of reactive patients and PV 
patients would be useful to test whether a significant difference compared to ET patients 
could be established.
The method used to quantify differential expression of platelet CD32 mRNA was a 
semi-quantitative method which compared mRNA expression levels of CD32 to those 
GAPDH in a multiplex PCR reaction. The multiplex PCR may not be equally efficient at 
amplifying mRNA from both genes. A quantitative assay, such as real-time RT-PCR would 
avoid the need to use a multiplex assay and may give a more accurate comparison, which in 
turn may lead to a more significant difference in expression, particularly between reactive 
patients and ET. The investigation of CD32 expression at the protein level is important, as 
an increase in mRNA transcripts may not lead to an increase at the protein level. This has 
been shown with the PRV-1 gene, where mRNA levels are raised in PV patients, but not 
cell surface protein levels (Klippel et al, 2002). This may be because the PRV-1 gene 
transcript is unstable (Jelinek et al, 2004). It would also be useful to compare clinical data
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from patients with high CD32 expression with those who have low CD32 mRNA 
expression to try to identify a level o f CD32 expression which may be clinically significant. 
This has not been carried out to date as the differences between groups were not significant 
using SQ-RT-PCR. A comparison o f the levels o f platelet activation markers such as p- 
selectin, with CD32 levels in this cohort would be of interest. This may establish whether 
CD32 is raised due to a general increase in the activation state of platelets from some ET 
patients and might be, together with other factors, contributing to an increased risk of 
thrombosis. CD32 expression may be dysregulated in ET patients. This may be due to an 
increase in the rate o f platelet production from each MK in ET patients, which may in turn 
lead to abnormal expression o f platelet proteins.
RDA has been used successfully to identify genes which appear to have a disease 
specific alteration in mRNA expression levels. CD32 expression has been shown to be 
raised in ET patients compared to normal controls, as have two other genes, RANTES and 
FLP. Further investigation o f RANTES, FLP (and NRD1, which was selected from RDA 
screening, but could not be investigated by variable cycle number RT-PCR as a clean PCR 
product could not be obtained) is required to fully understand their role, if any, in ET 
pathogenesis.
A G507A SNP in the CD32 gene had previously been shown to be a risk factor for 
thrombosis in HIT (Clark et al, 1989; Warmerdam et al, 1990). This polymorphism was 
investigated in neutrophils from 51 ET patients and compared to published control levels 
(Karassa et al, 2003). Whilst no significant differences between ET patients and controls, 
nor ET patients with clonal or polyclonal myelopoiesis could be demonstrated, a trend was 
identified between the presence o f the G allele in clonal patients compared to polyclonal 
patients. Also, no clonal patients were homozygous for the A allele compared to 18% of 
patients with polyclonal myelopoiesis and 22% of normal controls. This difference may 
become significant in a larger cohort and may contribute to the increased risk of thrombosis 
in clonal patients. The clonal ET cohort contained only 15 patients, and the polyclonal 
cohort 18 patients, therefore it may be o f interest to compare the levels of CD32 expression 
with G507A genotype in a larger number o f patients. Also, an investigation for mutations 
in the promoter and coding regions of CD32 may reveal more mutations and/or 
polymorphisms which may be important in either the pathogenesis of ET, or in predicting 
risk o f thrombotic events.
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A recent discovery has been made that may advance the understanding of the 
pathogenesis of ET and other cMPDs. An acquired G—*T mutation at position 1848 in exon 
12 of the Janus Kinase 2 (JAK2) gene has been described independently by 5 groups 
(Baxter et al, 2005; James et al, 2005; Kralovics et al, 2005; Levine et al, 2005; Zhao et al,
2005). JAK2 is a member o f the janus kinase family o f tyrosine kinases with a key role in 
signal transduction from multiple haemopoietic growth factor receptors including the EPO 
receptor and Mpl. The mutation causes phenylalanine to be substituted for valine at codon 
617 o f JAK2 (V617F). This codon lies in a JH2 pseudokinase domain which is thought to 
have auto-inhibitory action (Saharinen et al, 2000). The mutation therefore, is thought to 
produce a constitutive tyrosine phosphorylation activity. The mutation was present at high 
frequency in granulocytes from patients with PV; 434 patients were studied between the 5 
groups and the mean percentage with the mutation was 85% (range 74-97%). In 92 patients 
with cIMF the median percentage o f patients with the mutation was 46% (range 35-57%). It 
was also present in ET patients, but at a lower frequency, the mean occurrence in a total of 
280 ET patients being 28% (range 22-57%). The mutation is thought to be acquired as it 
could not be found in T-cells and non-haemopoietic tissue. The percentage of patients with 
JAK2 mutations may be higher than these reports as most studies used sequencing to 
identify the mutation. However, Baxter et al (2005) found 6 out of 51 ET patients had the 
mutation using sequencing, but when they used a more sensitive allele-specific PCR 
method they found that 23 o f the 45 patients negative by sequencing were positive by 
allele-specific PCR. This suggests that the mutation level in patients may be variable, and 
this may be significant for disease pathogenesis. Zhao et al (2005) have shown that the 
level of the mutation seen with genomic DNA was significantly lower than that observed 
for cDNA, suggesting that expression o f the JAK2 mutant cDNA may be higher than the 
normal gene, therefore investigating JAK2 mutation from RNA may be preferable. This 
would also enable analysis o f platelets to investigate the possibility that the mutation may 
cause differential production of mature end-stage cells in different lineages. It also raises 
the question as to whether the level o f JAK2 mutation changes during the course of the 
disease, and this could be addressed by a longitudinal study of multiple samples taken at 
different time points throughout the disease. Comparison of the presence o f the JAK2 
mutation with other factors which may be involved in ET pathogenesis, such a clonality 
would also be of interest. As well as addressing these questions it would be useful to 
investigate the actions of JAK2 inhibitors on cultured primary cells in an attempt to identify
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molecules which may suppress the activity of mutant JAK2 and assess the possibility of 
using these molecules as treatment for cMPD patients who possess the V617F mutation.
The work presented in this thesis has shown that ET with polyclonal myelopoiesis is 
a stable subgroup of ET, and that CD32 expression is higher in platelets from ET patients 
than normal control subjects. It has also shown that specific mutations and polymorphism 
in TPO, TGFpl and IL-6 genes are not related to ET. This work also leads the way to 
further studies particularly regarding investigations of the genes identified by RDA, and 
identification of differences at the molecular level between ET patients with a clonal or 
polyclonal myelopoiesis.
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